var title_f17_21_17744="Tracheal granuloma CT";
var content_f17_21_17744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheal granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic image of a tracheal granuloma causing focal intrathoracic tracheal obstruction in a patient with coccidiomycosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17744=[""].join("\n");
var outline_f17_21_17744=null;
var title_f17_21_17745="Erythema elevatum diutinum - upper extremities";
var content_f17_21_17745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema elevatum diutinum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD04KGUDkVPGuAMdqiQEDjFTxnj0rrKJU5PTmvnP4iTCXx3qzdW80J+QFfReQOc9+PrXzr8SIBb+P8AUk6BsSDPfIrnxHwmtL4ihYrkkk4GeO1btpgAEnLn9KwdPdcquDx0Brftl+YP0XGK8qeh6tM1I1OR0/DmpmKqhZjhfVjVeEhT8oH1AzWH4huHkuUh3YReSM4qILmdjaUuSNzolvbRmCtLGOOMmr0ASSPdGQwPv1rz5IgI8gn8Rmtfw7eyQ3KxMSEfoMd62nSsroiniOd2Z1FxCpI+UAiuY16AmKTIPQ11JcMvI59c1katFvQ7Qc+hrGLsy6kbo5ibWorHSE3sN4XAA6k1zmoeKWaER26Hp1NZviWBoNSfOdjfMo9PWsllJweTXbGEdzyqmIqX5V0J7i9uZyS8h+bqAa1tE8NXmpbXKmKE9GYdfoKl8O6OJ7yB7uJvKzkAjhsV63YW0ccKkYz27UpztojfC4N1vemzlNDsU0d1tryBJbcniQr/ADrrLjyLW03wrHGuOCgAzS3E9tFG3mKpPcHvXAeLPEUaxG0scKxJB2nIUe1ZqMpOyO2pyYeN2e8fAixjGl6lq0jB7u+lCKB1WJOg/FsmvTL2ePT7aW6vZVgtokLySSHhVHWvi/wr4z8RaLD9l0fUJbWD+JkALfmelS614k1jU1ZNQ1O9uQ33lllJX8ule3h8M3BW0R89VxCcr21Nr4061pvirxLLqGjI/lRxBPNcYMuO+K4nTLkmIrz6VetypRSe/BrHZfsV+ykfu3OVzVY7DKEVKOxlQq3k7mxbTGCXkfKx7dM1txmMoMe2DWA8R2B0+6eoHUe4qSyvWjkEcpBAP4H3ryXC+x6MZ20Z0sbbCN/Qj6VpW8CyLwMj+VYUUhZwr7gpxzWzZzjKEfKOxPOaxa6HXTkTzaWpTeYsn+dUZtIDSAquF75HNdFHcKQoHHOAOxp5Qeby56dSOKSuje0ZLY506VGhBLsq9cUGzjRcEj198Vr3TooAI7/xCsi8mczSbRx0ODzihpsluMdjNvdizBV7fpSQSsEY7jjHB96iml5w3UDP1qCW5CRduBTjA551BdSvNsfB4Hv1rML7IctwT1qIzGeUuxGBnaBVfUZtkWTjJ4UGtYwtuc86l0Zt2++Yjt2r3j9mXw0TLea/cIcf6mAkfma8NsLT7RE0kpOCcA19IfD34neFdI8PWelXEF3Y+SgVn8vzEY+uRXfTw00lNrRnEqicrHsJHPPSq2pzi10+4uCcKiFvyqhpXifQNYCnTNZsps87fNCt+RqH4gyNb+DNVmH/ADxOCDx+dU9EbLyPkLWtSfVfFt1dEj97MT9cd66LRkP9oyKvBCr/ACridK+fU4e+5jXomiwq1/K2CcEKMewrzKrOnC6nXaXZqFU9+praQLjHbtUWmwBYhyeTk1bfCrlRnNcEnqexBWRVm4GOeOOaxdQ5Vs/yrZuRx9T0rIuVAV+SaqASWhy998qsMZ9q4XULf7TrMEMYy0jBf1rutXdUB4Az0/wrI8G6edT8b24I+WP5j9a7aGrseVjFZWPoDwjpyadodvEowQo4xWu1OjTZGqgdBikK+pr1TgIX6E5xUTjt681M/cAVEV4HoOmaBkLDHb8Kibr61M5Ppk9KiZf/ANdIRGe9RmpWGOuaYw9OtAjSTpx1qdenHWoI+anTrQMlUfKcjrXzz8XG8zx3K6gjMaqc+o719Dj7hNfOHxIfd4vlz95Sec1hX+Eun8SKenQ/MGZjnsa6G3HygAgD3rB09gqjOc+oH6Vt2hJXrznkCvImexDY07cHkLleOap6jpXnP5icy46jvVu2bnngD1rVtwWVTtBHY9sVmpOLujoUVJWZxqaddDI8onmtTSNIlSVZphjHrxXSxxAnJ6n0qwEXad/BHT0qp15SVhQoRi7lQW4XaTk5HbtVG+iXnGa2XQbMgAnr9KzLuMjO3OfpWaZpJHmfjaxEluZVHzxncMdx3q14O8LpNBDNdDMxG4Kewra1y3EsDHGc96f4X1KMRoj4WRflNdcJNxsckKMHW5pFnVdHZIle0GZYjkL0yPSsi41+6ji8mOwuPPHHzDAH41r+IdbisULSyhCecZ5P4V5zq3iW6vCVh+RPU9a0jBvoXia0KXwuwzXdUv5HMdxOqE9UiOcfU1iKrPIAvJ6CiOOS4lIGWY9Sa17O1FsdxwT3NephcK6mvQ+er4hyd29SxaReVbtGpw45J9agblDwTz17CrG8eZux74pZkGxxt7ele3CNlyo4W9bhAf8ARyO45pmoW4urYgf6wfMhotjldtTRkgY4JBqpwU48r2ZKfK7lLR73kQzD5hwOcVoXunrLCZrc4dDnbWbfWBd/MgIVm5B7Z9DU2m6i0UhguQySA4IavmatOVObi90etCSlG7L2mXxmiMT8Sr1B7VvQThVycsp6D0PtWJd2cV+RLC/kXP8AC69D7GqbyanZsBPAXA/jjGRWLipG8ZuB3lvdRuuGPzN/d7f4VaS6JG7JUDhTXn1trpjb596MeGyDzV8eJIcBQx6YweKzdJnRDExsdTc3IaLBfkHlm5rDvrkKx2c8de9ZsuvQ7Sd/1APWsy51NruXy7SNpJD02CmqbInXT2Ld3dKhZmYHHAGeM1nMZrplYqUQ9OOtXbPS3DCW82s+fljHIX3PqasXc0FvEWbAP61potjnd3qyqyJawlnIAA556VhTyNdzkrwg4FXGE2puX5jtUPX/AA9aaI0UhY+FHFNbkNNq5sxwiKBEUYAUcUAfPx+NTliY04H3RUB5bj8q+vSXKjx3uVesriMhHBzxWpbeItcg06eyg1S7FlKNrwlyyEfQ1kR83Ltj5c0rMcgKxA7e1cNSnF62NoyaK2lQmPVYNykAEnP4V6n4VszjcV5bnNcNosUl5fKGxtT0HWvWNFgEaKq9CK+bx6VOfLE93L4txuzahQhQBkU6RNhyhyetWbWP930O49Pb61DMAHI7/oa8m+p7CVjNuHOdwGGPUVRkw6ksOCORVmdlVjvJGP1qrIwUMSRgjpWkRM5HxKFUAjr/ACqD4ea7pvh/Wbi71VZmzgL5SgkfWpvEp7Acd+OlcTIv+kMMjivUy9KVRJnj5g7Ruj6Z0rx54a1RgltqccUhOAlwDGfpk8V0LDIDAgqeQwOQfoa+RCVVcMMk10/hPxtrHh1lW3nNxZk/NbTEspHt3H4V7c8P/KeVGv3PpAj8qicjNcnpHxG8P6jDGZ7lrGduGjmBwD7MOo966osjojxuro65Vgcgg965WmtzdNPYjbrxUbe9SkcgVGwxn+VSMhf3qJzUrDNQkYB96CTVTtmpkxUCDip070mxky48t8+nFfM/xDl3eMbgYK465PvX0uOI3Ht1r5k+IYK+MbokE5/xrGt8JUfiQ2xkOB6npjoK3rA8hcZJ9K5qydchRmugsm5XHQdhXk1D2Kb0NmIlssMKB+tTG+t4UxJKMgZxnkVzWrX7xMsUTdsnjn6VQiXGPN5MhyTjP504UeZXZUqyg7I9Csb+KdCA4Ynn5a0kJbOWOfQjpXm9i32eaKa1OAWwyk/hXeW0j+WoJ+bPGTmsatLkOijV9oi2T+6PIJqhdllXaV9gKuoCccgY7Uk0bbc1kaNHL6hHhWyvDDNeeavDJb3rvA88bnvH0P1r1S/h3ZxyMcGuH8RwGGUTY46H6V34LldVRnszz8bFqDlHdHGyWV3cy7p5tz/7RLEVoRaXCUDF2cjqOlPdCCD78VIjkncp2uOor6uGDpU9kfMyqzlqxUghiQ+Um31AqJuDkccdKtf6wEjG7HIqN8Y6cHjFdUYq1jG5TBwBxz7d6t7sxrnHTFV2AyR0XtUsQ3IcdqErMbZVVhG/Aqz/ABBhyO9V5Vw45zU8B3LjrWkewmToQOMZU8Yp13psV7B8wJ2j5XUfNH/iKjVsHaTVq2lZJFIOG7Z6GvOzLBurHnh8S/FHZg66g+SfwswN1/pxO5GeLpvXlT/hWpaa6hwso6fw9q30MTrmVWhkPBYDKt9R0rM1Dw9b3BMixhGP/LS3PH4r/hXzftU9JHrewlDWD0LCXdnOPmCYPYgGhorCRdrIhxznaOawG8PXkbYtbmOT2Y7T+tM/svWl4EefcOMU9O4ry6xNd7PTBJkwRn2xwKX7ZaWiYiVIxjnaMVmLomrzHDlIh3LPV628N2sZDahetKc/cj4H50OUe9wUJvaNijPq0tzJ5VmjvI3G1RzViHQZSRPrEm30hBz+db0M1vZx+VptokXbfjB/Pqap3Qd2LTuT7A1PO3otC1RS1lqzLvpAwEUChIkHAHaqkce7kdOgq3KvmNsQYHr6VLBEA4J+6OefWtqMXOahHdmNR2Tk+hPL8qhcngAVASBz2FSSHPB5JqC5OI9o6n0r7C3KrHg3uyqinbkk8mmr8zlv4adIdqY69qmtYi4RVxuY4Fc82ldvZGsVd2Os8I2yRQ+bJgFjnJ7V6FpMsbKQhBI645ryphPdL5duwWCI4C9N5FdR4IM0N8Y1LGLHKkcA18fXTqOU2fT4VqNoJbHpCMVQFevoKhuJE2kgDdn6ZqxkFAoGAF6D0qlc8Hbngdc1556PQybkneG4KnIIqFiVUcjAHTGTVi53bS+Rwfu1RVmxuznjAAPWqiSzmPEIOCW4JJFcPcAic/lXd64T8/IJrhb7b5gAGMGvTy92rR9TycerwZHtALEvkA8HGM/hSKxY4Qcj17UgUuf51YVQowDx0r65U77nzjkKm4DAJJHU16t8KPFaxouh6lLhS3+iyMeAT/Af6V5WCD/9apELBgRnIOQR2rOrRUo2KhUcXc+pCuGwc5qJxgc1wHw08aS6pOmjao3m3gQmGccl1A6N7+9egOTkgkYryZRcXZnfGSkrornrUbc1I3Wo2zzipGaKnmp06VCp6ZqZetSBLklSCM5FfOfxVh8nxXIcYDL/AFr6NTnJyK8E+Mlvt1yOU4Axj9azq/CxrdHH2nGACQfWt/T1OF2kn3rn7ToBnrXS6exC5Bw2MH615NQ9elqh0+nmQhl4b+9jNM/sad5VICnPf3ratwWPPB7c1oxYXAJ59z1HtWaqyjobulGe5j2Ph0RTrJLKX28heldLBDtQ7iST0qqr5IH3RnJAqRb2KIEOwXPUMamcpT3NoJQ0RoRKc8DIHrxSlAchT0/lVa2ukb7pBHUEGriqD9/j2FZNdzQoXUYdDwOO461yevW4eNyeQRx7V3MkfynAODXNavCAzHtjp6VVOVpaGc48ysebSxkAjtnqe1QHKNkZz/OtfU4PLkkCY2kbhWS43RAkjI46da+/w1VV6Mai6r8T4yvTdKo4D3xhXU4Dc1IhWXjPz+nrUds2SyHpSFWViQcHPBrVIxEkUMQG7GmQZRyD0PAqcsJBx94dR61WcFWDU3rqCHSbcEBfmz2pkZIIJBAxUpIJyR1HBzTcbR0pgT4Bwe/enowxgnmoIpNoA6e/9KmPzfMpAbuMVsrSI1Rs6bcgN5chGPfmtLbasT8pBPOVOK5mOUrLEQM/MM4rbjkjk4Hy+ua+bzTLpSn7WjH1se3l+NSj7Oq/QuG0tXAK3DK3YMKBp8f8N3x/u1GIiFwMAe1P6FVJwPXFfPO60PbUU+gGwt1Pz3Dtn04qMrBHlY1AHqepqz5ZI6YA6Gq0qRqfmJ9wOaE77lOCXQqSuoQ/KAfasu6cyNir91KAm0YT8Mk1nbGJBzsX1bk/lXTRpTqu0FdnJWqRh8TsKI1UAYyew/rTnIC4AyB3pMog4JJPUnkmo5JQv3Rlj0r6XAYL6uuefxfkeFi8T7X3Y7A4AG5jhaozOXfIxgcDinSEt80jfhULscHHK469K75eZyJCMcFQBnvWhZKWkOzGVU7frWePvrxgY7V0Hh2HzJWbrg4Ga8/HT5MPJ99DqwsOeskSaVb3s6okcDp65HWvSPC2lNbRbpcGU/eOetV9Et22DfjHY11djHt2lVyOnSvkqtVy0Pp6FJR1LMcXyYI7VRuIyoPIwfXvWnFvO4MAATWdfjbuJ4zwB7VytnWjBuiFYhg2P89KoN1K7PlHX61dvyrSOWJwvAx3NUGYkEJypPWtI7EMwtVBAPfPUgVxWpDNxgcgn0ruNSGVcqSO57/5NcZqwJfIHQ559K7MJLlqRfmefjI3gytgAYHSnA8HPFKAMcj/AOvWlpekTXjh/uRA8tj9B619rVrQpR55uyPl4U5VJcsUUoY2lbCISfQCpnsWZcSsRn+FTgfjXURWkNrFshXp3PX8ao3Scn+dfNYnM513yw0iezRwEaavLVnLMbjRrqO+01nimjYHcp5U9jX0L4F15vEfhe01CYr9pOY5wo43r3/HivC7pQdysOCMGvbPhrph0nwXYRNgvNuncjp8x4/TFVQleGpjOHLPQ6Ju/WmEZNSN3weKifvWrEaKEHtUyk49qgQ4xUyGkIsxenrXz/8AGK+Fx4omgQgpbkRn3bqa98eZbeCWd/uQoZGPsBmvljXbp728e6c/NNK8hJPqc1jXdlY0gtbjLXlgRxXRacOAzEH8Olc9Ygsw447Z9a6ay+6qg9ueK8uruerRWhs2jg7R1PTOOlaSqVAAY1lWaguHbgjqR0rVRMRtjPBrmZ2xRV1ScWtrI+PnI5+tcj5+8Oz8k/xknrXVanbme2cEBsDKg965XoMMuMccdq68Pa1zkxLd0WIJmhkV1cqVbkZyD7V6Bpk5uIVYNwwzXnkduEgCsSCTkEiuv8JI8djtZjtJOM9TSxEfduXh5NuxvtkKQDntWTqqbkbj6cVtGMFOoBxVDUotkTcgnrnrXCnqdbVzzvWrfY+/GcVz4TKOoxkGu51KHzUbgHI6Vx0sJildMcV9VkGKu3Ql11R83m2Hs1VXzM6JcS9ORUznllPTsfSnBD59Ew+ftivpHA8S5E3qhwRTZsSRbgMt6ehpxGQMjDCkUYZgeh9KjoMjX5ol9utO65DY/OmxceYB0BpOc89PpSGP25TnpUkWWA/vLUagEfex/Whco+c8Vou5L1LQyGUkdCDkVorKNhyOvWs1ZMNtY4U96slgVXacMPatVZ6k6ov21y8Y27vl7Ec4qyJpC3ytuzzmseN9pHH1qUyA49P5V5eKyqjiJOez8j0sPmVWhFR3RqNK5jO7d16Z4qCWVEX5256HuaptKTkBuPTNQsygZ61y08hpRd5ybN6mcVGvdjYdJLuJKqAP1qszlm2rkk+lKd0rDHA9T0qJ5MZSH7p6se/09q9anQp0Y8sFZHl1Ks6jvN3A5L4B57kCkbagI7njOKeT5cfFVGZn6nnrVv3VoStRsj5zzlRUWTwTzxT2UA46HuaXjuRn0rFploFX5yT2rs/C0GIUJGc81xyqWLKM5OK9C0CEpEgAx6k14mcztCMD1MshebkdfYf6lBkdOa6KwUBcg8Y55rA0yMhVBxnvW7ajCg+ozjHSvl5bn0kCzcSYjzjjmsy+ck7c4b1NXZ1Zx1Oe/GazrndjccHOSPoKzsamNfqd4UY4BNZ7pmPkYA4HvV+7wxDEHd93Haq80fHynJPC56Ae1WQzEvl2xuOw7ngZrjdWjPz5xkdOa7TU1+Ujqa5LVlypBBxW9F2OOutDQ8O6B9pgjubw4jYbkjB+99fT6V1TIqAIihVXgAdvpWX4SnEmhwBjkplefY1qSNkDnkCtsTiKlaXvu5lh6EKcfdRTnj+YgrjvWVdqCDitmVuACeT3rLu0BY1hFmk0c7eLgnNet/CnUDe+GTbyMC1pJ5Y/3TyK8ovvvcDBNdV8H74weIbmyZsLcwkgf7SnI/TNd+Hl7x51eJ66e9QtzUjE54qNsA5ruOUvxtwCf0qdTnioFIwPapY+OtNIEZHjy7ay8FavKuQWh8sEf7RxXzhfYLQj0B4r3n4vS+X4FuFBPzzxL+ua8DmOblcHIAArlr/EbUizYsQ4wK6SyB4wu4Hg47Vz9hky5NdLaHLenFebVZ6tFGzaxEYPUHjA7Vox7nHAAUHnFU7Q4XCk5A4NaUWF25GQP0rlbO2OwrIJOwz7jtWLqGjfaGL252vjkY4P1roipZxgEtj8KfHCx5IGehzxmqhUcHdEygp6M5200GeREW4cY67e31ro7K3W3RIl6jgirMYO3oBn+dNc4xgdO4qp1ZTVmEKahsLM4/iwMDtxVK8lQqQcnjtzWPr+sNasI4RumfgZ7fWuVklulmaZ5pVwcnaeh9vWqhh3JXFOsoux0l2odDt7fpXKavbkPvA5FXrfWnjZI7t1KNwJQOn1qHVrq3VgHmUEjj0rajz0ailHoctZwqwaZhMP9JX0IyKjulzIcfnU5TEqcgjqD1pbpMvyBX6Bha6xNL2q67+p8jXpulNwZTdFwB371C6nIwO+atvxyPzNQSgnHOMVpKJlcgCgSSA8EjNABIB9Oam25kzjtUZGGOTWKRdxyjjBPJ/SkYYJ9aVAOoH1NP69eK0iSyESNEYmU5+cA/Q1q7942t9wDGD3NZFwpZHA6kVft5N0EcnXcuTSpu0nEJbJkpTPKHI9G/xpN2OqMP1p4Ix+lLkg9q1sK5GSo/vH32mk+X0JHYGps5GM4PrVeRtuRmm1YLkVxJ8oBxn26Co48gk9aY3zn60/kYrLd3HsJKxK8AGohxg459M0r8scdPyppGc+mOM9azbKQ0/MfT2qRFwCSOaYF59/X0qTnYRSsx3sS6anm3Kgj+KvRdKX5VA6A5rhtCT/AEsk9hn2zXfaaMqu0V8tnFS9bl7I+gyuFoc3c6q02lUwoyB17mtiJsRjIBzx71jWR3AcfQelaqZBAAIA9a8Bo91bDiwOfm25OTk1QuWDMTntwKvXOwgAnJPXHWs25UIMnGQeT6UhmZPwcYz/ADAqu4wSWI6deuKtOdzkgADOOD+dQz4EWcnIGPWmJmBqR3FhngH8q5bUxuyT34rqrpR0zz/Kuc1FMl93rW1N2OWqrok8HXG23uoicFZMgfUV0qvuXNcToUnk6rNGDxIn6iuphkxxn6VdRa3OelLSxPMd34VnXB4OOtWpXwvrVK6YAn09qUVcuTMa/wCM4xxR4TvPsHizTLnOFE6q30PB/nTb5uuDWQZDHMrL1Vgw/A5rqpaM462p9NyHDHHY4qJvrTbeYXFrbzDkSxo/5gGnPjmvSOEuocgcCrKdOtVU7ZqynpVMEcZ8Zif+EMQet2n9a8JUbrhi3Y4r3P4y4PhGFfW6Q/oa8OgG52OK48Q9TooK7NCxX5ySMGujtECrzjbWHp6Hbz+lb1qpZRnGAcc15dRnrUtEats3APc+nete0QHZzzn171mWUPPHUDNbtqoXDDAz1+tYHUtieNOfm5GeBUpEY3dR6A9qADjjGOuM/wAqaVBYZB57+lTYrYrzSoodmYALznpisq51222lVmXOOcc5/GqnjSUxRCEZVZDgsD1rnbOyCqZJP9WTtUL3rrpUedczOerW5XZE91uvbxpERjHnhz09KfLC0MHm7QVICgHpjoaltJvKmEW3gjAYc8UaiJNm0p8rHp1rrSstDk5r3Ma8iXzJFG1SeNvBU8dRVC8RjEkRQBugPUfhWksSxuV4VR17cVCmGgCt97kKTz+VC0MmuhjkNAwjIHJ4xyAatTMJNhQcMOpqHU2eWNkwd3RQOufepFRlKLJ3GfxxzXtZRivZ1PZS2l+Z5mOoOUeddBrg7MEVBIoyq9upq6y4xuA475qo4DTn2Havp5LQ8dEWD5nB4xTHB5/Q1Oy/vAD/AHaQjBI7VlyjuRDoCQM0L155p4AySF/pTF4PA49qSVmFxHA4yOKdYECEpjARiPoO1O2gDkim2x2zSKT1AYe9Nq0kwT0Li8jHfOelOzg8kE0xGBHB/KnPyeetX1ENPA5PFVZScnOasyuNvI57VUkznH4mlLQaGIDnOQaew46jNIvbAoY4yPSoWwMYV5x+YprnggUoyCeoHvSqOv5VG5Q0ZYDNPxhRwMGnqvPT8qcwCcngdTV2SV2Ld2NXQocgnpk9a7jTRhFyOPSvPNKkkFxGysyvuC4x2r0WxIVcHAxxzXweMk51JT7s+twS5YKPY6S1k2AE9T19qvxTqw5IP415xqOszzytHbPsiTKkjq1W/D+pzpdxQzMSjgAAjODXJ7F25jvVWLfKd6uWUsvPf9aqXXzkkDnGQvvViKQ7OB2ANQ3Od2WK8+nSuc1MybhPXByaqzlnjfA257jqaluDslKnoeaTy/mOOQep9aaJMW/i2rk9e/41zd+CQeOR1BrqLqI7juzhT0zzmuev0bJB6nvmtIMxmcyhEGrwPj5S2PzrpjIUOOetcrqAKFXXqDk10Zk3RRuMEMuePeup6pM4U7SaLvnDaCx/Cqd0+eKjD8HJzgVFK+V46io5dS76Gfdtk9azJuSav3J5yelZ8hP51tDQ5amp9CeELkTeF9JmY5zbqCT6jitaTnkdDXK/Dxy/gnS2B+6GQ/gxrp2PygCvST0RxsupzgVZjNVV7Gp4+tWScJ8apgnhu2jbGXn+U554FePW68c4zjNeh/HK/D3umaep/wBUjTP+PA/ka8/g+6D1/CvPxUvesjuw0eppaauGAAABHTPWt63XptJHtWLYoMgck9s10MClRwB0rzajPTpo0rQY5A4we9adoy7csfTr/Ss2HHAz05wOma0ohnrgH0PasrnRaxpIoJw+B6HHIoI3NnBC59eKrwq+VIyff2q6g3E7+CO/rmgLmD4h09rqBk2njpXFRyskhtwBtVgGGOR9K9SvYcrtycdsD9K5i98OrPc+dF8jEDgj3rpoVbaMxq0ebVGZFZ5gWV8tjjJ7Gr8NnJ5AkKli2cg9av2WkXskiidcRRk4UfXrW1NGsMLBBlV6kc8+tbVKyjbkJhRb+I8/vrNShDxZYHOT/jVK6sorfywGMjjDqOw9ea6XxBIiIEx87nBwOSawFlgS4VZM+WcA+qitIS51exhUgouxWjuLO5kG6JIpieNw6mqeoQ8Fh1HzA1Hq9g63c+NyFeRu45+lVpNU3RBZo87flaQdc+4pq8ZKUTGdrOMuo75WCHjkZzVWIZkLepqZX/dyIGzt9uxoRDxjGAK+8o1fb041F1PlqkHTk4sicYlb8BkUjDJI7indXORzu4pX5J4OfWtUr3IImX5aiXqR0zVhgdvJx7ZqLoT71LQCr0GaSJf9JUHAyCM+lAGGyOaORKhPIDCiWqBbk3Q4xn3pW/3aVu45PrimnIIHbFDAilPPQ4HQ1WfcTgHnrUsjgMQOTTI0Ztx2n1pSBCLxk0P7gZ9acVIAzwfbmm4A7c+9K2gxBycipFXjkUg3dsVIi5waIoQqLgDP/wCqm3C7lCKOTzUirzyQPTNNNtPPcK1uCcfKcGuPMqypYd93odOEpudRE1orFhsPI684rsdFeY6XclssV4Tdyelc9FY2tuFW4uArn7ygZ49K7DTJrZoIxAP3QGPwr4yrLQ+nw0Wc1pZ3RYlRck4PPI5rrNLsRJLE0Q+VeeRz/wDWqjqNzY2soUQh5mPzbew7Zq5pGtFpFjkiWMdeDScm46I6IRSlqzsrc+WckDp6VDcNlMckdB/jRbTeYvTjv6VJcKJFQLyfb1rz5HYYzoryZB+foSOlOwwGAR61LIuJPmbGPbGPWk4XnAYdRjikiWY90pAPoOtcrqC7C/HXnn0rsNRADHgkEHj3rmNQU8gken+FawM5rQ5bUY/3YyR06Yq5pU3m6WoJBaM7D+HSotUj6Dgcdqz9Nn+zXpjY/JJwfr611R1R51T3ZXNQykEg0ySUFckYpt38rZHX3qrI+Rg9KdiG7DJ23Z9qpydD64qdyTwOtQS9DVoyke2/DAM/gWx2qSPNkA9zu6V1UihXITcMAZDDBB71g/DWSG78CaVGtwkDwBkZHyBu3E7gR610V7Ksk+9GLgKFLkYLkDrXoR2RyMsR9sVYi61VQnjFJqN2ljp91dSciKJnx9AcVo9iTwXx9qH9qeM9RlHKJJ5Sj2Xis2FAVXoD9cVSikaed5XOWkYuT6k1owKTxxXkVpXbPSoR901rEbWXORjHvW7aBXUDPX1NYVpn5epPrWzZ5Qcgk5zmuOoejTNSMFUA4PODVuHBYZ3A57VSgcMwPUk5+lW42GWB/vdPWsjdG1aEYTcSv61ejl4G7GAOtYsEhVwAMn9DRf6lBZxGWRgv49aaTeiB2NGeYkjJweuDU1siOoY4Zs5rgT4peafbFCcEE4zk4rqdC1KK4RHjYtj1q5UpRV2KM4y0R0UO4MAew7dKpagw2EEDA7jnP1q1C7MOcLnio7mIEFAMZPfvUpFNnnmpB57xwMlQcc9u/FYjQkX8Rh2yHJDK38Q712lxYpDcyJIWU5yG7GuVuo0guwyguiklVHHfrXpRtyKxwNe/qJqcwdT5jBWjTarN1x6VzFyUmhZTuABwduME10V9LFOJUSAGNlJ+br9cVzrARjy0YYbgeYO1FO63M8S0/hKtm5JKAk87cn06itJVAUnP1rNI8oupGJEIfFajgLbgjuOK+tyWrzUpQ7fqfN4+FpqXcrryARzk5FEmd3UdO1OwCwwOgprcnpkdq9bocQ0jgdvrTMcE4JqUlRgc5HqaYw+bjn6UgGYI47U2TlTnqO1S42tzgjt7UjDI6DH1otoBIWyOpGPSo88gkY56U2OT+VOJBOeaT2AavXOAM+lKyjPyg5pWjI59aZnGP51TEhrDv2pmOp6fWpsHIxz9aTGDgEcVFhjFj+XOetSKuDnP4e1N289eM81KAMgj8aaQB8oUnv8ASpxcGziQLgSOc59B3qMAu6qRwTTZ3RdQUsRtjXAPUZNfOZ1V5qsaS6fmexl0LQc+5PFbjZ5khPml+eeo+vrW1p8v2W1uJYzghdo9j61lIUb5QzOfvZxjb/jWzbQO2m3QC7pSoIx09a8SVrHr0rjtMtxNAskik55Y575rVuLSGK1imj6E4Pc8e9ZmlMwia3HDNz8wyB/9et6GAGJ1OGJHzEj5celUloVd3NrQ282xVs8H5fr61clLIxLfKvoOtVtItzbWgDAg4yPYVPPyvK4z3HevLqK7dj0orQp3dygOWIPaqMeoxMfLRlyDgAt/KsbxJceZI8UL4CnBNc+mY1Dpw0fOO/1zWsMPeN7mM66jLlOzvJg+WxkYrDvYkAwxwSCfwrSs5Gls0kb5mZckfWqF6R8obJP6VnazsW9Uc1eKCCRyen6VgXKkSZ6c9q6i+j+UgDC44Pf8awr+PqQMAHHtXRTlY4a8bk0MouLck8uvDVUlP8J9aZby+S4b+BuG+lSXShWyD16VtbU5GxoPzYOc9agn4HtmnqdvI57GmC5W2uI5pIY7hUO4xS52P7HHamtyJPQ9++FckzeBdM+xNDGgVg43LuLbjyfrW1fNL5zee6mTA6EHj8K5X4V6jDP4RilTSrG3DO3yRq2Ovua6a4cSvuWNY14+VRxXcloc6LwOAM1zvxMujaeB7+RThpAIvwY4rpLUIX/eHArhfjZL5fhaCJSP3lyv44GaubtFkrc8aslIORyK1YF56YrOstxYEYx06VrQ8KSAQK8ioerRWhfgJAznH1PWte2b9315+tY8DAgD8a1rbAKnqB61zTO2nsatoqbTgfMefY1ZUcsQOQfr+NVLdhgYBAHNW4mHmA8kZxjFZWNywJCCpAA69+n0rA8VxNJHbsgLqG3exrffCo4GG2888VBPbi4syknOV6kVrSfK7kVFzKxy1lHbCz85wfNJIxnha0tFuvssxmZAkLcEDtjvis67iNpOqgqRj5Q3ANSW9rJMGfdiMfkT/WvQ0nGxwpypyPQNP1WGYoIpA4HzZB6Vcvb5MFmJA+9nsMV5zZpNZt5gYqobnHSreqalNdOkaMQDgkCuZ4dqVkdSrJxua+ranbzoP3wzkVg6gvnorxBWB5+T+HHapv7K+QmSRUyepyuKqRNLY3rRMu6AjAI5A9K6FB042OaU+d6mRcWmIw8jYTPIzz9BUMkIvCyfJGxHfv71salGHjJ6Anr2A71S/s+K3t/tOWuELbQUO0Nx0/nVoxkjmtqR3JRjnchXirUUhe1iB5PT6YqpeXKvPF5cSoofCqvJAPbNS2eRNKB0GP1r2Mnq8tfl/mX5HlY+F6d+zLKrlgeRikYY7ke9SHBTOMd6jOCDmvqUjxxjjjC9fSmruxzT2HPTk96QE4Occe1SAhxghvpQAD9BScHsD6mngYOcj8KaEQsBzjtzS796+5pRtLvk+lMXiV0A681LQyTkqD+WaZglumf6VKoyhz24phGMlWz680+gDOnUUmepxilYlmPPb8qVR0zzUiHKAck9O1OXrkHFNGPXipYx1wOPpVJDuRSy+RHNKnJRcKfc1UsSfNCsRyuScfd96tSlf7NmL4O88e/NM0ZIxdp5xIUYBB7V8RiqvtKs592fQ0IcsYxNmxsbuVSgjwp53lsYHtWt9tWxhW0sSskn8ch6CptSmWHTZ2BPAAAHas3T7fz4P3fCg/M1cafPuel/D0RdsnlZizoCWwT25Fb2lzRveBZB/uqT3/rWNp0LQXqRzFwM9R3HrWhqSmCXzBkFSCDntVyjeNhwlyyTO0DquMAjjGc1BLjkHPPJNV7CcTJlsnjp71POu88sFHp6+1eY9Gd/Q4PXD/p00eCN/B9xWR5LvOkPILAY78V32oWEVy37xRuPBbNZtlpcEV6ZWxkcDmuuNdcpySoOU79C1DamCzjU4I2jg81kaghJJX5SRzmugu59iDkAjt14rDvQSOgzjgGuXVu50vsYcoUjdu+QnA9zWXfxDDKO/etsoFxvALNjlRwap6jH8hPGPT0rROzMKkbo5SVc7vT2ojcPDtYHKDrU93Hjdj86oglH/HB7cV1wZ5lWNhS+AcGqWoS4XHc/yqxKeSPes64YzT7F/wB0fWtUtTnm9D6C+FtvIngvT1VGLOCRgda6u42KdgjkjkX7wc9/p2qPwtstPCmnRJvEkFqIdgQ4Qnq+am1CRZJx5ZYhFVCzjBbHc11ozWxZQjnmvOfjhKRpmlRf3pmJGfQCvRENeb/HJCNO0l/+mrjP4CnU+Fii9TzfTuCBzjmtULszjgg/nWPp5xz2POa2V+ZRnnvzXj1Nz16WxYtW5wD8vritSNiuCDxjrisqPAbI4HtWhaSdn69PrWMjrga8GeDzitCI5UFTj1rKt3I4/HHtWlA+VyMYPU+lZmyL0RBRem4jlR+howQG3Y2j09aVSNw2HKkAcdRn1qbKHjIOTgnofpQtBs4/xNFIBFKQcEgE9ce9Pu5HMdvHGyhAgwFOB7n3rdvLVbiOSKQfK3XvgVzhsJba4jjkJaME4b0FdtGatY4q9Nt6Gpplq8trNPgOS21Rxyehx/jUIi8nVWzwyZxu55qdp1iiRVUIqghSeij1qtJMk0kXknLBsljyc1vKSukjJRstTWvlMmj/AGl5fNZSNsLJxn1rn76VbqFDFLI6pnG4cg+mR2rW1Eu0P7uMrG6gkcj5vpWYsSQW21/lIGQD3zVtGcpJ7aD4WintRE5AmAzj+97VzupO0cflFmVCTmPsD61t3dmfs6STZbBGCPlP1NVLeGG7VpiA7oxBxUzaS1BJy0Rg/wBmlGSZj8qgnb6VWhOy9cE8Mnb61v6rLDAGEkgBxnFc4rg6ghRvlZTgiuvLJv6xBs5MbBKlJGhnOQBgU0/XIPalLZ+8MEd6aDjK9DX2x87caTzg5/KmqRz6nvTvUZz7ikIwM9TUsA4U8g5o4BJIIHoKCcD3pehPv60xDd37zt09Kik+WRWI6/LTnGGTOOp70S8oTu560ugyRW4YCmSHC42ge/rSxnOeTjGaaFyc0+ghoAJFAOGxjHNO4A6EUnVvUnv6VNhjx6ZFDnarYYg46UgUZ6dOtNmJEbZ5yQOlTVlyU5S7JlU1zTSI74MiWwGCOTg9zToBH5hbja2GDfzrRFulzCsUgyD396bZaPI02yST9yMk4649K+Cc1azPqI03zaGrflZdA3lsbguSe/NTeHZl+yGJSFfOSDVp7ZJbbyeAhGAPSsGNJbWTypUbPv0bms6clsdM4tM3mdjMIYMl2PDHpk981ta2sMK29rHJvMKgS5H8fXI9aw7OaQMpRBuIJ5HQ+tbWmWyG5M10xOSMA1pOajEKdNyZt6TEY7dOPmIwPrVmcfJk8jtjvzU9u8RQ4J9PQ1BM4ID8n0+lea9z0EY2s3hgjIj6gda5A6hK8rSI5JQ5P+Fb3iKVopDluCuW44x6fnXHQ/JGzggGTJxnvXZRglD1OKvUanZHbWVwLi2V3ALEYOPWq15tXcxJ78daTSIfLsYi4xkZ+lPuAWA9M8DHP41zS+JnStVcpeXuySSWIxyMcf41R1BAqkZzx161puAvTJx19ee1UL0Z474zSRMjmLtRuPXFY8vBb371vXi/K3uT1rEmHzY4rpps4KqKcz7Iyx7CneFrM6j4gsbcLnfKCR7CorwExMB2OTXafBnTPtOuzXkgJSBMD6muymrtHm1NHY9+tF3aesEUyIqwFDGzbcPnr/8AXqpqUiyXPyOHKoqs46MwHJq3+8FpbfZ7SKfK/M/l7jnPQ+lM1FFMEzeTFGY9mCgxhj95PeuhbkkUVcT8aLfzfCMU3OYLlT06A8V2yc4rnPiRGLnwhqEJ+8Y9w+qnNVJXixI8Ksnwcd++e9bFvIccY4PSuftH6HFbNvISoXjHqK8qotT1KLujTjLAZBxir0THGMj1zWXFJgkZ4/SrcDfL04rnZ2QZswyDjue2a0LaQOQVJHUGsS1fABLH3/8ArVdDgKCueMfjWdjoRtLIxIOOB69/ai6v4rdCZXUEdc+1UvPIjZ16jnNcxpiS61fTySvygZlBPAArSnS52Z1avIjfbxJCx/dhyWOc44qNbm8vZGCKUjX+8MHnvUFjEsUsMc9uoDMdr54Bx0rUDrKgQIrPjCqDgEjua64UYo5ZVZMpwwSvcFZGMmD8ox3rft7TT7KMGRt05P8AqwMbT9az7WCN0Z2YKAdu/dwpFOhtzdyYZhjPBxgnmt1pojGTfUsKv2y4BXmEZPXrWZqETQF1Q/eOcsMqfY1fE8WnWU7KDkbl2dwSOa50NPcxgxZAC53HtRJpbhGN1sLqV+HsWgiRlQ5zn/PFLo0JSwLuMbjuIqW4soIbVWnZ2kkHzZOAG96pWF+pjNs5ypBCEfyrKauhxklKxiaqXlZ5Gh3NJwuOwHasazLLcxo3BV8bfTIrVvyFgZA+HUgEY6YNZSusmqrs5QOoDevvXZg9Kkbd0cOK1i7muRwe+T3pjEbhjJHfNPYDGD69ajcAfdz+VfbHzwueMkZ59aXrwcCoySOhA5pQ2QTzU3GA6kDp6etO4wcAYx+VNPINKWHAA/KgBkoO0FiOCMUvVTwCDTJhmNieeOgNEZGBxwRSW4DocMEwTjHNHf5Qc0WxBGM4wac4xnPWqT0ExvXjPOfSkAwTjj2oDAD196GJx8pHvSGPHfPT2pkrZWNVP3nHFOXoMDmo5jtlhB5+br+FcuOlbDTfkb4ZXqx9TYtc4GB0rTilSMhiwAHUVjwNtweazdUuma6aJ3IiXAGDXwvJzNn1PPyo76yaOYFVYMc9QetX/s0UgJKhvTNcLodyYLhcSfuugC966i81IW6Dk7j0FZypuLsjohVTjdjtVvUtpEt4EGTwSBTwrpbb3ZVLD6kH2rAeZnmMpAE/ueMVfsrm1+wTteSN9oX7ig5Ga6IJRVmYubk9Dat9TkiuEgmbIYfK3etkTeauf4OgINcMbwStBMx5HHTtXWWU6PApU9RnA/nXLXgk9Dro1OZWZT1ezS7Vkc8AYPrVCx0COFmPBUdAR0J61sTkE8jnjHtUkJGxizZwP8ms1OUVZGjim72I3jCRDPyjBAx296pXDBQAwJH+FX513RFGPDcBj1NZsgAGByB/nmpJbIpCTjH3jz06Vn3JBznOBwQKuuQPmGeo61Tuh2x6nPrTRnJmDf8AIyeo9ulYM65YgDGK29QYjPQBjkDPasmUDJGPmrogclTcoTJkNkcdDXsvwp0xbDw0kv8AFOdxNeRSjI61678Kb77V4UEGPntZWjbnseR+lduHepwVo21PRLdIIoVBjkeVoWmJWQqGwenFUdQCJOvkrsgZFdVJJ6jqc96nEkUENsXmuQ2C6+WQAvYjnvVG7mE1wzo0jAgcyYz+nauhGJcQ9M1y/wAQbgRaPPnpsIrpY2G4VwXxXuPL0ecA8kYq5bEHjVuwDe2a1rZ8rjOawLZ8Yz0961rdsgY5NebUR3YeWhroW25B/CrVvIxPJyRWcH7jPI+tWIHBHB4PaueUdDujI24JPlA/PiraSKSG9eprJSQKgweOlXI5R5Y54zisbHVGRpoT5RXuRj/9dYNqJdMmkilRlSTIEijIPPGa27aUHB5PuO/vVPX7jEYijJyTk1rSbTM61mrk9iXuWXiSQIcKA2M/5FWhOQzQoUeQH5BGRkj0+tUNK8tBEUkJz931XHU5rVh0uS5jgltgkc6yeWjg4ZiQTzXatjjGfaoYSFYqrP8Ad9Prjua1bbVJltpGQoCilVYoMKR3FYmnWijUWjvmxcbzhsEg49xWrcbpHmT7Osj4GHQhskevpTV9xbGQ1tPfzefd3AC53BFPFWZlVoCsT+UB91SMbh6/Q1WuEMG558xoXw6A8j2qW8dr8B0JWPIVd7fdUdqzUbu7L5kloVpJC1lIZP3u48jBwMdya526cC4WVMZjkVQRwGGO49a6m7lWz00xr5kbEglRyW9j6iuZ8iW+vVAQLbq25uMYxVPRGb10QutWyTbih2vj7w71zJjFvdRLuzlxkj1rrtTO3djoO1cfdsDe249ZBWuCd6sfU58YkoNmwxwaHPy4pD14PtQflI6kivuL6nzSAD1oAOMZxSZGME4704ZzjrQMCSBQTxwfpTSefT1pM44HUetIBWJwcn8ahjb5RzjkindR83FRZ+d/QEMKlgTQ/wCsdQejU6Q/Oc5NQb9l0uc4kXA+oqVRkktzVJ3VgHKDtHINKWwMYApOpx2pGx0p3AQE5yM5qG6cb4OT94/yqQEgcH8KqaixBt26YfH5iuXHa4ea8jbDu1WPqb1s4xh+QRzVCREkv5GADxMuNxHGaZNNnT329WAXj3ogBVcrGQ5GASehr4xRtdn0cpX0JLCQ21wmPuEcN2rWuJ2muQ4LHHAA55qtAkVzGFQlMY3E8AHHpToVO9Xi+8nBHf60W6la2sbGnaXLdlgu1blW4WQ4DD1FV73SJbS4VZirO3zEJngVbTU7uWZlXCMR/CAOPrVi01jNysV5CssLDa2Dz+frSSuaPlsVEsi6lYmyoXcd55/z7VpaNI0cbxlj8rcZ9KWyjYzu4jAhz/D0A96zYna2upLhji3YgKSc5GamrC8dC6ElF3OsRS5wcc9vapxsRQFOOoHPU1nQT+ed6EnIyOfyFWlyqEk9sA1wNHoXuPudvl7udpPesiZsAEjAPp1q3O5/jPXHA6VUkUd/lAoIaK0jDOMe/NU7lj5bEnnI/wAirEknLLu44x3xWVeE/MA3I/WqSIloZd4QwYAdciqKRhnYE/MR+NW7lSCTkknPJNNhjGST09u1bR0RyS1ZRuEAXjp2rrvhBdtHq2oWZbCywiXHup/wNcteoBkDH+Fafw1uRaeN7JnRZFkV4yrdGyP/AK1dFCXvI5cRGyPfY5ZRZ24trq2hXadyMwznPXkVm3zSG5zNIkr4HzIQR+lTG8gI/wCPC3P4tVO4lSSUskSRDAG1Old6RxMuxkA+3rXmnxfkxpzDPU16SjdfpXmHxhB+w9P4hTl8LJPI4ickdq07Z/lGTiscNtYVo2r9q4ZI2ouzNpOUzznuPWpI32EdsdjUFufl69uM1I/JB7/zrBo9KLLySnbjj6GrkU/yAHp1xWQrlSo7E1btpf73JrNxNIzN2G6jRN7kBcZ5rNvLr7XcqYSZIk+9s6jnrVXUo3NpGVztDDcBV7wzaSJLKQMKQRlvQ1cIqOrHKbl7qNHR7gwSgJgkZyCBz9P0rqVKC2jnadAiMSsh4XJHQ1x0ubXVI2HKHOR0rrLVyoRxGAjYkbzACuPp3NdNN3RztWdisLi1CtLBImVb54+h3H+IeoqK7+0wxm4sVCKy7ZEfnd3yPSp763s7qZ/mEaMc52fcHtUc/l2tsyOGZdpUPnqe36U9SWYV3NdXZjWYxwxsRyvJatG2ZkjkgCJIyneAP880lnKi2VszxgqoJzjB61ViM4aWbZKkbH5JAOn/AOo0loEpW0G61qm5W8xMzDgKRgAY7CodKJj0sAn5jk8jkA1Sjxc6mzXJLSH+In8zWjNhVJU/L05rOpLoXBatmNqU37pgScY5965NG83V4AOgJNbOsTDnDcisLSP3mpM/UKprty+nerFeZwY6fus6EkFTg03PAI6UEdMDmkzzjt9a+yv1Pn7WF54560/OVBAyajAGBgmnLkZ6Z9qVxjhz3+nvTG+UkGnexxTG5JoAXPAAqKbCyIxyNwK1J0/wpk43RtjqOR+FDV0HUhlQyW2VPzp8y+uRUsMgZFYdCM80iZ5x65qK2G2aSI4G05X6Gs72aY9y3n0IB9KQ9TzxSdyM0jNxmtRCZ+biqmsf8eisf4HBqdXxxxUF+PMsZl74zmuev71KUe6ZpT92SZJEPPs3jU/N1BFPsruWXZG+xgD17gelUtJnPlqc4IrUihjkd2C4Y9/SvjZNJn0MU5K6JkLXEXneYyEnHA/XFWLaRoBlDu74x82fesq2eS3Z03EHODWpYEFWicDzFAKv2INSaxbNGEsXEuS23jPrWrEkSx+Yu8/Lu2kdD3rNto3JCrja3Xb7VYVpI4XjZQIg5xu69aY1ruWH1qeO2ktLNAvnqC64AwPrVe0jMloIZDuwnQ9znsfQVPcWha0R1X94O2KriRgNkdq5lxgZP3j6n0FRGaaNpQasafhgtK0seRsBwpzXQSoSCO5HA9KzdHtvsluFGN2MnHr3q8JVG4Ak5PUVxVN3Y7qekdSrcLtVnbIPof5VTmYBQOOtWrp/nGB04+ntWfKTySc9vaoCTK8xwuBx7DvWZO21WLHpxV2WQIV5yeprNumO4qDwOgPariZTZnT5PBHXjjtVi1H7rcFzjgGqsp3y9vzq7AWWIdye3pWj2sYdTNvj8xHp+dP8FypB420hpE3x+eAVzjOQe9RX3O454zVLSrgwa7p8q9Y7hD+uK3orVHJiNj6Xht1miEkWmZQ9CbjGffms3UI/JuzH5QhIAzGH34/Grcc8bJB5iSgNG1qxC5HPII9TzyKp6nIputqhx5aLGS64ZiBgkjsa9FbnCTIxBrz74sw79LcjqOf1rvlPSuW+IVv5+jy4HVTVNaEnz8/WpbaXacd/emSDDEHtUVcdhrQ37O4DKBn8K0VkBTgc9q5eCbaeuK0rW76BufespQOylWurM02YbDjqOw9KnsnAfBOcdKzJJeQQan0+QtIMcVHLobKep2mnhJIwrDg9qsXl2LRBFGAC/p2qjprfKpGR7iovEMdwxhuLdd0YG1gOoNYJXlqdd2ldDZXa4mjZ/m2nsOa6aK9WXTxF+8iAxlW7/wD1q5fTRd3iKkcbQuv8ZHX8a0orXUY0ZLmRCrDoBn9a6VJRMeRs0Lq7bykRZVSVRt8sJw6Doc+oqB/td2gWRwY15C4x+NMtIWtzlyuW4JLZOK04WUuSvl9Bg88VMqrfwmkafczre4Ee+G5+WQDam4YXH9TVhJYhInLsuNigHhzjJDfSl1S0juIF+Ulhzxyc1hMs1vNEoIVY92HZc9fWqjUvuZVKdtURaqjQHz44lRtudpbJOPTPr1p73HmWQc8AqCAeDzWfeyS3jtEw3AYDSDgY9s9aralcMqMFbAxinJJvQxi3G5h61cD5gDk0zw+mIpZPU7azb2UvKeeBW9p8Jiso1OQSMmvZyunerfsjyMZO69S729aaxAwOaAxxx+dDcHPU19Hc80BmnqePeo8+3/1qePp19qLgOJ5zjFNyD360sh+UCmE8Yx1oAVcc4zQMH/69IM56YpR1A/nVCIl4xj06morkbJY5V7Ha30NTKc4/EUTR74WU9xUPWJWzFByByaZJk8VFBISgyMHvmrH3hUp3Q2rEB7U1wWDLnGeMVKV55+tMYYpNaajTMjTHKTNEeNrV0dux2qehPHrXNXX7nUNwGFbmt2ylDKp618fiqfJNxfQ97CzvEvGwee6WWNgvZj3qbUbOSM27wc7fkYnt71NYsdwIPPatqHax2nvxXE5tHfGmpHP2d7syiAhyN2AOa1YZpLmQjHynB3EVduI4IU8xkQN7L1qFs7A4ITZ820/4CtItyE48m5qWqyXDCKPIO3cCOakkgmjUkshwdu4MMGsGW6OeTgjr82ARWrp0MF1bSOssq7ByjLnd7Af1qlCO1g9s2PlnkQrskBBGFHrmmRasFkMUowwOAw6GllAgiLqBM+9VRM9sf5+lY+qzqoVo/LLAfw56+tTKmmtCo1nfU6WVw0YK9znFZl224j5uvr/Km6e7yWaF878A80y4cbdoALZzn1rjZ1XuinKSylT171RlfnkjIFWJ225UEE46elZk0mwkdTVRRlJhn5zg5I6VYVsKcGqcXzPydoqa4+VD/drWxjcz79snA6DrVLT42k1mxRFyzTxgAc/xCp7ojJzV/wAARSTeMrCWNmX7OxmLDtj/AOua3pLVHJXloe9MYbm3t0N15DQqU2ujFTz94Y71W1KdZ7kFNzBUVA7jDPgdT9auJcfZ7S2L6jdQ713CJIwQq561FqtvnzJhdPcOioWMiYJRvusPUV3bHIRK1Z3iOLztMkX2NXFbNFyvmWzrntVknzRqkPk3sydMMapGun8dWf2bWJCRw1cyRXJJWkwQ2pEkK96iopWGXlnOMDpVvTpdtwvPXtWQrEd+KngfDKQec5BqXHQuM2mekaVKrIDzk+hregcYKk4A46ZH41xWi3XygscZ9eldLbT4Q4Yj6muOa1PYoyTRtoq9w5z0AYYp7yAKRi4TscetZqPyCQB7nI/lSTPGu4yZB655I/GosbN6FmRkyd0yoPRohmlRn8seW7TYONqkKfrWN5ylxiCQjPZjzUkNzArE7J1IOCA9aqJi52NrczYDQzKQdwIPWs/UY1GTgg46kbSKVbtAqr9ok2HkKT0+pFZ9/dvsUPkY4+//ACqrEymipdOAMDJ+nSuT1q4ILAHitnULrCt247nmuR1OUu2M1rTjrc4q89NCvaxma6RcfeOTXUDHT06Vi6JFlmlPbpWueDX0+W0+SlzPdniYiXNK3YmXjr0pCeeaYp59aXNelc5h248kdPSnA5x71GTjg96VDznihMCQk5654phzu+lKSP4vSmtyaaYhwb5hSrgnjGO1MHX5uPel9ccjFWAwEA/8CqQ8jrULHCLjselSAjHP51EewMqj5ZWU9KsowAz/ACqGdfmB7ntSIcVj8LsabosEggnAB9qZKvdfypFIPOaca0vckyNWT5EcdUOKsabL8tPvoxJBImPmxn8azdOm2NtbNfP5nStU5u56WEqWR1FvexRsA+d3fHaujspkkVWjIJ9q4INiZ3zg5BBBrX0m8eK5jI4RuGA6V41SnoerSrO9jo9bLmKIAgbWBwaS0tJXkUMWYMMuRzn0qLUd8lsRH95SCOat+GdQhMypdx+WynCk9j3+tFNK1jSrqywthFbahvnjb7O2AN3IzWtJEu9Ge5EDYZQoj3O4HYelW7rULKKGHYC8ofP7xQduM1kTSy3EUjsqrMwyCvXHXNaW1uLmsrFDU38p41tCc7dvmMOR9KgtNLeUBrh129gBii2El3OZpjiNOFycZrVluI7MqJQyZG4ZHUeorCpJ7RNqcYvVhtWKMIOnbIrOuCAucmrpnjlG+Nsj+VZOoMNpA6mubqbyemhRuHHJ4J9azXkaSQ8YA79qmlmG05PXnFUt+9sDA7VtFHLORcgO0dvbNJcycsvHHPPNQtKIgwyPfNULm6yvBqkrszlNJEV7PycHIrpfhjMi6hcjA8xlAz7VxE8uTwa3/AM/la4gzgOMV1UlZo4Kk+Zn0NbMn2G3+3G02EEwiZGZtuf9ntn1qtqVxcK00E/lEyFWLxjhkA+UD/Z9qrwXltLaQLeQSO8S7VeKTaSvXBzTdUd2uU3osamJDGinIVMfKPrXSSSqw9fyqZDlaqI3epkbp3qyTyr4qWYWVZQAOea80cV7l8Q7D7VprkD5sZrxGVCkhU8EHFc9VWdwRCaSlI5pKgYZxSg7SCKSkzQBuaRdgEKxziutsrsBByAT1BNecRyFGBFbunaqsYAlJKDrg81jOFzqo1+XQ7+Gddq87c/3Tgj+lEz5PBkGOflYN+lYFnd2k3EU8kTMccnI/EVLNK0BUM8ZRvutlhn6GsvZtHYqqaH3kiK53yFM8hlQ8fhUQvHHKzxuwx8xfB/WoJ7p2XGXBHTY24frWbcyNjO73+YLmrUTGczVl1IucHyT23IcGq3nlyQuM564zn+tY7ybTlmHPOD0/Ko59QCDCHtir5TF1bFrUboAEbs/41gSEySZBznpTppjJjnipNNi8y5X0HNb0KfPNR7nLUqacxt2caxW6r0OMnipjjPU/X0pvHAI5pAR2PFfWRXKkkeU9XckTr1p2eoqIHPXB9qeDwfpmruSxx9M0q8HpUZ7UoJ6ZoTCxJnijoDnikGOc8ClznjrVIQLggZH5U4A84NIvHOOKcOfwq1sIgk4TnpmpSeaiuD8pp5znJqIvUb2ElU4qu3BH61aJ4qFxk4Bz71M0OLGBsHrk57VKMtyWqA8HpjNSI3Hapi+5TQ4g45rn7lTb3j44XOR9K6D8azNXhygkHJXr9K48wpe0pXW61NqEuWQgYFQ+Rg/Kc/zrT0xlluYQq8A5yOprDsZhyrdP510mk+TGMoME181U2PWo6yOqQb0I9RVO5s2zvTK+4/rViykPGSMYrYRMqMAdelcibT0PScVNamLaXFxCeVDrnG6rCm6kBWaX5H6g/xfQVfMYABXaWPcGs7VGeOItEQ0mD05NX7RvQl07K465lggYRxyNMB1I4/Cq2o3Vs1sWlnL3J4Ct/AtZC38Ug+csso6Z6D61SuUF5cFbcs7nv2Hua022MnPU0NCuS00yg4Qc1LqE20fL0H+c1Lb28dnbBIwOxJ9/r3rL1CbhgW4NYWUnc1u4xszPuJ8dDk+9RrME5JAIqncSnccVVaYAk55963UTilVsy9PcD1NZ887N3qJ5WY9eKjNWo2MJTchSc1ueDZIY/EVmboyiAvh/Lxux7ZrCFafhyJ59bs4ozGJHkUKXcIufcngVS0ZB9D276S0ClW1DGPRKbqdxFPcI0AcRpEsY34ycDHamWukXcUXlyNaq6cMpuFyDUN3E9tKY5GQsAD8jhhz7iunQZaVsdaljOaqBsU+JznmqJF1O3W5tWU9we1eHeLtKayvXZVwhJr3hSGBB/GuT8YaKt3A525NKS5kI8ONJWlqunyWc7K6nAPBrNPWuZq2g73EpDzTqTFACU5etNpV60AWLa5KMNwyAc/h6VrRa7LbwlIFUKTnDDdj86wBT2FKw1JrY3X8S3DjDwwH/tkKrT6okiHNuFY90JH41k0r9R9KOUbm2K0rv1JppJJ5pKKdiQrW0iMqjN0Ld6zYIzK4UDg1vRIEQIB0GPrXp5dRfM6j6HPXnpykmQOe/vSBiWo6/wCFJjGMHivaRyEi/exnpTieMng0wcHFBOOO3b2p3ESFiCMnPvSAnPr6UzJ7fXFAYA5HTsKaYNE3ORTup69qZuOfWnA46/pVxaIY9SAcEYo3YyOSKTnrn8KFO0Vd9BEdx904/Cn5HGKhnPysak4wM+lZp6lPYcMHI5pjZz0GacRnpTcZYYpvUSIJMg8g01XyRjgVNImePSqxyD0rKSsaLUsrwcqD6VHIu8MrYwwxikhcjtnvmnyHPPahtNAc86mGcg5+U1u6ZPjaaz9VhAxIPxqOwl2gDPQ181iqHs5uHToenQq7M9C09l+QDjPpW/FnAJIyTx3JrjdIu13DJbb+ddXFfIqkF5AMYxgCvNasz2KcrouynKsuwkjsT0+tUpNrbRlW9Qp4/Oorm5XPJQL1VMY/MD+tVHuGfk8/7yk4/DjFS1crmQy5061mcnylJ7ncT+VEdtDaodiYPcmntOOpUK2MEkY/rVe4mG0gsAffv/hSd9gstytdSHkHIz096wNRlzu5zWjfT5GOKwrx1VSc9fetII56s7IozkDjOKpu4OccD+dLNKXY+lR9jXQkee3cUmiiigQtaGiQSXeq20MEbSyu4CogyW+grP8ApW14Tgkm1q2EO/zA4K7PvZ7Y96FuDPc7ay1KaGN7izuWkCKm4x8kAYGfX61HNFJbyGOaNonAyVYYOK0Xs9XnxJKojmKgMouACxx1254J9Ky7gSxzOtwHEq8MH6iulO4FoHNPQ4qupqZTxVCLCHnPT1p80YmQhhzUKN0qdGoA4fxP4fS4VjsrzHVNJmtZGyp2g9a+griFZlOea5rVtFjmVhtGTUSjcLHhjKVJBFJXZ6/4caLc8QPr0rj5o2jYqw5FYtNARUDrSmkpAL3p0nFN9DTpPvUwGr1oPU0Dv7UKrHoKaTeiASpYYGkx6VNDb8561oQIqLmu/D4Jyd57GM6ttENtoDB+PtVpThvQUwHjAJx709WyvHPqPSvWjFQVonI23qxS46mj5SeKjI9OKTyyMkGtbiJjjjPQU4jI56CohkDHf3pVJPGKYrDyAOB0pB0xzignIPHSjtQBKuApJFO3ccVEDxgHI70o+6Bk1SJZMuc9hSORzzSL0zz6UMDk8Vbd0SQTHgjqakzkKT7VHMcgqAMUqHKqDnis1uV0JkII6UMRwRTA2Mjt2pxxx2qxDjyOagkHGOcHpxU2eODTS4PHak1cE7FXkN1qThlzmntGG6H86j2FMg8Cs2jS9yOVfMjKHuKxDmKQj0NbjY2k5BrJ1CPbLuHRq8zHwvBS6o6KLs7FyxvthALEHpW3Z6oQpIbDDj1Jrj8mnLK6/dbFeJKCZ3wrOJ2x1TPWZznqSQP/AK9I2o7zgc49ck/ma41bmVehFSJfOp5GankNPrFzr1vQo7/mP51BPfZzkj3xXOf2g3v+FRPeM3GOKn2ZX1jQ1bu9Hr+vSsa4mMhPpUcjFzyabVqNjCc3IXtR2NABwaOwFWZiGlHSkpy9KTGKgyQK9E+GVubHUodQePcYmDbc4yO/NcloWmvdzrkHbkfjXr/hSCHT7q0eUDylcFiRnHvj61rCPURsyW2mg5a7uo93zbZLb58fXOD9ah1S4FxdKVSRESNETzPvMoHBP1q1Jel5prPVrgXUDHidTvMTdmU+nqKg19kN9GI5UlVbeJN6HIOFxWiKIkNSKfeq4PSpVOKZJOjfNip1bkYqopqZTz14oAsqcj3oeNWzxye9RBj+FPz05oGZuo6eskZBXrXlnjLRDbu0qLx34r2fIIwa5/xNpq3Fs4xnIpSVxM8EYYOKb3rT1iye1unQg9eKzK57WAB1p0h5wKRRlgPerRjG7pzWtOm57EuSQ23hLKWNWFiAOaljHlxgcGgnmvVo0Iwir7nPKTbHqeBg/lTw3rzio1+9Tl5JNdaMyRT1wKVjnqeaahx15o6iqJaFB45ODTge/cdqjHSlOQfaqESBic55zT93JzjBqJTxSjp71VxEp2k9xTCCBng0hJxxjijnOPXvTuBJuyOnIpQSOD0pinB6cVKGwe3sDVR3JYm5gxKsCPQ00O+ThRzTmxzkYNMGMgrkeuaG2FhsrkdRgn0p0RYqvXIpjjzJfvcdaep2gDvUq97jexJnjk0ErjryKjJ59P60w7gDmrchJEwkUZpC67qrt83NNdevJwajmY7FoSDOetMkkDdOKq4wep9KdjnHek5MpRHZ7np2qvMgljK9wcipnPGDUcJ5PrWE0paPqWtNTKdSjYNNrSuIQ+emaovAVJwa8fEYSVN6ao6YVFJEZpKVgQeRikrjasai0neiigBaKB1pQpzTsA+Fdxph4JHpViMbR700xM82EGQa1nT5Ypkp6kIGcVq6VpslzIOOM1f0jQpJmVnUgV3OkaSkIGFH0qYwuVcNA0tbeNflFdEqElVRSzEgADqT2FRxoI1xirOnTLFqMLyNsTJG/wDuEggN+BNa2sBK1lGrGOS9t0nHBTDFVPoXAwKpTo0EzxSrskU4Zfetva0d/byM0qPEix/ZlhLFgBgqpHylW65J71j6s6/akRSrGKJI2YHI3AcgHvjp+FK5Q8HmpQelFFMkkBwalU8j6UUUgHqeDTwTRRT6DHA5FNuVDQHNFFAM8w8a2cPzttO4HivO5gA3FFFYVNxDYv8AWp9a0FoorswezMau6JG+7TQcGiivSRkPHSndF4ooq0QPj5HNOxg9aKK0RLExwPeh+BRRVIQL1P0o3HIFFFADlG7r+lL0eiigBxOASOo6VIODkdSKKK0RLGsxCjn3oxkZJPNFFDAFHzGjPX2oooQhRyeaaxyKKKGNDO1KwGRRRSYyMjIH1pmfmooqGWhWHGcmoV+9RRWctxoVwM0zAPBFFFEthogmUY6VWdQDxRRXj10uZnRTY3AowKKK5epqTxRr6U9lAYGiiuqKXKjJ7geM4rb8LQRz3LeYM4xiiiir8I4notpbxRj5VxWqihVGB2zRRWa2NBpqIjpRRQMd9quEhMKzzLEeNgc4/KqxoopAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous plaques are present on the extremities in this patient with erythema elevatum diutinum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17745=[""].join("\n");
var outline_f17_21_17745=null;
var title_f17_21_17746="Signal transduction in T cells";
var content_f17_21_17746=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Signal transduction pathways involved in T cell activation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 593px; background-image: url(data:image/gif;base64,R0lGODlhUQJRAvcAAP///39/f4CAgAAAAMz/zLu7uz8/P7+/v8DAwEBAQADMmTMAAPDw8BAQEKCgoGBgYNDQ0GZ/Zu/v7yAgIODg4DAwMF9fX7CwsC8vL1BQUM/Pz5+fn5CQkN/f33BwcB8fHw8PD09PTwBmMzM/M6+vr5m/mV1dXW9vb4+PjwCqAACIGTOZzABmTL/vvy4uLn+ff4yMjD9PPwAzJhkAAHKPcgCZchcXF7/M/yMjIwsLCwBVAP//ALLfsiYvJqOjo0xfTBlMZgAzGRkfGQ8AAKXPpR8fAAAZEz9m/1FRUQClfB8AAH+Z/0ZGRnR0dACyhZeXlwwAAAYAAAA/Ly8AACYAAAMAAAB/X8/Y/wC/jxYAAFlvWW9vAAYTGe/vAA8PADo6OgBMOQAz/wAmHGlpaSwAAAkAAD8/ABMAAIyvjH9/AAwmMwCMaQwPDABZQil8pe/y/x9M/y9Z/wAMCf8AAG+M/09y/4+l/xZCWRM5TF9//6+//x9ff28AAABEDO8AAAAMBiNpjCkAACZymQBMJg8//9/l/wByVp+y/38AABwAAAAZDAAGAwBQEwB/AAAkDABfLwA1AABdGS+PvwMJDABhBgCBFgBKDwAfDyMAAAB3JgBSKQAmEwAqAABuDAkcJgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABRAlECAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sEYEAhAYXsxYqgABZQUMgNy4smWkAwZEHuDhsufPPykMmFAWwYAEoFOrtnnhdFnRDVbLnt3Sw2SzFQYops27t8gJAyCYlfzAt/HjGVuTNgubAfLn0B8mGMAB7YPb0bNrJ9i6gfOzogdQ/9hOHjoD4JTR2kZdvr1v28vTnqfuvr7s1rrZmg6OEPHj/wAGKOCAAO5m34FhQdAAdmxxMEADwhkkgAEBVGjhhRhmqGGFBqSH4IdbMbAge25dV8F3BAkQgEcBeAjii1UxkNuJcWUwAI0prthRizD2SJWMD6L4FpA4CqQiiy76qKRSEAAHIV0MTPekkTpyxOOSWCal4GgR1nVdA7sduWOSWZb5kwOZFWmXbfSJaSWZZsaZ03WnCXmXAwtm4EGVBL1xA0E3BPrGQFcssYQeBl0p56I4UZAbZ341mRmfA9kRxp8ChWEoHFcAsMQRetyQxxIFKcroqTJxsGADDgDGgI2UCv8ExxJ5DBSGQHoccQUcfZYKJ6rAnvRqmuMJtqdBV8TxBiG2CnRIHUvQoZCpwVZrkqqZ/cqXmwPRYQcAdSAKgKZ0cGrotNpaq65GFEx3Y5eDcStrHEfAUeu4gTpbB7rr9usRA5Jly5i8yQq0bKZ9EoJpIeIORK2/EFOEZ2YJFLuYvN4OFO64BV1RB71HYOpwuhGX3N+jE1xgmbwZPWzyywch4G4DAth5cawYuQzzzjJnNsADNg+M80U671xyz5k9YLFnLOdMstHWIv3z0p81TfTTUKPqgLtTz2a1RUVnjSoDHACXNNWqTbjh2mxb2KHY61LgwYIP1uybfwTm/d+jSRf/CHe1F3A9QatYIkDnaYT/jSoFApg9QAYGlsm42Q14gLbiS15gY2YTCHC5mZr7XIEDQWOOIARz+5yByupO7vMDrJt+IAUc8D0BB59XazjdDTwAr+zZMbC1z71H/rIDm4/mwe/A9yZ88o8nLrbwti/fPG3P+4x46WLTbjvs139GO/QV4B4+Qd4T/wDp5xcGQe3aJ2B++wdRgHz889O/1wUeOB499/obiPAeQDflxS6AcRmf9np3AQAiMGb9014GOMC8B5KFAfzzXwU8YDwLRkSBPpvA+nLnQawghmuZmSAJSxgR/vHNgA5kIVPel4EC3oiDMgSJ/R6gQQ80MIdNoaEN/0XogBUCkV0cqKH2NljEIw4FMUokngqduBIhak+EFKQiTjAoABQ+aIIV1KJKIOAAHmrvNAL4IUvwRqAOhu99Zrzi+sIoRphQwIVnnMAE3SgStW3obeG7YxfPeMMLGLGONIGiDW/0AA7wkSNfC9vOBJmARTYgA4lBJFIoScgKNBIBMZRIJLEWtwt0cZGn8eEhNTkUMnrAi6PBpCEzMkqeOeCVhEylA+jISqiQ8ZSETMAnQymhoQFAkoyCgCkz8MLMNCABHthlL8UiyAz4z5nQdGQoaxksZQqAmbnUYxpXOU2vIMABwAzmA9JYQW6aiQHn7GIzsRnNR5azLfDkwCuvyf85aCYGAu5M5H8U4x97mgUBpnxAJXP5TA9o856BiWcGYDmphCBzJWp724QAyRwEcOCbFE0TJh1gUIgKhgIelecAjBmABFwAAeQsyZF4pKKLTgUCKVUoP0WXAAE4MqYmFZpFz/jMnqYRAbwMyUwhU1NSIgUB8XxlSLE5UpgGNTqRFGYC5nnGCiQAkwIgKShBslQANJUpKE1pFxOw0yt+1adIvap7AgpP/yiUq51MgD/hClViFqSsZ/VJWtWqULbmkpATeOtRgSpX5ARUITj1j1Tbeli96tUD/3EkVPtq1hXRtEJO7UhdNwsgqW71sIctKlhfWtLGIuixFEkrOgVgWsr/oraiAXjmBCqUWMtiVm/AfUxhLUtcVN62snpdJ1+T6tr6bLZYg7VqZy0aWotENp7/Ia5hV3pMEEwqAGf8wHG9e9zynlG7yn3MZsfaXGBNRgDlAwDeekol6t5kqYar0APWa8rgBne9AGZse62lGfmSSCATKBZsY5JRyDzAABwdsEl1g4DVpag49UWITVOSgQ8E4AMZeICHQSzhq75XoQJsgMUW/BIEgEACAJAACF4cYxAwt8RULDAAKhAmDGf4IBs+iQBOMJATEFkgJ6gujktY4POMR0RLY7FLhlzkIwMgyUu+52m2SjgB+PjHiVLySC5AYxmXGQQHzHJ7pdwSAYBg/8QzhnN1pSvf8VDAYgYCaBrVHD42s2TIGwjABiwAYUFjOSKuke9tHjOQAnfxpevkc/P8XEUaW0AJiFCCBWTc2oL8TDEPiDSjBaKZJhHEr5IuGaVXIuITDMEPc/DDED7w5YcEJwMUAKtZjSoZs3Ym1X1mqZhJsjU+zOHYfKi1rQGgV/+Ydb9Q1cyogT1pYedEAMZGtpg1IzOzMjU9mkEeta+3apZA4NWxHkKnDaJjb7ub1AAQ0W7uOG7FlZslD8C0EpS97IEwetoFhgAzm13vv92bJeiUXsGvevCFO3wjDX+4xC0S8YlbPCIVv7jGGZLxjXv8IB3/uMjB7KuRm3wiIf8/+cZTrvKLszyRnI2I8Q7MELytu+WOtfZS3juBG+uY5u1WiKpsgAQTIMEGDagOzuvz8pkUOHAACFwGhGO/LrbKNGE1q0C2dh2BCNylBnmVDWBQgLKXHQY2yACql+41nSulwMjTHAMoMAF49vw8EBBNXDUjd9EAwFEUiJLxHoADEpj98CTAAb/Z/hw/aijCmKFtz0P8mAlAlT2M1rFmLAwAzXDAqPQdyAVsYPjDI94GaWb8c9g4oJvzhMICkd9m4Yl5yGie2buRNrTpDIAJNMH0wG9CfFQf1HZ/UyBz7/aOhTOA72gGs/Hmdt29PhAI5AD42M/BjYmvxaB7wKsVQOn/MytAGfh2RjNR6incwR87B3wB+8D/gsK5317lY0QAJoC/6U0wbPqL0f4XgX/6d3j8538q534DaHbyZ4AnZ30JWHbax4An53sJKHwSeHKjV3rYRwKod4EnR3gaiHg4kAEeeHJiR3aHh3Y50H8lSBhkwwFrxxbXQXRGZwM5MAYF2IJ6oWes81zcEVbfQTYC8DsKcgZnMCV6gX8wYAJMiII5qIN38WiGY3uPMVHOgQAc9ErxNjgXwGMEUQEzsAALMAMVsC35B3xPCIV0YWoC1HkDsTWeJl9l+G5mBQViKIZQwIImkXBbl3U1IYBoqIdq6BW0xW4E0XMDgQDLoVeBYzET/0AFd7gAVDB8OPEARZAGRRBql5iJf3iG+yeIg8gV09ZoBJEAuyEjivEqLhQhFxAFkSiGUZB6E8GDAuGDoudTfoUAXtAFO9AFXrCLvegF21eLAOZ1j9GDMQcRgPiJoUgX4haHAzF9MkI4+iQQmiMQD5AFr7gAWbB4yuhSU9h5VZgAV8hBtfMQArAFO7COW6CO7OhUj6FX/waOkcZzsqgQy0iAoNiMWSFvAkFvOvYAnTGNb8geHIBhj7iNk3gRbIh8brh1ByYi6OiOO9CO61iR1TVqDRlvDwl1yuiJ+tgQtChfUIU2DDCMqodSHzVQKOkTAudVpth5ekV+RlJUCSAc3//3Vc4hGtsohuJBcb9GEO2GiAAQdw8BAcDoi0npBa73boUIjQeJcSBpdmmIEFJYj+OIIjJCcxJ4AQSUAy7ABExodC6AdBnAPmRxAXbYk1Bwjw4xivA2EDEJAGQ0hw5hiZiYARmwid6Ij+WXJKfhVWuXj1SZLhvpHDoGhwKhJ1zpf41jA2PwBPrnA03gAjQTg1EhAGHYkzPQf88olIcoJHN5l2ZgBo9Rmn3pl1tHgnGoiIM5lWVXlRISlKQYjcKxPgDof4roAij4gAXwBF/QAG6ZFQmgBD25AErQmA/hj3+nMgHZGRDgHFAGEQ9QmqdpBqmZEKPGnAApEJ8nldgnm3//BZileE7FkZvc5wA36JvABwM5kJ1VUQGQ2JNUYJcU8ZIEt2U0GXXgN38KgZdFoJd8iXLpgZ8xGZDw6W+wWQDiSRCfWZsIln5bVTkGKAA5IJnsCXyJl6BSMQDH6ZM5oYu8qJQjKow0QZixmS7c6ZwDIZAEgZ6MdwEXmqHwl3i0uRUe+qFBd6IUaZHveKIL2qAEYaCKoZ8uAqNLJyICQKP69wQ50JRLgQBreZxQ8FtNNBPpeJE+ipFAGp77eIEC8H5mBwNkWqYFAAM+UHY+kKY+UKa9yaDK+RCs5190Wqf/lRBSepxTcAYDMAQzMANQ8DOY+RFIWaJLCaVKFaRfKoEN/4ChsWkCLuACTFgAA4ADj8qgkjqpZkcCOSBg/kYhbROqojqqGQJ5LzqlkRgIVTAEZBCJZDAESPgSACqgmMihJoGiDLqoBggBNhCenjgAJvB7k6qp8eef6GhMMFE0HKCNrzgFUXAGx5kF0wcTUVIEmWiJRWCKs2WnrQdgtoiOisqPEOEALuCrZjcAiceg+WcCTECmaRqSFfE1yformrmNMzAEH7oAecgRc/oYpqVXxnVY5GVeBFteMKlXYHWMDxCu4vqWQfqrDNoEw5qpb5qrFIesL1E09fqKVdCqH0oGseEQm7WSw1WwPjOwmfEHf2CtEzABLLtX3Bog/6pdAXtbQf9KfseYjA3LHeWKhhCbeMO6oBYbr0MjAYGGAh0QERuwAQTRAUkrERq7mXdIBWWQr2JYBqcIVbM1UVN1WH+gCIpwCUHQBzqgA4wwCJHQCZTACCLQtiKQCSqgAn2QBmnwGHSrqw0BYCsZjxMQpLcFk4+hWZ7qWvC0rUelEbxqrmU3ALFpA+sqtAtItAfRARgQAAewAR8AZENTIQSxtBMRta84A8yar9Jas8RjWf/BWl0iAEHgtiKgAimQAirwurE7u24LuymgA9YpANZpE7hqAkZlWgR7WXyVZagDHC7wBWMJqThwGvlDEY3qs+dadpz6uBvYqRd7ECHAtAIhARJQJQH/IAGF1gHfSyEwxrkaEL4HcAAAsAEkEAIh8LQBYACbBmT0KrVi+KdWO4anu1dQhZKs67q4O7sDLMCxqwM9BVXq5bsMGzMIJVx6ZbD+RFKDW0IykwNIULGIJwBM0DUUEaZMOoDAG4A4MwAwRhAYwL4HgAEAYAEWcAASYAGeZQHHFAAdAAJMy7kGcAISgAI0fAIrQgIGYL8J8QD4O4aj+6HdOKgS0rq3W7u0K7sGnLt42xG/q2R1BcF41U/r9FJMHEgJYAO/x54kYAKQMhFKGsLY5wNPSsIHsaOD1sI5rCMgMBB1HAAngAHcq8MqPMQgYCE7ekyQUbgg5TNHTLX7i7UQ/+fEbVvABfzEVMwTV8wRWbxWNftWDyVDCoIEIciePoADavIQMuqoalwANnp/OPMBGmAQIKABdVzDcemGAfBmqwzLBtDHnbe+6wtkbdUAFZDEYtix+QqyFQEw0lkzAQzJBAzFkKwDVQxJDcwQOGW4YRVXkOUfEVxZVYVACjLGpcwEofyWM1rKG0pLOBMAIXDCKCAQH6YjeCwQIUACAHAAIVDDrrzKfDzPQ2wA6wwAtVwq2NTFu5GnoYuq27ivFJEAXIAaCt1TjBzFyyzFzfzMEJepywup2jJAuWEEMiAFLPDRHy0FMmAEjISWC0HIE3VYieVQ7CU7FNAA3lzKBQDOEv+zniHsnraKj5uLARBGwwDQASYsEJRrABqgARBG1LC8Aa2czwcwxBIQAhiAAfWcKN5I0JHorMB8h2cwrRIBAVywAlzgAF/NBRnw0I7MzI18wBR9GHnDR/cjAyxQA1igAHRd13atAFhQAywgA9EjEfnURTvVUI6kOAmABDJtejggZrupwZMZnMOJcRjbuT5tEkVj1am6qh4rhq8aqxiHBytwBwPg2aBt1lD8yGkdyUsBMA0gBlYw13f92rCNBVYgBpdpXcvEVYnFTjxDeohHyk/grmaHfyZAymfqHfE6AZBJ3IdHmZZpNxAX2QPxAU9L2dqSo9u4pwMABX86BIJqEQn/sAcrAAgDAN7iTdpSbNpR7MxLoSoyUAOw/d7wrQA1IANJtxHeBE7qNNgQkwFjYHow0LNlF5YmgAO/hwRfAAOVWbEuYKyi/JUCzoRIUJaXZNLPnRNhMwBU8KczMJ93OACzdaUW0QBusAJuMAAjXuLmHdG2e9rqjRQQUAFG4N7xPeOwXQNGUAEt6RC/tFBd9Unq0gDvOqYAXgC8acqMy7ibanpjwJoYQQEKVSA5rozQzRLKOgBRkAWiGwVVkAhiWJ8dMQArEOZgLuYpDtFT3OJGgSdt8NpOUAM1kAR07QROcNdJ8NFrEN9twCojAU/fxE+epN+LwgBInoJDXuRsTORf/yAAQZ6CcSpKa/1XU74SLvMqUcDhXR4FQzAFyckRXh3mbvDVYc4FZY7euIvmROEAcnDnr73XLCAFYKAAH23Xe70GNQAGLBDfayAHDP4vHvUA8wRNIC4SChwgUGUYCGCp/l3oYinGpjwGX2ADheffjR4R0CdkkQ611x5mB/EAZTAFPTkFZXAGncmvahDmglDuYa4Go47W6f3oIoHqcA7bsa4AYqDXt07XSWAEdu3a8J0Eur5GfU5UmISoCDFAwIEDLlB0YxnhzUtEX7wWgt6ehT4GMNDJMz2VMDDtEDGaMhUrNmzDMUwh3UtoPHxM9Atj7gu/MDa+5Ru+83y5GxDy9f9LEA/Tit6up1r+2DKH7uce5iug7lOs4mfu7iBhGvEu7/duBHV+77C+5jRu10mQHwzBODGrNxbDRTwuOj7ExBVWqSbA2P494I9D8GsB5Ml+eEVudv1ddl8Q0wWw5BvB8STBMgNAIZTLvkAMAHoMACSgAXkvxACwwwCAAvXswjAsw8dEw7N8AhsQAuvc9yVXEBNgnPmqBD+5ERdwB2EOCJof5niw7hLN4kT/Lw1gBfHN6jLw6vMO60xP11YgAzJg+u9tBca9EAjgYaTaNh/AR2QURyE0QnKaADlgAovuySaQA3KfFxmA8WAZqU+Q9mXHBDbgAjgAmwse92QvSrFSYBr/gPuEpgEsbMeAHPjsK8t0bMew3MLxPN0jUxAQUAX7uwBV4Ny0BARhDgT2f/+gv+LtDhAABA4kWNDgQYQJFS4U+ECKAogRJSpgAaaGE4gsWES08nDiR5BSHjBEYIDhSYEGEDBkcMFDggExY0544IBCQgYPcpggUcDnT6BBhRYgYSLHAwYolS5l2tTp04IIbPQcWtVqARgNkkItmGAlV5QUHDyYEMDgAIEHMBxgq+GAyYED2LIFYOCAQLQBzAJAixeA3oEbLIC4SzCAgIIOhixg3Nhx4yFRGkAAO1AAkBUrgGDODCSICNAiVKRIoUI0adOhR6fQgbjya6YUBmAEGVGj/8TbELHIqQHRyZraH50MuKmwJOy6X5UiEABT5gCaNglSqODCx1XsQX24qFAc+Xfw4REmQJLdfAEcrmF7FS+wpYcKz/cS7CsBhAaBGux3ACChgwEU8qvrLhJC+OsEgUIgAYADDASMQYFOmE+gwwoSYIbHMmRshhmU0Oq1yzrjTLPPVEPttNJCQ7G19loUyAMwgrNtI9uMkOFGBZKQQowbe5NRIjA8WOg42FSCijnnZKrAgwsgaICJ86IsgIkPXbTyytgaaELKqpioALwKlEMOguaei+6BCf3KDwMDMDCLBDYN6ECCEDDAwMA2DTAAvw7Y1EADPff8a68A4pSgoAoJuv9Qwww5XGCIkSoLUbMRPVNxNdMwvZQ0FrEEr4EkfhR11OCSaGBIuF4zsjIknxsASqB8gAGG656gKigSmjBBAKu89PRXYA9ycksugfJyK+T6eo2BsRqQqYEMOKBMIAHS5Mqu7xIdSDFGHxtCiQXIGABZqCbdLDMSN01RUxNZUy9YriAwglR664XIiGkRIpIgtw7gj0G6OmjroFWRc6kBHISCwQUXYCig4aHGGGNhE6xKD16Mf3USiVuj9AGHCsiFTVmoyIxPSQ/EtMxaqLBFTluBIKiiW8eqCISxITiQlLNzOysRNE3ZBZrTdzNuygEZ7FVaVBkcMC7VgQywoNAN/hr/wKwADAggBAsMKvi7BhwWyoSKHxa7qoV9MsGHtX/Kymi4XaQgARuINa+oAYQUj2SmLiDr2ZpEtpDluAeCWaAJwKVZiSgaU+JLsMyt9GcUMz2x3U4LX0oAGpf2/CMWio4K6pTukqCvvh5cq6CvYZOqKrJ9gtgqE2AdwIW2f7JBZc175wqBBHJA4myhSBCAiQEe8C48vllyIANnY1oy34Wq9d2gwwG4IIopup0iCkwam2JchMgU4AKBEigIgqQcuCOzPd7PDA/Kg758aHevR4nzz/vHTXSC7Ctqd+kACNT0oA/ghyCtA1F5hhI7s/nkCQxzYAGeMBWfDGAoSACg/jyI/xIIeGACt/uCCZBANhfgYAAJ4MDy9haW5z0nWi5kiPU++BcAPqAM3cvQFMpwhseUgXcAaM4FEPAAxPDNA5RBgBoyIwgnZkYNPxuEJXSggz4MohL3W1EHb0itzvnvc6F7mtem9oGq8YVCWpOa14YYubKNrWyzE8oFn/ATDY7Ni1/k40EYgAAHeCBv53tjeChwKoVQgAMnG0ADAvcUG34wewBgQAaiQIXHUCEKQ+BhY7IgOghMgCBJGcAFEhAp6TTxiVFcwRQHsYkBYGBqAbAABgYAiUakBn+Z0x8FLiAAYF7AO0j7SA2kIAUWYMQKN6KRFdZwTCywQAaGyMgaZNAGLP+AQQa9cYI2pRAqiTStjKxDwQEOdUAL+ItghSxXBYMCQToCxY5AyWNQOMgU5gBTn/vkZz/9+U+AsrOP6dPbr4CHEGYx0pHoixzhNHc4BHAAmCOMQhZmkIUoVCERGlJCBgwigILGxWkZcBp7IMCFzLgBpZnhwiJAEIB/EaQDAQCBIx6BuT1ijAEcmAAItKYXA4BgAgJggLwm4gQxOAELYuhNDbCgAClYQQHXxIIhmIoFI2BkAFI9phOSMC+v5mheEsHXOBdYmLhQyKEMZJUNhtIEG9TtYTigIFBcYAOGuSCDQ9kdUwTwU70EVrCDJWxhDUtYA+R0oLKh3pUOOsoYxmT/ocj562Ete1nMZhaorjliLGdZy5gkQAATwKSGqAA5RYmuL8AEAHv4gq4BpHQAITgnQuj0B03sUrHAusAEDLAgg5DAAA24AKgkYog2QGSbCnCCNI2wkeXWIGlT7c0AMkIj6yrACtrMLkRMhSqvobUuAzDJg9YpnrAVS0pv86tDXTTJgVpIfQadr/YeADiGfiefAOWvPxMg2v4GmJ8IyMlLYzqQmYIgAwOgWfOedxZqIca1DXDDCtwwADdIYhJdOwkKFhGEIPThipzYracEAALgJoQEIGhAjGak3IsYATi3ie50l5vd3Fi3DWDQKpBCehABgoWtkkqYes9zsfZiDL7x/yXIBJzmKeCFMHrJy28fWfsdCFSAtgqh0wBuxqgqiIwBDfiKL9VIRAl/JQF7WAEgBrAHT3AYJScYwIB7d2IFLqRPs4mINSHC1BqIASJggG5TbVzd60LEujIAznAiMhwajg45Q65MBWBl5Kv4qimRBNaSmSwQBFTJSgwQwHMS4ADB8fHKsBmznBeCgiqQgVFQ4B0EMlCB/65ktWmmFh5WgIcBcAEDTcFAiXl7H6UU0CMQaYMYwGCE3oCBR8ikrgKkC2MF4Bi7Yr1md0VCEtJdS6BQGfOlMS0U5FUA1UmGl6c/DYAMRKpFnZ1JC99tGWOfpAKuZsgJyjDrcS/kpCvggv8D5NKUA4hacwyYQIpRQoKtRuSpCsiqGINjBYXrK9wtC/hTqGOdc8fKBROY8gM6TkT3tsjdnz7kyZey0xE2cgI/vveqK8OBYTMFAxjK0Bmq/JQEcOHUOQeAwObiLwkoUALmjNqTe8eBVB2dLvrJT54NMABw2kgMUrU4SJIwgIAj4AOa1csJJGTYD7i8KTnZSceKVZSjMCChMpkAB1I9OCXnu4+LBA8EHhA9dZNa7/qzOVgaUBijz2VOSmc6g6rQycbMYPAGIXVOApQWvVwtAGyBiwVcjQKP+q4CKQbqTwcEAA0kcCAHGIAcwNn1UsnB6QuRzT8F6QF+eqABFQBopMH/A7ydXIdLbMuBawdCAd1L9gGNxXu7J//FCujsNQ5I0vLxfW8LPd8gFyD6ATKvF84LxPMLVJxjJI+cCohXTQwyyfj5JcreUcCAiJqPXVKfZ4GAwANyAA7sQbIG2VMKBmgeghKWBtA+11kwHDAB4kEbE1ChDGAn6pOJU0MITiOIK7gBDdTAN1AKOrgCADiChFi5dws130MJmKs3kSm8mkNAgniAy6OP1Ws/fkOBxXiM8xuZg1CWt0CBjSPAjLmAcDOv3/oA9QOAEHAAB2iA5PI/iWiDBpg9hqC+g1iku3MSeTMaZvkbujohsjGhFIKORzoJv6M7omo+gziEJcgDOFiC/yUoBKU4ghsAgDAYQRf0oAcIvaagAAGIngT4uevDvkCstCPkQQAJNw1oHBy8w7SCsLQAARCIQRm8M2shwg/4gNoyHMTIMmhzwhowggpgvoVwMoOAgAEQxYFggApACt9BgP3SJ1ckt9FSPu+4wIK4ARE0iCuogyOwAwB4gzw4giUQCDmkQzsURIUYM7WjgPuKCetLCJJCxgjTQUdkEEiUxLhoFEZcv0lkEEzEgDTqxsKxRSLcgA3AgEzEoYHggAZYLjGSrgaQvs1BrVSMPpaogJCRRqVwAEZSHpRTCFw0iEKAgyt4A1+Mgzmkg2EsxjpECBK8NweAv5NgRskSgBMcCP/jE0QWfAoC5MFvDMdsXET0K8QZRD3VGwgNkMhxrMT6uwv308RR6sOtmzh7wQIrEIMDvDuFWELmewkUfIB8JCJ9JIkkSYAMcK+ALAg7oIOBuII2XEMRZMhjHMqDEC2GoMhGOsOTyEjs20in6MiSvL+CYDCRhA0YrMa3yI+TBADQ8x0hxJ6WFD9XS8KDiCEZYAGn+hEsqAFpGoBodAqe3L6MW4i/K0NApMr1acarAchcJAg3HIgbQEgNBEGpdMht1B9TPEGszMml4MoWhI30Q0u4EMv8UETHOAMp5AoHIDqmMIDUNBr5gwoQQEVKGov4sBFk0giNkAIZMIIBWMV1ewr/3WO+MTvM6nkWnURMgaBIpGxMyIQDgShIQgBBAKDMOWzIg3hI7PNJymtGzmQKz3w3r2yKs3QKG8wQWgObI2SIhEtOeGk4pzgAlRQ4QOInB0AA2hTABAjFqqS5kzA4mdBD5UwIWySIpCyIJYiDI6iD6lTQOFjI65zKAU3FCagyUnOW72yK8Py08WSK1XwKAyi/xkhP5MA5YrtM2IA6p0gszVlCD0g1K2yKC3CVUppQAk259tBO7OutrYjImHhRrmiAixyoDmWKw0O4x8uQKhjSpti3pTgBeuwdhnO4kyCBwQwW4JkAlWEfADDF/MSJPjQT90TMAr0SHcW+BFgi58gA/yZlCCDk0Ms0UZ3jucd4U3JrAH5LCBSYjA+6AGRDiQIyTixhFujJoSi0R1mcMv/UnJd4AGlpqLyz0fVRErVLCDuNryJlCidVCn8zrSiFjVDasoSgkwn4UrjBs5Pok0W1EkVasOhLtQGciTFliTAFuw+CgIj6u7qb1YMoUys503crrpiQx9e4VCJF0VZDCViTtQzpqPaoJAMziATLAF41mhOj0uDSP2B5D5IjqeQEUOkx1ZO40Amo1iBMgAN0Cl99LxT1nUqKiQwgxWQZykxliiwTVdsKgQHIAkb5JBfpLFnSC9CKQCbrrd86COEiLigrkyXpOEaKidd8CsGLLwTAR/9xVRQcFQ9gHShh1VIACDVzXQhjtbJ2paQHiNaCmNYL+DcNESIsiShYDNnCgTmfCqygGiqZxacymbkLMFfZeJaLlVRqUVilWFeVK1m4yYkfRZZ4c51P/UzxANjPsiWCHUDIY4zxyVmhDYtfCqagXbtfggngbNODECTp0doJLa6I7dWMDY+NvaEsa6Sfa7nXeCxBjDnJmjeJEgAOQACSqQARZYzH2VpphAAO+Js07dnKiDlWJNylcJK1tRDAIjvKPSwWRcwlXCEYfdqmsFvsU0y/hDKV5IAbdIyccVwmg4BAgokJiJZKVYgZHQBiRV0QItohEbB9OpkDxN2AQsxm3CP/RP2d+sI+cJVdKBveAWRWxhAXtKXdFvmjw2XdDBAAAmuPvxPUouVdAeudwAQPpdVc58UJmCCzIRFSsPDce/vZmPharuAAAQWAByjdR8nC8NWpiHoJZzkl6m1eFCzVYq1cyxpZEwtK8Mhc/63fUYoP/mSIPDzf4cW+k5lPFym8MVMcD+FfBFYKXJWo/wotJGoSeJE7aizW60nT9nCSRmJfxERhAl4IZXwKV3yAVY0vs6XfCQalBjiDM+BTxGSWBx41V5Sol3COCdDf+8Tg6xHgk1BiLKFb8VBFiEVgFLbhhYjIp3hY8tnRKPaUvyyInbI7zF2wmEAOV3RFfXqA/2Kk//9CIuqtXtRlYpHVH55CYj8S48id0Cl2Cqvs0qUwW+mRxpgg29fYUMT0mymLiTJ2xa71JzT+L0d2FVz7L9zj2zIGFgfQ3gC7Y5SAY4Xg5CvZY+vdYsdluOR5ClPkRwneyeeY3XfbT2Ah5MIVIRqVHkf+L4Dq20R2Y/1JgFkCYMKygB/+SgSbi4JYupRFgQDYgNryZCvJTBdpxtf9NCim4v6VCUFWX+KQRpB65Wjmo1+K11nu5htKgPWMz2BuCmXJmgA4AXAcCBQ4OIE4RxI4ABT4gEbUnwegZuS4Lx4WWlfV2lBb5aUAPH2EAOwND1hGTEDCX1udUHKGjQM4Z6ZI5/+9kIDVAYCx47AOwMSBWOYPemEXiY9yFVoOaCS0DSVTWwoxRlrCNd/6pQA69p2Hfo2IJmG1CgwD0QB0nD8UQJAdvKHmGLX4kOjCRWSwgGKZqNZSO8UMBgtmbmo+munKqOnKoOiSPIEAUZBBSQk9uWf9AekWQWFWHsr4YESkrlGU8NtUhmqleGq2/iCpzg+2OJS5OCcN0IsDSwuibmvDmY8NQJAPYJMP6JoNMJB7dmsrCWorAVBBHqiS5lynQGp93sEZfutOtmzljGsA2IDB5g/NUz0FIYEPyGuqduq+VssO0GmBsA+BQKPDdixM1qfbi207W4gF22tpdhZxprz4QCT/lAgTzEbn4KZKzT69MxMugsAA/GMQ3F5iw/mANgkB/MDqgdDqDrCAQPHpM5vgyfVl784axRqzhqbXFQqPdw1alnZcxB7uwilul+mLwk6LqTGI0uaK9fbq9jDaoz2JUmvugRqh3U4IJGLv9rhvAs8Y9y6MqzmBk+wAOCFt/47jEW4R/c7R3RLvAI+bGYXs6Ttw5vFwQUxwvKAL+iuI+oYKA99uCm9bty2xUpvs+LqvsQbxG0pxGvcUEVfxDvgXAwBJ5rZpIF/xjHnIn41pjHGWxr5xo7FxJbcSzT4BEFBuHWcTDNDu1Yvwy57w/GZx8NDO+DhoPjLFtW7yJG7yP0rk/0vG3ftMZCPvinJGOCy31O8mLCZn2yE3tlKrbD7y2zgnXNr+c0BHiCxm6z/q2gzoYJkYAUVX9BiIAEd/dEiP9BhYdEU3NaMMJl3W4zdnihOHJAGrs+1NbC5fig1oEwklifJGxlJL73vTvDl/9csCwoSW1PtF1wFQdC2IgBcogRJoAQL4dWAPdmEfdmIX9hbg9Rdw9EpvgDTtW/Dc9KXo9Bapc0hicanDvDSSAGTeccM+ddqDDm2uM6jgQ0Avd/5KcnH0IFnP8IHaKZgQgh+ggRLggWKvd3u/d3wnAB4oARr4ASFYITBmiOJ+CmkvcEpUCsFCC7U4gPlWELZAgRAwgP8TSEeYbGtqX9huFjtY3/jASjsU56N1p91Si4EXoPd8P3mUT/lf54EXiAFxX4iBN+dfufhNc6gAEC4r3+yuOYGq6RO2dJOZqhoUwMaKR4n/eusgixtKc1OQHw92/yIH6AEiUHmqr/p8J4IeuGNe5nhgnvmDF/QFCYEY3A/jRgu6DoENCBASIHoKYXUbTXq4WXoJlykS7w+0SrrVbjwEQ2ZlTjy24A9jRj2pS8eQd9yon3qrT3zFB3asv+M0N3d90uTKKN6Xt1aH6ou0pBAOe28AYOcerwsDwFdEcfsJhXujkfssJwjvU5Z3LozMf0mB2OgNOIATCAHvCwDNu4vW32z/Who7mBpLpx9l4BkAkk/2SD/+R991Xud1X1/8YT/25S8B43d0l9/dflrzMm5zuXGVp692S00LuCB7JCyM+VuKt4XqIFu6A8APc/wO9df7BepmIFSWjAZ/AID9m15tr65/+wcIAAIHAhhAkKAHAQcXMmzo8CHEiAMZILggQECGBAkGcBww4uPHGBFGkixpMgbIjx09jhAZAU2JFgRm0pzZogSakShHrEzZ0iTQkjtBrtSY4eIFBAwkMm0KsULHBk6nNhUQwKFBACdQCAxgYSCKEwBIhKAaQCHVtGrXsn2IwMDBDhY+bAAQ4Gpbggc+3P1wYKEBBGuzLsyqAYMEEAIP/xhAAXfhARAo/hIkfDjxQMYNCR+8mPfzVAQcPCRowFJLhBclYtZs7fo1bJo3S7wYqZLNCC00aGgZweZ06tUyYxMvbnN17QgqGyTwwEEw6LUeOmaIvtYqVgMYLEgAkLjDQAkGtGswi9Y6+vRs30J+fBeAhgASDoQwwB3AARIWDJTvsCGAAXXJZUAI5WlmF14EBTbYZgJtBUAIJOAHgmQDjffYAScYMEBdAhH2YISLPVZYQ56plx4DHGwkxA80lMCDcTHKCBsPJP2wEm4/BLVjUDDOaBwPJdDwgxADJMDBUidCdEFHHChZVYIkKnnWk1VauRB7Bx14Vwcg1KUBeCh8Bf+gBBootpcGEnwAZnkafIAfBvkZAN5BC6rFWWUCfYCBAR98tZcEGHTYUAeEEbZnn1/hN+JBeA5k4pVOUYQApQgIwBGLPI6k2mrC/fgpASXwdReppZp6KqqkflACqDPy8EIMA5wX6UAdQUCrQ9g1OOWsuPoKWpZ6uXeCoAJJgEIIfCIokAEHbHnVBvsZtNddBkTJLHRpOeqdYocZeyZcbpZHEAl0ulmrQN5yK+KuCzlQ3a8AUGQRRhr1lJJLmpI0lEodhTQSTMO1OlMJjEZnAKsDz0hEDw7Eu9EE8S6k669USnzxWsFm5h4IawqEAQrzwfUeAM0+e4IF4E37mASO2qn/rZYYFPugQBEeKK5eMo83bkEOclWzhAdKiWUCtIpGmmkfocapwArHNltyt+XmIqgFq4ew0zIy7PCvlz6A8aPX0mox2GUzpTG7CJpZ3gDdbTDyVZgdiIEGBkhY6KLpvllntlRta7aHDSFQ9JMprtjii1krXlOQQxY5Ag1NE2d1eljDNlunyem7KXKxeiAxBANwDTbFA3VAZwd/pYke2YC7zhDah4Eg1nsbgKDBBh/YN7LuGAQNgnZXuWnACdMCTx5gfU/1N+B/I1DBk5fG8IKPi1tPI6wDRODaTTlFgFIPBoO2IUtE+Yvv5vv6VFQCRwmQVJInNkCB2aV3FffMPIPW//rr/QuE9lRIlja1vMxv/stTu9LjgB4Q4XoONA7DVMMb3wBHguLTgLOcdRAMHoBODjFAD3ITHNY8UDbIsQ1PmOMc5eWlVxezH4IC1aENgCcAJLDPYupzHw3UBy83LNBC+HdA1wHQKQLM21oKuLwhBi6B6FlgA0soxdYwbAAsclH1akI5BVmAVHXqIvEeYrkpukpIRDISkpiYFhjeJQQJalZB6hKCL4XpK7c71lhCIIEOfKA7BBGiGsFWxIsp0SnMMxvzBhC/9EjvBZJbHOZOmL4Rdmo4LcheBLIImy1aiDKA+UvLxJgwMrbqVbFyYSAfwkYK8QyOWXnPsZIFlw+c4P8A3QlBFwPgl4MAMpUSG6TECtmUAaSqmMY8JjJTxbwKsNA6hrMi4h55OZzopF8c8Um+NscvnqzEIwAj4Ws4yaxcXguO5/rgKEk5sK35UiJstADOSvaXV14FZCLzDrJAIJ7JOMuPA+llO30FzHgJkykXOShCE6rQhcpqoQ596EIdkoBmqudopWEJ52IipN78RmkjlKb1oIbCAeBGN+kUZ8n46Ulm8clj6FSn09gZUFWKrXaIkWfPltU2ALwNPx87QADK4h0PdgWVM8UVAkaVzKUyNVUfoKjRoIerBFwgXvO6yEYwhThNwpQ4jTsj5G4iPjgypFmJ0R9g0tnVGF3ylCX/gihc4Rq9muJlA4hx5f14qrv9QEhmYtEKnzBAVLsY9aiRokBcE6vYxdIPY4PzFaQk1kiurvVTphxADMa60g7gxZz6xM+gLKTWyrbmJo5D4yIb1VSmHrKFYosUQA0r29kSRACfw1VkfwVF0l6PYWPl03jwkxWy2lUCAAJMCDMKUkhKcjnNeY5EWnunuUostrS10qQUSqnUUiW7Cd3u63JrJQ7AS2K75S1bOyXJkoTvajTw3k7uBZJs6mub7HMf/AyYHumyBYawLex1TwQB8pqGTycolYYwMIAGZIADt2LKgDNQYOIhWDsLbvCDMZaB0UXqsRhrJEgjSZtJUtJTJoSv/zXL9y+T/EB8nxkj99QrJBK7iDaeQw9/9Xsi/17JugEGTYomAAILbACtDMGdBUAwgTQ2JMhDLnJEkKxkJj8MqifyMMYYcCloxvd88yWxfTvSUREybUYoffFoSyhT0DgqdQcY1+kEkjpj/QcFg83pjl/bYwD/OC8UeMAAQpQWsgzgAY0dyJ8DLaFBh6DQh56qldXDgBynx6JJI7OJFdcCGvDkionL2pnzAuMprvkzjgJQUMeEPwFhIAAHyN3Q1MNjK/m4z2oRgGnIudpSWWDBCbmIB3K961P1ugF8Vo8if0XpzzzT05S9XgQwS70HimrYyFwVGdsqKxwHES9xuosMa/82KH+iS0mzrlKtbS2pBPBFqdZ+92rbnQDuPmnZ0ZlAhqs0WXXOJgJsoIHmNsepSsamRiThJklH8AOfFKmbDu+IEAYOzoGZ9oxHondbTo2XNbUxQTvFCnXjlW51SwQCE+CO0NRoVgvgm1b2Bs1Er3Re5qIY4Sr+ySTDfE2cw4Sa37P5zemrKZ2zxCUBM+GIlZPC50Y640G0Fg4DwMpyg9zc1oL3uw1wbJJLhAEnH6DKKcNyjKPH5PHasMwZ6LSNUtCjZZ6iSJW+kh5EYOIPjHuKOdI+pCjF5UG0QAe7Ak+XutSJ6LHUYhN/0IY6tOlcj0gChIrEQJIVABYgXJWwjNv/rX8GxDPadKe3it6Cm/FxkSPtV4t0cWV3+4/QumlQ/fgzBM6WmY8/kQP6uDFfVl5NHL4y5nF72ys1O5qxifb0nj16r2Jy+ZflfHQ07nqBFNcuwFUU7WWbkNurpwKhTXm6xlUm72TQlhsI7WcyeGecDmQDUn2S5o0WfKON5qIfySgN1L78mPbgBfsnQKlZyctF13VdwPxxX15AgGIIC2CAAHhoBrVwyRGZ2l2AzCcdBAjkW0Ud4JU8T9lcVb1shP79X6tE0P8FYJUMYESoIOBQAAsiIEM4gOSBHbN4Rd6k3HvEx3zoUHfkx370x38EiIOMx6JlBfix30CEwO+lB3lZ/9UL6pu0LRcJllbzjZ62QR+bIVuAtRwMdt61HGGzzAkExsmbIUiX0BEAiIldGECZnMmaqEl5SIiaqIyzCJqCrBRh6RsWWscTVknxuYgU8lbFmV4g3l3poRbr7VeAPYCTdKFraYlmHQDgwUUE1kUAEEuHxJKykIzJuMdVZIgBgMA83QVf1Qkejtyt7WF02F4qWRpGfVS2NZfN0Z3dORDeLd0KYUwfMsQuYgwHfI0jtoUMQuIFBgglMorUuZQ9aQYnOosnkgDd4BRhxIkpHoQS6qHExNxRgWBGZNXOfVnOrU9HGAXfVcRFdKN8rVj6EB05vk/fNQ/WKVOAIUDEBCNbKP8gMVbjXhyj661NQbgN3KzL3MSHWATKPBnLBwxW5QlEBmJjvGwfyU1KpXDAYj1Hpbxjd13kAyRARV4kRgbSYk2A+yjWjyWbPa6F9zFgNZYMP/4TtNxO7uyOXfTO7wSPd/BJsszTeBTLSlLf+5mbKoKGbZ2kZAUl92mjPbIiUVJF7vnTEX7GET1lU/TeBywhIxllXhjgUnYNVj6eSdojRG7lVCQA9kllW0Sli02lJ4UAB17lL/2kWFqJeMWl2RHlu8TlVHidopjl65DV2F3JXEZKL+JlRATmVmolUdIjYTqFyaFcWvbPynGhXHZlxj3aYsoaZaqbYSLgYDoiA7DbcaX/krV8wLzRymZWCVJeJmaqJgBQ1VYqJWtCBK65WzzWplMZG2Rl5lqgXWy6pes4gOIF50VYZQNoYDAyYm+WHKANQKsNm4IV2kItZ3Pu2nM+gHFO5gvpZnLWlnbCnK7Zpqlc3kJMmlgO5XZGhJMRmZEthJRNgACQXXpCGUS053sW5cXc5XnmxQSshFSYTQLgYXocwAHGnz0SaH42RISZxngcGKloyIYwmIM1RYIOwIJW2INiGOkM368Y6IE6xXJyRHmBzX9WiYBODDAuJQX0Z4cyhXchFHixRYse1IuaDYcSX2f2pgOsRCOWzYg+SYkeBHKK5VeuKJECQI1eyZAWKVO4/6CtAE6Phkf57RHq/IWbeRIH3dmPEgRsEmVqKumBHql1IF5CTcADJJbjJSdUDEA9+iceRmAAcNaqreEl6p59BABPZsYBJulJBqmXdiiYRocAXN2uaR1BiKlwHiqiyuivTEehuc6Tgh248WQz4lQo6cX81WV5amifnuefCqWeRUTrBCp4jmoxEaqvMInoOGqbkmF5dNw/AV5P4VSXaMn8OUBbBmOnbipeYqq+fSpEhKqv+g8qRt8AWCbGPCp+jIolTl1XXJ3vlEwX0QWtdkZ3Ghav6up23miuBKtDAOtMDSvMwaWItikyDt64kMwNpZQtQcb8uSZeaiu2qhu8MsS5Pf+EtwYUuHaepo5rPuZV9ZGMGi6kpR7E/BDmBJxpvC7lvE6MnpFAANhZQ9zrBt3FokHEY9ZJXIDHCRgIqFarhFaVqvbrsvAUYuiSdugREk7rRCxsO7lrwvZmwcqlntVS7pDbP80KG9mNJHJrjuHJ+eHUxRaVaiJrgAZfriJgWL4sa3ZpnlksgOZh2GzQ3hgLCVBGfowFgUhIVrxNygCAfwBIhwzADe3lX8DRVXxtYwSRx84W0aJHlgKAeeJl3Crt0CJsf/nqAWBAxOLstVziQaRryZAANO5RXRjEBujRXiRrmngMh0CIJV4FXu2FLSUkL62tbLWtdbwtn8bl0dKtI7r/bMgxhFfY7M3WVt+KTULyEYRUbM+EAGXwx7Pk1Hu8R+Q+hsDm6+NhbnS87ZZupWJ6rmqepqd+kL3y7UEc7kKIyYMspEGQVSfmFT0tS+0yyym6kKEGp92uR6Iqj+6CxtuybECBL/C2k/B6oVpI7LdQRgfI4Qfong3CR8+EhXe8yUDK7lXQ7kEeyO26kKgOm6nKpaCu1v8KBFmSKrFh3u8uZrGO72LOrbl9qsD+kfFukCz55V9JgAXwyVUYBAbLTE22WhPNLuTmr+1WL8Oer+XSK7fu7UEAZ6Iq1ujg52IyLQMn5q1aR7126wRHBOU2BV+i8AmnBe5SRQ6zMMYkLV6C/24NL2XnXscKi+4OP0S0TMUPCzH/PrHaRkoRQ7GIgmwDp/ASp1KKAiYWV67pfusVA/FBQABS4HAZSzDYxGwD72sY26P4wu0bl27U4msaN8Qe6XBnUBUClKlDMICxAsB14nFDOOwGkK7QXowLsiZi1rHCkh2gBnBTDfAWA44Q8RhjfGrr8OpSkAboWgpDtKV/ZQgoGvEv3bANU/JW0vDhQRSZQlTf9K8B5zKA9PHTgTLO7mtVed2hmfJCoHKw/s0Q6ytrjjEsc2n2psfmQsT1vjA1KxYLzdoEwvGjWC/SCMZFbORF0I8Lu6cAKM+5JS4XX0yDxeYdN7PrIHHX0DEMYv+zLxOEDAvEBVTArcQcpfwieEEApTATAljmrBkkK8dL777rIbuzpFCKdn1kWsToRcyoO4Hx2bjy49EzIE9EA0AHBVjE5zCAUhLzQRizH99pFl9MO7fsMzP0hBpYhSkYhCYyQ7w0hTWohc10REyyxDDzSWr0QSNyBlSARigFUQ91tpA0QZj0QoTbRseLB8amLDM0Q8Tnem5QtEwZfHKAkKlnlGX1kpFdEyPbQnMfj/WJ7gT1A4vu8fBHOsfLPV9mNFM1QySaHU4FoRnaQdg16zpFXh8yeYpoS9PWJpsxGavxQ1q0YZXvdblwNT+2VeLaAHznsBXbr9mWsGFdsaGSnvr/CjzPcx4/sswi9q9MdXkqNo9Sti4nk3gSxGe222qPqrylVkLjyi8SZWFr82hb8cXIsWry9O11r6+8bWPek2jaEsvlWwJYJVKJK2iTdugGEGo3hE+z5lgflXDjSpbqJQ0OkV9OQPwwtpIEtj3isgBvnXiXCCYz1QAjFUYz8XtfV3bTSpZG3u4d90C0NgA0IdhIpiNOc+I5XnrDzvZKljzjJXkfJR5yUHcELVVw0Hr+aFPeN+V5ku/9T3w/iRIr7YDbGm/25kpnIx7mTtfeaJ2GwAwuBuGkJIUPhAaIX3nMRwZJwM9mrrOs30K6n0AkuH2Ob4f32cFmaxcSLVllBQpI/4iDLpoNhRFPkQXKvo21UG8TDSw+qqSCOOANKhWc4lgFzl4nYeCDLTDG2CoD/3hJnqd/5y6AFjlgdQf7qoyEhABXhBGy4Mct1UVjANVfDewwWrmF2CAEIqPwyAd92EcP6odbo22HJHkTgSEeXmNrDnZ0XCuHT3f/RHVymvaPETllcMhN4YeGiGJOaQabc1afQG4XEctglaj9OLoYUiKrmqGXwEcdrWEbKi4cjsX80iF99HXKQi0hg01nx6uZXxd/Z7qk+xKne4ifCAQ0lgde5U2R85GE4K+DfGHRtHokTmKy3oUlYqKxIMsmdpYz5hUoijoxeYVmGbYAnOjF1Da2Fv87bX32ZWp6gC17645JQVJjVizvX5BF3gpEF7HfHE1rn7e4lBvj5NlFx4zLMgakPD3Ls0vjQFDjHVoj11w3esx1wso72yY70lq6iB/ECYBANHLwdgQKgfC7dtyHduyM5eEk5AbWnuMpIi8gwuPUPi78XfjjTvUULIHLxxDkTR7krvckQz4Yj8eLA7+sx8uWmCfn06vRfFfdl6vFj7J4dztvS/orTO4V72jHB+PPyuukdqBfyur4QPg2VGc4kU79TFV3b8L9EFW9E0WwDxPOhHc3VEZJFYuRhVflUnuxxCx9x4s84AB3bNL9Adm9ldR3WTq4EPu95H/QWs4f46sF2x///lJmvrrFNdc5PoliHncvPBN9d2opfmkTvtMjvtl8eHJqfMs+rcQQ98kZd4VjcJojsopmJ93uZ1Sc5O5bt9sbVgHHdlPp946DZuWDzWiWJkNsvq+Avq5+6ACEaBeG+FHJvi859mNTc2Q3AG0i/7t9AG5KFOv/CqXrao42SYE6N/HT9UNAgHRaW3VeRC1/M0dM52oBBIYBAx5AAHAQYUIAAgQodPgQYkSJCAcwmHgRY0aNGzl2REhh4ECDHkmWNImQw4OTK1m2fAhhgkuZM2nWPMiAwwQQFjZouKhhgwUQEwRYPJgAQUKcOnn6nAhUKFGjEy8ksLkR6VWtWztWGBiT/2tYjB4aijUrc8BZtWtdQuCQocEAAwZOBLAb4MTcAQ0ycBiZMKtDt3Dl0r2LVy9fvxsZpGWbkOxjyTU9DFQ5+WxgzJsjOub8GfRNBAgYlhYweupDzRAZjDbNEHXJCX8fO7gcGjfGCwMd5L5a0Tdoz8GJFz+alO0DDpghVDD+/OBACtBZQmhAXfJw7NslJ7hQO8Nm7dxBJ3BOnmRV9GfHr3d/leFjCtcxr34/WYCH+xvj79fa3r8ATeqPrdkwi0zAxyD4LkGJEuitwZkAjJDCiQhcSznMHAivwg4xM9DDlSpALsQSHUpJMgesmgwmE10Mq7EXS7JPRg8RWJGtxlJjC/+4Gn10CYHzftSIxiEbvHGyChjsbkkjneQIxScvKlLK/YKcLErJLnwSAoaaBOwhEkuiYLrnHiiryoioTPO9CcOaDzP1qhTAOwTOfKg9HEtyAELj1mTzTzbRczMsJSeLUcoWEbLIgwS8i+6gqjL4riEKHKBzOQAgyOBRSw9yYDoH3BotKQcuyCCDMnHrUVCHAm11uwZUZSvLx0B0Mj+HvmNggunSuqACBjxNC4EJEOCVzAooYAApJAHIKgGiSGsoAQ9wug00RWFV6NVtoev2Kjgny/DJLQFAoNEGkkpr0oSIXREpDhJgaF5noUUuvqycDU1ObxEC11/iALbJUMlqHXL/Q4WANSirtFZ79zgBHiCVAnuTCizfpPYFzdxtBw44N3INxnYtbY1kQN2DKLggVwZGBCAtiQ8yCOJnR5vAKAiaA8Dli/GlVmM9P3sUZJuLXq/js8SVTNZEM6jA0WOhfnpdnh+AuqGas3IAakOfptrohYA+V2jObg3446M/yxWzgh/LoE+1fUS06LTlxmzjxw5Wi+27a8zbX7v9fgzwtZZm68rBZdzbW8EVV+twySqIey1WHw9RZJAdv9wsQsV6azKiOffw5aM3H52rpjHTUUv9UO/QcrTFfD2001uCW7LEaW/QZM1n350z0SdTcbLY1U5aQOLVNh74A9E8VHW2HlQc//kAq2/V8+b5fn7cTGkl+XjuIxQe5Oy1N6vfOMFiq/fwQ2yAtvLPB61wW+M/K3q5r7+P7qPNn58rkZuMB1zHlr4Mbn/vqd+2+gfA4mWLPmxJmN8S6J6+FW2BDjzL2dr2JbMIsGgVXE/mQJZBDYrFdi4Bna1+BzIRoqd0RzPhCblCwkMxLywEpKD4EvS/KjGOhmZ5IVcOyBZg7bBD7fvMpV7TRCc+EYoCoNxFhhhEmUzwM0d8TP5CyMMAYRE3CbDAYchYRjOekYwWKNtEbGhFscxQLfB7m/eOVkXs2DEsCTjAVg6wRge10I0BjOBnPAA+sYCxix0iX3n2qJU+coSLgf8Uiw/fNEil4bBVEwjJXigUyaE18iqP3AglJdkSY4VximJxW8AesEkOJQgkAgPlQSRwAFseQAId6MBBOrDHXtoSIRqw5S4VIsqMKLGUW0nhFf3IFSC2ygGbpGOA4PgYPRbzA3fpgF0AIAEMbAAAATAAXj4gAQAYYIzfLGYzw8TOZFLGi5JB2azMYp2jgSQk99vPBcM4SwAcwAAJsYs3wRnOABzEAHtMaDe1Y0zduPOdM+EnZx5QQLVMwIPb8soA1pegIvrmmgk5AAZs6RO7hOCgBwmABQ6wgYCe05cgWCd/4hlRmlTzLPZkSyGPVhmCUCiGuQkpQg6QzQCAMwAgAIH/U8I5zgBggATnHOMHCkpUiCYEjzbtCDLblkqu6BRkuxmAV+9Dysz4E6ACtYAGPuAUbgKABAE1AApw6RCHXgRBWuWKWbmivLVg1H8DoKd/ilWcoR4krQjh5gYwYM63osACMIXIXSeyTL1OhIOcmedODQkr81AIkf0s5ktVmlLGSiAAHzAABkJgzoU+hLJ/vCxXLCuTirLPkt6aqH/yClJ/0iS2EcnsbGfSWwjuSCyABdmCKLTI2v12JsGFCF+JqxGZgZSsWrludcXiSUby8aoU4e5VcKoWrrEFJMgdL01A+FzwaqS96z1JfDeTsrVMTr5aKa/0oCsT6Tpkv/nFCCYx/7Pds/hVwBK1KEjHiEYHP/gwakzItJ74AKJAEZAJVlOGMZPetTRmsMFBQJnIhJHwGi7ECSmxTXBXHCZGEcYxZkjcBOBUCJfRADXVsEM+mpsM6Ngmd4LOAM6TQOpm9SJ8ekh/lEwwDg9JACntSACAvGOE7PYzhV2Llp8zACmKDQCgAoCnACCp7zhGUgahwAMSkAE1O4A0gJlXxRDAJwRw6gEWQcAF2IyvNhtkUwlYjqg4QKownyoDFnGUAOg8ZjZDyFSoSvGAtxVlklDZyhlJX24mkN2rKNc4FXFOxshW5mANq8yJpgDOKADomCCAL897wMQYIIAGeEBU00ERnVodE//QLWjVEMDJs6SVL/2AbtbHio+xGIC7al2LJLoTlKU9gulMXwSsvkGwEF9ZnJgx0WhIapd4M3AmAZzSNgmoGVbL0h+cPM0q/UkL10QFAA5YFGNjgxmYxQaBFd053CdWSGjnJGWFkCAAKDDnQ6x97YkQeHX2PQuIu8yzCpAaSQ97VqFRU0hflVoh/elPBTjQmniXxTHouvDz8h22mLX7NP+2ir4EDpkq+4jaxTzBAVCAAYg03OEbLo6BzXLbUB/k3A1pF/GuS7OFcEhYnVr3lV0nb4swHeWaskhVtMywnxntVAupekMaYBEBLIfmJKmtgHL+EAnIlOE3z3QbQQOSSZP/t+xH51kDGlKsBLDZaljbNwA80LVeV2vqKoNal8rigAn8/eSQApZ5DCKAqYUtX1BLgJoXHx9gVSDPASeJYCttcIVsIARRjXvQLdRZ0BhdLfgN5NovQl9cmT4hQPH56lkfkQCrxTrq3YrjJUl7qtT8RW1/yGsVAvTeK6SBIJ1mcjP6/CUvmE3KP4gGzPl2YjZf7pkeLr86KkTkO7zFsNI+XDGw2qqC3/oQmZ5xOv1hibso0C86ZekvHX4rYzk0iG8t6KRGZkP4EOL3fIO6SmT9MML54i9Szu+vnqwmUIYCBQQBvAzO8Mwo6KQgkq5U/m46LCXO6MTNRExI1A/3MuIB/yEwlp6DAAdQAtEDJBBAZ3RNJXhqQbhmxDakNV4t1n6t+jbjmaSkAS+iBSFw/ELDAu3vAgPEMd4NagAg7w7CWTIAOTbPWehNnwjJ/2TkCCciCeMv/YZuBgfkDLnDMUjO5AbPCuElC0cDR1TuC1HoCX+kxm7MjHIMApfM9ZhQjtSCVzxNQBwDOIhn/iAgce6NZ15tRYStzNLwNw5QSijMNBYtxu7w2qRt6P7wKgSwRBzD8SBPUxzlURzFARjgagzFWSavArqww3KrboawDxHwibwsEzfD7qSnDvNr04qGdWpRIvJQD8mIDzdj1nDr7hwOyX5k24TRIcJQIsbwkpbRJv8aRRjL8Gh6DBqjcQUdsBdpIhk/DNTibwkZiPS6ESKkMSKosRoRpwqtL/pA5rzUcR2/kZaYCv4+YxzXAhuHZDSoKQVNhxCF8Qi9ibT2UbMCURAvDsrCETeKEFY8zB6XDB9DIC9+DiJpIgZL5v6SbyNfLyRlhKcq0iIhgicSyyHcURA/0iwcwLs8pBnLQxOlhCFNEqtWMCj+KSEFaiRloiP9MVhqZCY/A+IEpR5xMuRWcC5WCwROgPdAA2VocSuuhhIjpCg3I9uKpv6UciklQiUVEjRAMTmG0kWyMk4k8UW4zCuvDB95UiN9oysfwyrP8icL7C5LZP7a0i37zzcuIB7/yxIWEwQtQ6cgqwTWrtIe2TEuQSovPcLWlqRiKKQwJeMcBWVe+PIrq+0x2yIdc2cCUsXeCEIxuaMyc2QBZSQxNTMn/TI4HqDbHoMBKqPwBqIBDpM6TnPL1NJEMpM1r8zGitEujtE3mlAXM2CTBiABrDE375ICZAw6o5MhMmDlpNM6nYg5ye83Jww6W6mJalItcmKJknMgOvMqWoNULBETvzM9SxMBjEo441M+57MYPwA8PwQ3tzMh5pI6HHIzkJM8Oeo+bcI1JMZR4mIgmnIu6mI4g/Mu8kJBQ6IBHMXcAtIKe9JDDGBAa6P89DMjntE4rCM7tUIRX+wSqZJAL4VT/wai/caIrg5AH3/uLR3il1BgpVZrIMwDQztEQ7HDOD2UI/YPO/6RSy4lWgaAtY6qri5tRjOilsTpRXo0N3mTL0G0OAbxR1amUQZAtQKABGL0JN6KJcIyRKT0OXYRSD3CJY1jNU1kMHRinJa0JsR0Jcg0QzdULfoxTTkiKKkDVTzEUuACBEIABcDUJuj0JOxUImoJRmnipfqLJcy0ONp0TzkCZQazOPmTmjxAJwjVULcCUU1CUSOiAyyAqmjCMXZ0VDdCUgXGPNuS6KAD1kb0Sm2jAT5g5yYjVEtiVSfrUUnAAgxAA+IqsgBgA0ggBFpLnFBg+0LAAFTPpSzAMQ6qVP8NIARMKpv2KK6ulSNa1TcotVItNSaJo/DegwE2BElR4Pt0tUk1oldh66XEqQM0AATAKQTAiS4koOdw6QN0CQM6QAISCllzyRABYF4BgK2MlaQ6YGA7oJxYFU9R6FX5siS5owKwDzr4rAEwQF1DY1dJ4l3tKl5TaloPaqESK6FQwKnGKfUgZfCCwgDSIrFCoME+AFKXL2K5AlzDlSPQdDvmA0XrjlM/oGNz42M9ImRHq7RclptO9qUSaqVuqQNeq2BPwAJ2SWaf9kXlFCO8FTdkj2dJQk+xAzAxlTNUZCc+dTM+YJPgLlF3FCxHlmlNdo9Q1pYeFmHrgqEg5VkNVmb/dy8AQoCW1vUivHYsOzRsN8Jnt8PyShO9bO2bFi44pDUkBLdO4RYiNAADntKg5lay7FZhV4sEAnacCpat6CJVDQCcTqD9/hViiYNXgjZxI2JssQPwcMNOBoCloGMDNolZLzdKcxY+qLRSF9dHQY9+EgAEAoBwi6MDNkltNyJpA8RwdXEAzHZ22cgTYRd5NWQCiFZysUMguLQlptc/qrc+MDZ7FfczucNltvcTv/f9uOMEBqJYgddF0FcyANNx15d24Tc43nc3T/U9SGAg5pdXMfcsuG8jJCB6IUJ/c6Qc/dcjjHc7XCbRxMLfQOB392MgmhdkFXgrXusEHhgu87Yj/yLYH4l3dmv3gp9mJPxzJlRxecP3PlbLJey0WgOgkcTJAszpWJOVmLY1Rl1qnGgpWEv4A8bIWBm2kQ6ABKqVW1OLhzsAnFBrnMwJioP1t1T4LGaVglfCgrmDA7wMAgbiFYGyAa62QfAihzGUpACAifU2rs7pBPQ1shoWbxHLnO4VANSJBEaKrmAK9Q7iXg82YRnrAHopoJh4pZpqXj/AIbxYLHhl+sLYIyrWPSggARC0PFkiSOI4Qob1jRVCc5d2ee0iLZwWAGjWLmw2IbbJALLplBHitRYKBHRJko01WLMWsQLKbWXqrcaDknOIhdf3R99D3TZJSDtiNjlYbcg0sf+4aQBuSaHqVq62VnIdNqrsIixveY/swkYBwGqx9oTTyjPSYpgnWXhbAowxmSX6FD0aI0CtpSMAMwRA2FvI9O3MSW/navs+N6ACd3CJavfGyPu6aWpVb6Ectl/PKaqe9592L61a9gAEd50Vopi1YirhuSWSGT1uZJmTs5kngoZVT27slLGc9aAkIAQwgLUE+iBYd7XW1QLaD6XYby4Ytv0kq5WL9XTrF6FUN600oClNimTZeWgA2KMxggMG0j/Q00Ivolhaa3DsdOF4IkE22iYat6ldQlNxDpoVx05vGgOgcqvb2SRgDXu/+kMR10WYBQNM2F/Mdz+4eoZv061lwjf//2aNbdhv7PqG1Zokunev3TkwTSSaEPiqRTitxwWqD/skyk1GHmCpXqeo6FOzN5uzU4uwoQRnJFsm5qOt+ScBGot2tqmzV5s+BYIsopNWr+gmRTuejzk3XOaHw1UCLMAsicM6ZJe2NQJLk2iNZ9cCZjs0rCM/g1vTEltArKODExcFkJsz5uOSmXslqoVCrIOxeXYDqPtQDBu7R/t6eacBujtsv7u0uUKAx7smLC9BuNuj1VuzxNu9Z0KG70O+m5q+w5up77sj3tlcGyC6PXq6Y3u07RvAi8u2J64C7tetebt/ZcI6/nvBnXkCrps6xIi2JQz4GkDDLxyxEZwfUVu0/73Jwk8impZbxDM5sp/DAUAAsPf67VicJGzts1scIvIbOqzjZr/6AMDbJVTxMnW8Jc44x89zAgo8uFEgtG2iORJgwo3cJHJiyiXjARx7r0MgxZt7Yqn8If70OS5Axhf87YA7I1SxAdAczFeCV76cJVAGpQGcBJy7JPzuytv8JKwjyV0iAyxXxEMgNkliNkFczyVIyPGmzFv87SLW70j80Fmi8PKcKyYAvd17A+CaNeB7zODCxiPdzxt8QLQcu4lzIjgAQSHAOykd1D9awaHnx907yK/yAjRpkx4A0ltdJtqbMzwAwqncAtSXbMhT2HUdcviuugdAn0X8eQdrzQKUyP+M/TOUGxl/HcwtgGT8zRS33RSlfdpvDXqWvcU7wM69PUQnoMtbQgAAPdJDAM7NvQJBj9VNYgJiXcQPQNPhHXbNI9dJwgF2T9cx4NP1fYDW/CwygMkPfQMGneDH/NbmHb4GYMb1XALat+Gho9kmuCY4gN11PQRC/OKDo9ZXgywgPiEq4NLbfANePCws8TpfHuats88TzNbmzyturd9vQuLNveJN/sYdlLWDXj5N/Te5pgFa6db73QE63thDYOBPgjGxgyWVkgJ8KjkF5wESvtVRIN1XIuqpY+qVUqwCdJUyYgLoGsw1IN+1q12l/t01TADQGBM5bsopwG3typrzXu//957v+97v/37vZ+KXAJ/w/V7cawQEcv7G2x7s3541LwBzC0NBJ5/yK9/yLx/zMz9CZyK1NN/zMT+b2MQAvuQBxIztJ+v7FlkiNAAqHTgsxAmBw/6rjzA1eYTzGZ9J2cT5QmICPOACfN4bp+tRB+Atixqtmw/3J6KQAVv2mzoB5lwhar9ybh9Uk99DSEBoyP40gPIbdXePLICJmyq3sdhZDRacLhqdXGucdClYC8qWNmADdjv9EwKLA0D9mXclHV8zz74zAAKAwIEECxo8iDChwoUDFjo0GCDAw4kII1K8iDGjxokaJhQcADKkyAEZOEDYSFCAxIMDNIToEMLiCYkk/wwAmAlgg80DNjV0AIDCAgALFg5I+GA0xAYAAUCc2BACBQASGghakBhAKFGjEAWg/Ao2rNixZMuObZgQ7VcNEswyNGvRLcG4cuvaFagW78i9ICc8cEBho0qEDQ0YOGARRMQADUG05QkAsgQUITDYtKjBZuQQTFdaCEHiJ0EQA0nTLRjA693VrFu7fg2AAum0BnWK1mzY8FKCh8tmNhyg7Ue4K3mv3LBUZ26BQQXmXj63OOzpF0EEHsg3e8gKHi4wuDiYZeTLEgccOH8AAFrIkDGgkADZIuTxnQdusAAiPfb9p+eqpg5ggAIKiIBmhEFkgFDq4ZVQbwSdJ5xAGlQ1UP8H+gFgIYXzRWVQXmL1p54BP1nU3wcfUFgfRNINyOJABiBAkHYyhpSAACc5FF6H0QFggFQAVIVBejXRN0BbOjF1gkCOMSVVXPrhNBBom6XYVYtWXoklWAUq5GFnIi4I5kGHSYCBVjN98BNwGCwVAAYnhCDUATGFkOR8T3WIXp567slnnlfhKRSJ0pEQVZICgchUUX0uymijjj4K6Z6iPWQABwhcisCMmoLUQEnXHZTjcANZJEFlGHCmwakW7GTTBh8kaFMHlmlAAgZlthVXm4ZF+GNuVSHK1H9ZDktssQRxYOiBqAVwgFBoDbCchQekKaeCAjUrUW8dfJAimgJZ2ND/ASAYgAEIk2K3abohrbigiCS+asBSFmyw7ajsMqVuvvruy++9CFnAr7p+OfBdSv4a61BqCC/MMIuh6rgsjx08+2BE6ZFr4AkYBGBAtvo1FNdhqV4VrmYkcPtRwDKyG+5VWEkHAgkHnHjovYypjHPO+x4Mkc4zcgejwQ1fpPDQRh9918Oi7tgsxQh1vGZkGNTMY3r1xoWmASQwOF+Y2D0Hdthii/0By879SVetEdFJNUTwjg133HLPTXfdYO/2UAATJMB3Aj4PMHDBBimNdJWFH474V4TvFzGPTos5LQj0fkDCBhvzeIKcWB3G8U1FnRBukHImyzhZIK43wMsDzfst/8qIApt4WEXrFXCnHHya0OKJzx57774jpLvX1+qnwUoH0/tjcMVvcB6PFh96Fd4oBNCBRNVHtDXEprNbHArpNc9chO9FduGOv5suLL813jiR0uUTJMGqG5BelwQoUsT7+fr3HnyXbjnYto347yuwG0sB94e/9KWLO97RiNIMVBALSGVIcpmPBuiXN2EhcINI6x9rkDcQ8AmQOKs5IAcXwrsZDQx3DuQehjbAMals6yrsCUGCHkOCVdEqQQLZAKFCIIEYYmhVIfhV2aa1lCB2DIerel+wTghFo3HAWuIp3ABRYkKwZDGKBrEAB2LEl5KwLyxKCxdSjtIBMnkPMj4BSv+gRKQByQFAKZibTJDQ2IGqaIBblpsWZND2xjyizD9cLKSxtkQbK5LwLls0pHOCRrsBVEAAkCxLGelTtUxKhjKWSRFaLNKb+fTmPgYo2bVsMhsAmGYlXcqfI19JIAjiKVK0rGUtr7iRrNiyln+CpUNeRJAJdEdwcrmkKC/2PZu4Bz7kYVB9QombA5zAAj8xJZH4w0rD+XKb1JGNQuwGznCK0zBmUc44wYk3bh7EOtQxZjQ1aZMi5aSZYAJlMp3Dk61NTGqnnOPW5ORJbapzoKzBJUEPaiWD1sWd+IRnTl61qoA+855V26MBQOeceLHRVxIlJEI/6pYJ3A+kJBVQRwD/FLzDubKkLMVIArLX0pi+hgQJQCnPVKpBmepUISndqU8JmNPW9BRpK/2pUS8gS6Mq9SsGuIBNEVjUperUm1Kt6kbY2c6bFi6qVm2pSLsK1oec9Kn742pYQfoAH511rQVBwQMCJICOLWaudK2rXe+K17zqda8GCCpbQeoAzvx1sCFwQIAQIIDEKnaxjG2sYx8L2chKdrKVHCxJGSBPy55VAgMgpmY/C9IKpBO0Ut1ABUiL2o9yQLCpXWoIvtja2G6TApmV7U45y0Lb6haKGRjtbku6gQz8drhQdMDUiMtSDBgWuczV3wSc2FxuHsAj0a1u7ATAWutyMwR+1a53jcWA/wac63eI2at5z4ve9Kp3vezVK3Qf0oEGePa79DXWA6j4O461d7/87a9//duxjVjgrfUtMMJoO97eNZKtC67QAHJr4AhbyQP4VbBWLdtggVjAAxLucJbC+16VXniwGT6AfD2MYivFVX+IKl4AYMoR0tmvYR1I8EJCnJAM9zXFPGbRBHyLOBBxTGa9fFBS+zmQCxorLsh5iFqOjMIR24e6Pa4ydRCwJN/1Z4/wk9m1SBCAI86TmvQJok+WcoAcOqgmRSxIB1bFrEPdMDJq1g+bR6qclcTvohIAjrQ0sJsOSOUEhvln6tjUwwT9pAMw7JGKLiIBEFTWypRmTQayu7sVBf+AfhTUWh8ZDcSZ0adM9OGYIKcCxG3xKkhDkQhOhmRqLhNKAqp+UFvoGDWqbCWI1JtNc7aGR/NUpSFQgQ+3ZmYUb5lvIiEQbqWf3ZrwwjjImmYXmuq1If0YQAM8IUo/49IQOEUEKUk+bmIWA7JsijvM5aueAcqWKvNZhI7ekqYB8hOmcGub2+9ctkNIcGJoC/wuF8hypgsCFYME5QRSOSY+DzCAD+wmPtnsEXoiNB+LmAc9AbU4hCpEuc50LUXy2bZNalWV3qilMNo+T7/tNZFIO3XgNK/LA6BstP5EWj8dALaJHnNcFCTpKOM5CprpCTLB0nogkW4LThz9o4AGQOn/kzrAca8S6Z/QetNtexWbhs7qzDZE6AAgusP9rZAQELjmbC8LAyagVhEbxCWWcZAFkqWb+Nnqnz2RHMWdqTFynctyNpRIqWzFGXALJPAYOJcFLBOTqdS9xrOKCwpQRiYDVCY9bUpSQ/SOAb43FO0IQcEE5tv21KMEAg3A8cK2qOzVCId1ZdUqxMeo+tyjxAEGJ+qF7+Oax7tpgweM9HJ1j3yUPAADvMq5lBnMMzKtPfnUz0gCKtywDIe1gBaoafW/jxEGVAD7r3/+WmFngQqgHvzsRwgFGhD37Mv1v/Svv/3pH+CDoKABEG6//w3CekBmLOV1fwVogAe4V9C1AQ2A/3v/54AA2AAC+IAOsYANOIEXCAABiIEUUYEb6IEDoYEfmBAdKIIfyHrxV4JAwYApKIKsR34baAEryIIiKH4W0HwYGD8V0H8zOIEMkADM94FkkgDrx4MY+AAgMFIOGEfTV4Qp6AADIIHftwEDAFtNyIMI0AA2+H/x0wCTZoUp6IMYkITJlypD+IVnKAAggIK6hwIg0F1nyIIIMAFAlHylMgFeCIdFyABHOG1sRwIg8ABEmIdFeAEN8BJtBxMNMHODyIgAwAAeoIY114YeIIiNaIUIUAGs9mxWVwF4aImDKABZaGMd9mYN8IafOIh7qBg3aGBBBIiViIqMCAEJEIkdtv8BIJAAFhiLuwgACJAAEmdgrpIAnsiLvOgAEwCM3uUqE3B8xeiMB3GMHzA+zDUZH8CMz4iNCuGLijGKqVU9uEiM2SiOCPAAA1AUttU0DxCO4siOsRGKa8KKbCUBlmOKO9iO90gQDkCLFjCGYKUB+JEAzYiPA6kQFOAByIgC3fhT1WONHmCPBAmRBXEBD9AA7qGQLCVoGNAAD7CIEemRD8EADpABA2CROpWRJEEwH6mS4ecAFPkBmUNS0vQBG5mSK2mTGoEABwkCUdGPXKQBlAECwtSRN0mUGkEBItkAO4kCPXk+PxkCINApgFGUUzkWEMABGTAB48Is8Yg0EgBm9zbHAWJElWPpFkfpAX7zKi/GlFlCKxzzAQOQAB4glWRJl3cBAQ4gAAkwASQZE8zDla8BHzBUGQPQADXiALpYl4lpFwyAAHiZAX5DkgkSAGt0kRohLdOzKhgAEgmQAQLgAAgAi4opmq5xKYn1AHzTACEBNjOhV4T2HCFRmAnwAIl1KaNpm0jDmJiCWJNFSboZmrcJnMEpnMNJnMVpnMeJnMmpnMvJnM3pnM8JndEpndNJndVpndeJndmpndvJnd3pnd8JnuEpnjQXEAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The provision of antigen specific, costimulatory, and cytokine signals leads to T cell activation. A number of pathways exist that transduce signals from the surface of the T cell to the nucleus. The end result of signal transduction is the transcription of mRNAs that code for a variety of pro-inflammatory proteins. The numbered steps depict sites at which various immunosuppressive agents act: 1, Cyclosporine; 2, Tacrolimus (FK506); 3, Rapamycin; 4, Corticosteroid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17746=[""].join("\n");
var outline_f17_21_17746=null;
var title_f17_21_17747="Urine sediment with bacteria budding yeast and hyphae";
var content_f17_21_17747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Urine sediment showing bacteria, budding yeast, and hyphae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The background contains budding yeast and hyphae (white arrow), as well as a bacteria (yellow arrows). There is also a broad hyaline cast.&nbsp;(Bright-field microscopy, 3100.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McClatchey KD. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17747=[""].join("\n");
var outline_f17_21_17747=null;
var title_f17_21_17748="Nodular ovarian malignancy";
var content_f17_21_17748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ovarian cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross intraoperative photograph of an enlarged, nodular, malignant ovary.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mitchel Hoffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17748=[""].join("\n");
var outline_f17_21_17748=null;
var title_f17_21_17749="ECG tutorial: Atrioventricular block";
var content_f17_21_17749=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ECG tutorial: Atrioventricular block",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17749/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17749/contributors\">",
"     Jordan M Prutkin, MD, MHS, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17749/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17749/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17749/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17749/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/21/17749/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5185873\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular block may manifest as conduction delay in the atrioventricular (AV) node, intermittent failure of conduction from the atria to the ventricles, or complete AV block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     FIRST DEGREE ATRIOVENTRICULAR BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PR interval (a measure of conduction between the atria and ventricles) includes the P wave (intra-atrial conduction) and the PR segment (conduction within the AV node and His-Purkinje system). First degree AV block, defined as a prolonged PR interval (&gt;0.20 seconds), is not a true block but is rather delayed or slowed AV conduction. The conduction delay is most frequently in the AV node but may also be in the His-Purkinje system (",
"    <a class=\"graphic graphic_waveform graphicRef79990 \" href=\"UTD.htm?8/25/8601\">",
"     waveform 1",
"    </a>",
"    ). First degree AV block may result from the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Underlying structural abnormalities of the node",
"     </li>",
"     <li>",
"      An increase in vagal tone that causes a reduction in the rate of impulse conduction",
"     </li>",
"     <li>",
"      Drugs that impair or slow nodal conduction including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , beta blockers, and non-dihydropyridine calcium channel blocking agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As there is no actual block of conduction between the atrium to the ventricle, it is more appropriate to use the term prolonged AV conduction rather than block.",
"   </p>",
"   <p>",
"    As the PR interval includes the P wave (interatrial conduction) and the PR segment, a prolonged PR interval may also be due to a delay or slowing in intraatrial conduction, (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41574?source=see_link\">",
"     \"First degree atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The PR interval generally varies with the heart rate; in the presence of sinus bradycardia (usually the result of enhanced vagal tone), the PR interval lengthens as conduction through the AV node slows. In contrast, the PR interval becomes shorter during sinus tachycardia, which is the result of enhanced sympathetic tone that enhances conduction through the AV node. At very fast heart rates or in those with AV node disease, however, the PR interval may lengthen due to decremental conduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SECOND DEGREE ATRIOVENTRICULAR BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second degree AV block is defined as an occasional non-conducted P wave, resulting in a long RR interval. Second degree AV block may either be Mobitz type I (Wenckebach) or Mobitz type II.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mobitz type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mobitz type I or Wenckebach second degree AV block is a result of intermittent block of the impulse within the AV node, with subsequent failure to conduct an atrial impulse from the atria to the ventricles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Impaired AV nodal conduction is due to progressive slowing of each subsequent impulse in the AV node due to decremental conduction, until the node finally fails to conduct the impulse because it has arrived at a time when it is absolutely refractory. The result is no conduction to the ventricle and no QRS impulse on the ECG.",
"   </p>",
"   <p>",
"    The ECG correlates of these electrical events include the following (",
"    <a class=\"graphic graphic_waveform graphicRef71453 \" href=\"UTD.htm?41/47/42742\">",
"     waveform 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a progressive lengthening of the PR interval until a normally occurring P wave is not followed by a QRS complex because of failure of the node to conduct the impulse to the ventricle. There is only one non-conducted P wave. Any pattern of block (eg, 2:1, 3:2, 4:3, etc, or a variable pattern) may occur depending upon the AV nodal electrophysiologic properties and the degree of vagal tone.",
"     </li>",
"     <li>",
"      The completely blocked P wave is on time and all PP intervals are equal.",
"     </li>",
"     <li>",
"      The impulse that arrives at the node following the completely blocked beat is conducted normally again because the node has had time to become totally repolarized. Thus, the PR interval after the nonconducted beat is less than the PR interval immediately preceding the nonconducted beat. The PR interval following the pause is the baseline PR interval.",
"     </li>",
"     <li>",
"      The baseline PR interval (ie, the PR interval after each pause) is usually normal duration, but may be prolonged, since both first degree AV block and Mobitz type 1 second degree AV block reflect disease in the AV node.",
"     </li>",
"     <li>",
"      The incremental lengthening of each successive PR interval becomes progressively lessened (eg, 0.20, then 0.26, then 0.30 seconds, etc). The greatest increase in PR interval lengthening is from the first to second conducted beats, and all subsequent conducted beats have a PR interval that increases less quickly. This results in a progressive shortening of successive RR intervals and is one of the causes of grouped beating on the ECG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these features may not be seen in each case of Mobitz type I second degree AV block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mobitz type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mobitz type II second degree AV block is usually indicative of underlying disease of the His-Purkinje system that is characterized by episodic and unpredictable failure of the His-Purkinje pathway to conduct the impulse from the atria to the ventricles. The block occurs below the AV node and within the bundle of His or both bundle branches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to Mobitz type I, there is no change in the PR interval prior to or after the non-conducted P wave (",
"    <a class=\"graphic graphic_waveform graphicRef58649 \" href=\"UTD.htm?33/33/34328\">",
"     waveform 3",
"    </a>",
"    ). This is because the His-Purkinje system is all or none, ie, it either conducts (always at the same rate) or does not conduct an impulse. Mobitz type II has a higher risk of complete heart block than Mobitz type 1 and is usually an indication for a pacemaker, even if asymptomatic. If complete heart block were to develop, the escape rhythm is almost always ventricular and wide complex. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9873007\">",
"    <span class=\"h2\">",
"     2:1 AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;A specific form of second degree AV block is termed 2:1 AV block. In this situation every other P wave is non-conducted, and it is not possible to determine if the block is Mobitz type I or Mobitz II.",
"   </p>",
"   <p>",
"    The etiology can only be established when there are two or more sequentially conducted P waves, and, therefore, two or more PR intervals. This may occur spontaneously or when there are changes in the sinus rate, such as with activity or exercise. If there is progressive lengthening of the PR intervals on the consecutive conducted beats, the etiology of the 2:1 AV block is presumed to be Mobitz type I. If the PR intervals are constant, the etiology is Mobitz type II.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5185959\">",
"    <span class=\"h2\">",
"     High grade AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be more than one successive non-conducted P wave, resulting in several P waves in a row without QRS complexes, termed advanced or high grade AV block. The AV conduction ratio may or may not have a regular pattern (ie, 3:1, 4:1, etc). This is an advanced form of Mobitz type II second degree AV block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5186043\">",
"    <span class=\"h2\">",
"     Variable AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variable AV block is usually used to describe a type of ventricular response to atrial flutter or atrial tachycardia (",
"    <a class=\"graphic graphic_waveform graphicRef74851 \" href=\"UTD.htm?6/45/6872\">",
"     waveform 4",
"    </a>",
"    ). The AV conduction ratio varies between 2:1, 3:1, and higher, ie, there is more than one non-conducted P wave, but there is no reproducible pattern to the AV conduction. The PR interval of the conducted P waves is constant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     THIRD DEGREE ATRIOVENTRICULAR BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Third degree or complete AV block occurs when there is complete failure of the AV node to conduct any impulses from the atria to the ventricles. This presents with AV dissociation (variable PR intervals) and an escape rhythm that is either junctional or ventricular. The atrial rate is faster than the rate of the escape rhythm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    .) This is the result of intrinsic AV nodal disease or disease of the His-Purkinje system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coronary artery disease",
"     </li>",
"     <li>",
"      Drugs that depress or block nodal conduction such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , beta blockers, or non-dihydropyridine calcium channel blockers.",
"     </li>",
"     <li>",
"      Enhanced vagal tone, such as that occurring during sleep.",
"     </li>",
"     <li>",
"      Congenital. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"       \"Congenital third degree (complete) atrioventricular block\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infranodal block occurring within the bundle of His or in both bundle branches. This is usually the result of underlying structural heart disease, such as myocardial infarction, hypertrophy, inflammation, or infiltration. On occasion, it is due to Lev&rsquo;s or Lenegre&rsquo;s disease (fibrosis or fibrocalcification of the conduction system).",
"     </li>",
"     <li>",
"      Infectious, such as Lyme disease",
"     </li>",
"     <li>",
"      Post-cardiac surgery",
"     </li>",
"     <li>",
"      Cardiomyopathy",
"     </li>",
"     <li>",
"      Rheumatologic and autoimmune diseases",
"     </li>",
"     <li>",
"      Infiltrative diseases including amyloidosis and sarcoidosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain types of muscular dystrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The P waves are completely dissociated from the QRS complexes on the ECG, ie, there is AV dissociation (",
"    <a class=\"graphic graphic_waveform graphicRef65545 \" href=\"UTD.htm?12/50/13095\">",
"     waveform 5",
"    </a>",
"    ). Thus, the PR intervals are irregularly variable. The atrial and ventricular rates are both stable; the former is faster than the latter. If there is AV dissociation with an atrial rate that is slower than the ventricular rate, this is not complete heart block but is an accelerated rhythm (either junctional or ventricular).",
"   </p>",
"   <p>",
"    If the complete heart block is the result of AV nodal disease, the dominant pacemaker activating the ventricles is usually located in the lower portion of the AV junction below the block, resulting in a junctional escape rhythm that is usually at a rate between 40 to 60",
"    <span class=\"nowrap\">",
"     beats/minute.",
"    </span>",
"    However, the location of the escape rhythm is established by the morphology of the QRS complexes and not the rate. With a junctional escape rhythm, the QRS complexes are narrow and resemble those of sinus rhythm. However, if there is coexistent disease in the right or left bundle, the QRS complexes of the escape junctional rhythm will be widened, resembling a ventricular complex with a typical right or left bundle branch block configuration, which would also be the QRS morphology seen during sinus rhythm.",
"   </p>",
"   <p>",
"    The dominant pacemaker is within the ventricular myocardium if the block is below the junction within the His-Purkinje system. This results in a ventricular escape rhythm with a wide QRS complex that does not resemble either a typical right or left bundle branch block. Although it usually is associated with a rate that is less than 40",
"    <span class=\"nowrap\">",
"     beats/minute,",
"    </span>",
"    it may be more rapid if there is sympathetic activation. Hence, the diagnosis of a ventricular escape rhythm is based upon the morphology of the QRS complexes and the actual rate is dependent upon sympathetic-parasympathetic balance (",
"    <a class=\"graphic graphic_waveform graphicRef54024 graphicRef51446 \" href=\"UTD.htm?18/10/18602\">",
"     waveform 6A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     VARIABLE ATRIOVENTRICULAR BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced or high grade AV block refers to an AV conduction ratio that varies between 2:1, 3:1, and higher, ie, there is more than one non-conducted P wave. The PR interval of the conducted P waves is constant. This situation commonly occurs in the setting of an increased atrial rate, such as occurs with atrial flutter or atrial tachycardia (",
"    <a class=\"graphic graphic_waveform graphicRef74851 \" href=\"UTD.htm?6/45/6872\">",
"     waveform 4",
"    </a>",
"    ). It can also occur with Mobitz type II. In Mobitz type I there is only one non-conducted P wave.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5186175\">",
"    <span class=\"h1\">",
"     PAROXYSMAL ATRIOVENTRICULAR BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal AV block is an unexpected episode of AV block occurring after a premature atrial or ventricular contraction leading to a prolonged pause and ventricular asystole. It is thought to be due to a diseased His-Purkinje system, where there is an increased rate of spontaneous Phase 4 depolarization. Normally, no ill effect is seen with abnormal Phase 4 depolarization, but when there is a pause following a premature beat, this allows for more time for the cell membrane to become less negative and development of sodium channel inactivation. Subsequent beats are unable to conduct through the His-Purkinje system. Only a properly timed escape or premature beat can reset the membrane potential to normal and allow for resumption of AV conduction. Most frequently, patients have evidence of right or left bundle branch block or intraventricular conduction delay on the baseline electrocardiogram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VENTRICULOPHASIC SINUS ARRHYTHMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A ventriculophasic sinus arrhythmia may be seen whenever there is second or third degree AV block with episodic or permanent failure of antegrade conduction through the AV node. This is manifest as intermittent differences in the PP intervals based upon their relationship to the QRS complex (",
"    <a class=\"graphic graphic_waveform graphicRef75898 \" href=\"UTD.htm?21/56/22407\">",
"     waveform 7",
"    </a>",
"    ). The two P waves surrounding a QRS complex have a relatively shortened interval (ie, occur at a faster rate) when compared to two P waves without an intervening QRS complex. The reason for this change (shortening) in PP interval is not certain. It has been proposed that it is due to baroreceptor activation in the carotid sinus resulting from ventricular contraction on the conducted beats, leading to a shortening of the subsequent PP interval. Another explanation is that ventricular contraction causes both an increase in pulsatile blood flow through the sinus nodal artery and an increased stretch on the sinus node due to ventricular contraction which enhance nodal automaticity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/26/44449?source=see_link\">",
"       \"Patient information: Heart block in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H389426909\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First degree atrioventricular (AV) nodal block, defined as a prolonged PR interval (&gt;0.20 seconds), occurs when there is a prolongation or delay in impulse conduction through the AV node (most common) or His-Purkinje system (",
"      <a class=\"graphic graphic_waveform graphicRef79990 \" href=\"UTD.htm?8/25/8601\">",
"       waveform 1",
"      </a>",
"      ). It is best termed prolonged AV conduction.",
"     </li>",
"     <li>",
"      Second degree AV block, defined as an occasional long RR interval resulting from an occasional non-conducted P wave, may either be Mobitz type I or type II:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mobitz type I (Wenkebach) second degree AV block is usually a result of progressive slowing of AV conduction through the AV node with subsequent failure to conduct one atrial impulse from the atria to the ventricles (",
"      <a class=\"graphic graphic_waveform graphicRef71453 \" href=\"UTD.htm?41/47/42742\">",
"       waveform 2",
"      </a>",
"      ). This is manifest as progressive PR prolongation before the dropped beat. There is only one non-conducted P wave.",
"     </li>",
"     <li>",
"      Mobitz type II second degree AV block is usually indicative of underlying disease of the His-Purkinje conduction system and is characterized by episodic and unpredictable failure of the node to conduct the impulse (or more than one impulse) from the atria to the ventricles (",
"      <a class=\"graphic graphic_waveform graphicRef58649 \" href=\"UTD.htm?33/33/34328\">",
"       waveform 3",
"      </a>",
"      ). The PR interval does not change prior to or after the dropped beats. There may be more than one non-conducted P wave.",
"     </li>",
"     <li>",
"      2:1 AV block is identified by the fact that every other P wave is non-conducted. This may be either Mobitz I or Mobitz II.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Third degree or complete AV block occurs when there is complete failure of the AV node to conduct any impulses from the atria to the ventricles, resulting in an escape rhythm (",
"      <a class=\"graphic graphic_waveform graphicRef65545 \" href=\"UTD.htm?12/50/13095\">",
"       waveform 5",
"      </a>",
"      ). There is AV dissociation (ie, variable PR intervals) and the atrial rate is faster than the ventricular rate. The escape rhythm may be either junctional or ventricular and this is based on the QRS complex morphology and not the rate of the escape rhythm.",
"     </li>",
"     <li>",
"      Paroxysmal AV block is the development of complete heart block and ventricular asystole after a premature atrial or ventricular contraction. A properly timed escape or premature beat is able to reset the rhythm and lead to resumption of AV conduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5185849\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Philip J. Podrid for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2124 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-BD74261493-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17749=[""].join("\n");
var outline_f17_21_17749=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H389426909\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5185873\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      FIRST DEGREE ATRIOVENTRICULAR BLOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SECOND DEGREE ATRIOVENTRICULAR BLOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mobitz type I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9873007\">",
"      2:1 AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5185959\">",
"      High grade AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5186043\">",
"      Variable AV block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      THIRD DEGREE ATRIOVENTRICULAR BLOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VARIABLE ATRIOVENTRICULAR BLOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5186175\">",
"      PAROXYSMAL ATRIOVENTRICULAR BLOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VENTRICULOPHASIC SINUS ARRHYTHMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H389426909\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5185849\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2124\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2124|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/25/8601\" title=\"waveform 1\">",
"      1st degree AV block tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/47/42742\" title=\"waveform 2\">",
"      Mobitz type I second degree atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?33/33/34328\" title=\"waveform 3\">",
"      Mobitz type II second degree atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?6/45/6872\" title=\"waveform 4\">",
"      Variable AV block tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?12/50/13095\" title=\"waveform 5\">",
"      Third degree or complete AV block with narrow QRS escape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/60/29639\" title=\"waveform 6A\">",
"      Ventricular escape tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/52/29509\" title=\"waveform 6B\">",
"      Third degree or complete AV block with wide QRS escape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?21/56/22407\" title=\"waveform 7\">",
"      Ventriculophasic block tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=related_link\">",
"      Congenital third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41574?source=related_link\">",
"      First degree atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/26/44449?source=related_link\">",
"      Patient information: Heart block in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_21_17750="Traumatic hyphema: Epidemiology, anatomy, and pathophysiology";
var content_f17_21_17750=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Traumatic hyphema: Epidemiology, anatomy, and pathophysiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17750/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17750/contributors\">",
"     Christopher M Andreoli, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17750/contributors\">",
"     Matthew F Gardiner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17750/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17750/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17750/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17750/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17750/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17750/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/21/17750/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic hyphema, or blood in the anterior chamber, is a common complication of blunt or penetrating injury to the eye and can result in permanent vision loss. The goals of initial assessment include recognition and characterization of the hyphema and identification of associated orbital and ocular injuries. If ruptured globe is suspected, then emergent consultation with an ophthalmologist is critical to ensure preservation of vision. In addition, optimal outcome following a hyphema depends on early ophthalmologic intervention focused on prevention of rebleeding and avoidance of intraocular hypertension. In most instances, patients recover with vision intact. Vision loss is more likely in patients with large hyphemas, sickle hemoglobinopathy, or bleeding tendency.",
"   </p>",
"   <p>",
"    This review covers the definition, epidemiology and pathophysiology of traumatic hyphema. Diagnosis and treatment are covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link\">",
"     \"Traumatic hyphema: Clinical features and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyphema refers to grossly visible blood in the anterior chamber of the eye (",
"      <a class=\"graphic graphic_picture graphicRef71507 \" href=\"UTD.htm?41/26/42415\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Microhyphema describes dispersed red blood cells in the anterior chamber that do not layer out to form a gross fluid level (",
"      <a class=\"graphic graphic_figure graphicRef60334 \" href=\"UTD.htm?8/13/8405\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of traumatic hyphema has been estimated at 12 injuries per 100,000 population, with males being affected three to five times more frequently than females [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Up to 70 percent of traumatic hyphemas occur in children, with a peak incidence between 10 and 20 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Required use of appropriate ocular protection can significantly decrease the incidence of traumatic eye injury during recreational sports in children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In younger children, traumatic hyphema typically results from blunt trauma to the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. Younger children often report being hit in the eye by a ball in the course of playing baseball, softball, basketball, or soccer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/8\">",
"     8",
"    </a>",
"    ]. Other high risk sports include hockey, racquetball, and squash. The hockey stick or racquet is more likely to be the source of the eye injury than the puck or ball in these instances [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Teenagers and adults are more likely to develop a traumatic hyphema after a high energy blow to the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/4,9-14\">",
"     4,9-14",
"    </a>",
"    ]. Assault is the most common mechanism, occurring in over 40 percent of patients in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/9\">",
"     9",
"    </a>",
"    ]. Other sources of injury include elastic cords (bungee cords), paintballs, airsoft guns, airbag deployment during automobile crashes, and other projectiles [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paintball injuries to the eye result in hyphema in over 80 percent of patients and are more likely to cause serious damage to posterior structures (lens, vitreous, retina, and optic nerve) than other lower velocity projectiles [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Most eye injuries from paintball occur when the participant is not wearing ocular protection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Airsoft guns (guns that mechanically propel BB-sized round plastic bullets at high speeds) have been reported to cause novel \"donut\" erosions in the cornea on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    staining with significant deformation of the anterior segment and hyphema [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traumatic hyphema commonly accompanies penetrating eye injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Common etiologies include BB, pellet, or shot gun blast injury; explosion with shrapnel; and foreign bodies produced by high speed power tools, such as drills or saws [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/5,9,10\">",
"     5,9,10",
"    </a>",
"    ]. Thus, a high incidence of suspicion for globe rupture and intraocular foreign body should be maintained when evaluating a patient with a traumatic hyphema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link&amp;anchor=H6#H6\">",
"     \"Traumatic hyphema: Clinical features and management\", section on 'Globe rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior chamber is anatomically defined as the space bordered by the cornea, iris, angle, and the lens. Clear aqueous humor normally fills this space (",
"    <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The angle of the eye is the recess formed by the irido-corneal juncture. The scleral spur, trabecular meshwork, and Schwalbe's line lie within this angle. The trabecular meshwork is a fenestrated structure that transmits aqueous fluid to Schlemm's canal, from which it drains into the venous system (",
"    <a class=\"graphic graphic_figure graphicRef71234 \" href=\"UTD.htm?10/60/11201\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Blunt trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt force to the eyeball results in an instantaneous increase in intraocular pressure, equatorial stretching of the globe, and posterior pressure being transferred to the iris and its root. The transient rise in pressure results in shear forces acting on the angle structures and can mechanically disrupt the angle (",
"    <a class=\"graphic graphic_figure graphicRef71234 \" href=\"UTD.htm?10/60/11201\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Bleeding results from tears in the vessels of the ciliary body or iris. A grading system has been established based on degree of anterior chamber hemorrhage (",
"    <a class=\"graphic graphic_figure graphicRef60334 \" href=\"UTD.htm?8/13/8405\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/3,19\">",
"     3,19",
"    </a>",
"    ]. More commonly, hyphemas are described according to millimeters in height from the inferior limbus to the top of the blood layer in a sitting patient utilizing a slit lamp.",
"   </p>",
"   <p>",
"    Following blunt eye injury, the bleeding usually stops quickly due to increased intraocular pressure, vessel spasm, and formation of a clot. Maximal clot integrity does not occur until four to seven days after the initial injury. Blood in the anterior chamber is cleared by filtration through the trabecular meshwork (",
"    <a class=\"graphic graphic_figure graphicRef71234 \" href=\"UTD.htm?10/60/11201\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main risk to vision from hyphema primarily depends on degree and duration of elevated intraocular pressure and rebleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Elevated intraocular pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged intraocular hypertension (greater than the upper limit of normal: 22 mmHg) results in optic nerve atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/5,21,22\">",
"     5,21,22",
"    </a>",
"    ]. In normal children and adolescents, pressures up to 50 mmHg can be tolerated for five days without permanent optic nerve damage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, patients with sickle hemoglobinopathy (sickle cell disease or trait) can only withstand intraocular pressure (IOP) of 24 mmHg for 24 hours (Goldberg's rule) before permanent ischemic damage to the optic nerve may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/22\">",
"     22",
"    </a>",
"    ]. Elderly patients and patients with vascular disease also more susceptible to elevated IOP and require expeditious treatment. In addition, patients with traumatic hyphema and sickle hemoglobinopathy are at increased risk of ischemic damage to the retina.",
"   </p>",
"   <p>",
"    The pathophysiology of intraocular pressure abnormalities following traumatic hyphema due to blunt injury are best understood anatomically:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated intraocular pressure and secondary glaucoma occurs when occlusion of the trabecular meshwork by red blood cells, associated inflammatory cells, or cell breakdown products decreases the ability of the eye to filter fluid from the anterior chamber (",
"      <a class=\"graphic graphic_figure graphicRef71234 \" href=\"UTD.htm?10/60/11201\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Angle recession, a separation between the longitudinal and circular fibers of the ciliary muscle, represents physical damage to the fluid drainage system of the eye and is also associated with an elevated risk of traumatic glaucoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link&amp;anchor=H29#H29\">",
"       \"Traumatic hyphema: Clinical features and management\", section on 'Outcomes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Rebleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary hemorrhage typically occurs two to five days after initial injury in patients with hyphema and is correlated with anterior chamber clot retraction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/9\">",
"     9",
"    </a>",
"    ]. Rebleeding predisposes the patient to increased intraocular pressure, secondary glaucoma, and corneal blood staining. Each of these conditions increases the risk of permanent vision loss. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Elevated intraocular pressure'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link&amp;anchor=H4#H4\">",
"     \"Traumatic hyphema: Clinical features and management\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential predisposing factors for secondary hemorrhage in patients with hyphema include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/5,7,23-30\">",
"     5,7,23-30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial hyphema that fills greater than 33 percent of the anterior chamber (Grade II or greater hyphema) (",
"      <a class=\"graphic graphic_figure graphicRef60334 \" href=\"UTD.htm?8/13/8405\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High intraocular pressure at first examination (&gt;22 mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pediatric age group, especially children with poor adherence to limited activity and shield use [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sickle hemoglobinopathy, including sickle cell trait [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      African American race without hemoglobinopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Systemic bleeding dyscrasia including hemophilia, von Willebrand disease, and thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/5,26,27,29,31,32\">",
"       5,26,27,29,31,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antiplatelet and anticoagulant medications, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , coumadin, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/5,7,28,30\">",
"       5,7,28,30",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Ocular hypotonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cyclodialysis cleft is a separation of the meridional muscle of the ciliary body from the scleral spur (",
"    <a class=\"graphic graphic_figure graphicRef71234 \" href=\"UTD.htm?10/60/11201\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/33\">",
"     33",
"    </a>",
"    ]. This creates a new pathway for egress of ocular fluid and hence results in ocular hypotonia with vision loss. Chronic ocular hypotonia may lead to phthisis bulbi, a shrunken eye without function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Penetrating trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyphema occurs frequently as an incidental finding in patients with penetrating trauma to the eye. History and physical examination usually identify those patients who require immediate application of an eye shield and consultation by an ophthalmologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link&amp;anchor=H6#H6\">",
"     \"Traumatic hyphema: Clinical features and management\", section on 'Globe rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Spontaneous hyphema",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition, hyphema can occur spontaneously or with minor trauma in conditions leading to neovascularization of anterior chamber structures or bleeding tendency, such as [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/4,31,32,34-37\">",
"     4,31,32,34-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Iris melanoma, retinoblastoma, and other eye tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/35,38\">",
"       35,38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Juvenile xanthogranuloma [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Clotting disorders (eg, thrombocytopenia, hemophilia, Von Willebrand disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Medications that inhibit platelet function, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"       warfarin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/30,34\">",
"       30,34",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children with no predisposing condition or witnessed trauma, ocular tumors and abuse should be entertained [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17750/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of retinoblastoma\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview summarizes the important clinical features and initial management of traumatic hyphema (",
"    <a class=\"graphic graphic_table graphicRef74146 \" href=\"UTD.htm?28/28/29133\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyphema refers to grossly visible blood in the anterior chamber of the eye. Microhyphema describes dispersed red blood cells in the anterior chamber that do not layer out to form a gross fluid level. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traumatic hyphema typically results from blunt trauma to the eye and is seen most commonly in boys between the ages of 10 and 20 years. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary hemorrhage increases the risk of vision-threatening complications, including intraocular hypertension and corneal blood staining. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Rebleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traumatic hyphema can lead to intraocular hypertension and optic atrophy, resulting in permanent blindness. Risk factors for poor outcome include large initial hyphema, sickle hemoglobinopathy, and bleeding tendency. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyphema in the presence of trivial trauma may warrant evaluation for systemic disease, eye tumor, clotting disorder, or child abuse. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Spontaneous hyphema'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/1\">",
"      Kennedy RH, Brubaker RF. Traumatic hyphema in a defined population. Am J Ophthalmol 1988; 106:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/2\">",
"      Agapitos PJ, Noel LP, Clarke WN. Traumatic hyphema in children. Ophthalmology 1987; 94:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/3\">",
"      Edwards WC, Layden WE. Traumatic hyphema. A report of 184 consecutive cases. Am J Ophthalmol 1973; 75:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/4\">",
"      Walton W, Von Hagen S, Grigorian R, Zarbin M. Management of traumatic hyphema. Surv Ophthalmol 2002; 47:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/5\">",
"      Brandt MT, Haug RH. Traumatic hyphema: a comprehensive review. J Oral Maxillofac Surg 2001; 59:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/6\">",
"      Pashby T. Eye injuries in Canadian amateur hockey. Can J Ophthalmol 1985; 20:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/7\">",
"      Sankar PS, Chen TC, Grosskreutz CL, Pasquale LR. Traumatic hyphema. Int Ophthalmol Clin 2002; 42:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/8\">",
"      Napier SM, Baker RS, Sanford DG, Easterbrook M. Eye injuries in athletics and recreation. Surv Ophthalmol 1996; 41:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/9\">",
"      Rahmani B, Jahadi HR, Rajaeefard A. An analysis of risk for secondary hemorrhage in traumatic hyphema. Ophthalmology 1999; 106:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/10\">",
"      Spoor TC, Kwitko GM, O'Grady JM, Ramocki JM. Traumatic hyphema in an urban population. Am J Ophthalmol 1990; 109:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/11\">",
"      Alfaro DV 3rd, Jablon EP, Rodriguez Fontal M, et al. Fishing-related ocular trauma. Am J Ophthalmol 2005; 139:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/12\">",
"      Motley WW 3rd, Kaufman AH, West CE. Pediatric airbag-associated ocular trauma and endothelial cell loss. J AAPOS 2003; 7:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/13\">",
"      Cavallini GM, Lugli N, Campi L, et al. Bottle-cork injury to the eye: a review of 13 cases. Eur J Ophthalmol 2003; 13:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/14\">",
"      Brouzas D, Charakidas A, Papagiannakopoulos D, Koukoulomatis P. Elastic cord-induced ocular injuries. Injury 2003; 34:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/15\">",
"      Kratz A, Levy J, Cheles D, et al. Airsoft gun-related ocular injuries: novel findings, ballistics investigation, and histopathologic study. Am J Ophthalmol 2010; 149:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/16\">",
"      Thach AB, Ward TP, Hollifield RD, et al. Ocular injuries from paintball pellets. Ophthalmology 1999; 106:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/17\">",
"      Farr, AK, Fekrat, S. Eye injuries associated with paintball guns. Int Ophthalmol 1998-1999; 22:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/18\">",
"      Alliman KJ, Smiddy WE, Banta J, et al. Ocular trauma and visual outcome secondary to paintball projectiles. Am J Ophthalmol 2009; 147:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/19\">",
"      Read JE, Goldberg MF. Blunt ocular trauma and hyphema. Int Ophthalmol Clin 1974; 14:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/20\">",
"      HORVEN I. ERYTHROCYTE RESORPTION FROM THE ANTERIOR CHAMBER OF THE HUMAN EYE. Acta Ophthalmol (Copenh) 1963; 41:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/21\">",
"      Read, J, Goldberg, MF. Comparison of medical treatment for traumatic hyphema. Trans Am Acad Ophthalmol Otolaryngol 1974; 78:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/22\">",
"      Cohen SB, Fletcher ME, Goldberg MF, Jednock NJ. Diagnosis and management of ocular complications of sickle hemoglobinopathies: Part V. Ophthalmic Surg 1986; 17:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/23\">",
"      Fong LP. Secondary hemorrhage in traumatic hyphema. Predictive factors for selective prophylaxis. Ophthalmology 1994; 101:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/24\">",
"      Lai JC, Fekrat S, Barr&oacute;n Y, Goldberg MF. Traumatic hyphema in children: risk factors for complications. Arch Ophthalmol 2001; 119:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/25\">",
"      Nasrullah A, Kerr NC. Sickle cell trait as a risk factor for secondary hemorrhage in children with traumatic hyphema. Am J Ophthalmol 1997; 123:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/26\">",
"      Hallet C, Willoughby C, Shafiq A, et al. Pitfalls in the management of a child with mild haemophilia A and a traumatic hyphaema. Haemophilia 2000; 6:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/27\">",
"      Morsman CD, Holmes J. Traumatic hyphaema in a haemophiliac. Br J Ophthalmol 1990; 74:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/28\">",
"      Crawford JS, Lewandowski RL, Chan W. The effect of aspirin on rebleeding in traumatic hyphema. Am J Ophthalmol 1975; 80:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/29\">",
"      Ackerman J, Goldstein M, Kanarek I. Spontaneous massive vitreous hemorrhage secondary to thrombocytopenia. Ophthalmic Surg 1980; 11:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/30\">",
"      Koehler MP, Sholiton DB. Spontaneous hyphema resulting from warfarin. Ann Ophthalmol 1983; 15:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/31\">",
"      Lifshitz T, Yermiahu T, Biedner B, Yassur Y. Traumatic total hyphema in a patient with severe hemophilia. J Pediatr Ophthalmol Strabismus 1986; 23:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/32\">",
"      McDonald CJ, Raafat A, Mills MJ, Rumble JA. Medical and surgical management of spontaneous hyphaema secondary to immune thrombocytopenia. Br J Ophthalmol 1989; 73:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/33\">",
"      Aminlari A, Callahan CE. Medical, laser, and surgical management of inadvertent cyclodialysis cleft with hypotony. Arch Ophthalmol 2004; 122:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/34\">",
"      Kageler WV, Moake JL, Garcia CA. Spontaneous hyphema associated with ingestion of aspirin and ethanol. Am J Ophthalmol 1976; 82:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/35\">",
"      Arentsen JJ, Green WR. Melanoma of the iris: report of 72 cases treated surgically. Ophthalmic Surg 1975; 6:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/36\">",
"      Blanksma LJ, Hooijmans JM. Vascular tufts of the pupillary border causing a spontaneous hyphaema. Ophthalmologica 1979; 178:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/37\">",
"      Bruner WE, Stark WJ, Green WR. Presumed juvenile xanthogranuloma of the iris and ciliary body in an adult. Arch Ophthalmol 1982; 100:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/38\">",
"      Shields CL, Ghassemi F, Tuncer S, et al. Clinical spectrum of diffuse infiltrating retinoblastoma in 34 consecutive eyes. Ophthalmology 2008; 115:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17750/abstract/39\">",
"      Calzada JI, Kerr NC. Traumatic hyphemas in children secondary to corporal punishment with a belt. Am J Ophthalmol 2003; 135:719.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6570 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17750=[""].join("\n");
var outline_f17_21_17750=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Blunt trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Elevated intraocular pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Rebleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Ocular hypotonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Penetrating trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Spontaneous hyphema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6570\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6570|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/13/8405\" title=\"figure 1\">",
"      Hyphema grading table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/6/2150\" title=\"figure 2\">",
"      Cross section of the eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/60/11201\" title=\"figure 3\">",
"      Angle anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6570|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/26/42415\" title=\"picture 1\">",
"      Hyphema grade IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6570|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/28/29133\" title=\"table 1\">",
"      Hyphema rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_21_17751="Mefloquine: Drug information";
var content_f17_21_17751=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mefloquine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/38/31333?source=see_link\">",
"    see \"Mefloquine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/1/1047?source=see_link\">",
"    see \"Mefloquine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Mefloquine&reg;;",
"     </li>",
"     <li>",
"      Lariam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F192267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimalarial Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F192231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Malaria:",
"     </b>",
"     Oral (dose expressed as mg of mefloquine hydrochloride):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Mild-to-moderate, treatment:",
"     </i>",
"     1250 mg (5 tablets) as a single dose.",
"     <b>",
"      Note:",
"     </b>",
"     If clinical improvement is not seen within 48-72 hours, an alternative therapy should be used for retreatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Uncomplicated, treatment (unlabeled dose):",
"     </i>",
"     750 mg (3 tablets) as initial dose, followed 6-12 hours later by 500 mg (2 tablets) (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Uncomplicated, chloroquine-resistant P. vivax malaria treatment (unlabeled use):",
"     </i>",
"     750 mg (3 tablets) as initial dose, followed 6-12 hours later by 500 mg (2 tablets) with concomitant primaquine (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Chemoprophylaxis:",
"     </i>",
"     250 mg weekly starting 1 week (CDC, 2012: &ge;2 weeks) before arrival in endemic area, continuing weekly during travel and for 4 weeks after leaving endemic area.",
"     <b>",
"      Note:",
"     </b>",
"     Prophylaxis may begin 2-3 weeks prior to travel to ensure tolerance.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F192251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/1/1047?source=see_link\">",
"      see \"Mefloquine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Malaria:",
"     </b>",
"     Children &ge;6 months: Oral (dose expressed as mg of mefloquine hydrochloride):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Mild-to-moderate, treatment:",
"     </i>",
"     20-25 mg/kg/day in 2 divided doses, taken 6-8 hours apart (maximum total dose: 1250 mg).",
"     <b>",
"      Note:",
"     </b>",
"     If clinical improvement is not seen within 48-72 hours, an alternative therapy should be used for retreatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Uncomplicated, treatment (unlabeled dose):",
"     </i>",
"     15 mg/kg, followed 6-12 hours later by 10 mg/kg/dose (maximum total dose: 1250 mg) (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Uncomplicated, chloroquine-resistant P. vivax malaria treatment (unlabeled use):",
"     </i>",
"     15 mg/kg, followed 6-12 hours later by 10 mg/kg/dose (maximum total dose: 1250 mg) with concomitant primaquine (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Chemoprophylaxis:",
"     </i>",
"     5 mg/kg/dose once weekly (maximum dose: 250 mg) starting 1 week (CDC, 2012: &ge;2 weeks) before arrival in endemic area, continuing weekly during travel and for 4 weeks after leaving endemic area.",
"     <b>",
"      Note:",
"     </b>",
"     Prophylaxis may begin 2-3 weeks prior to travel to ensure tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20-30 kg:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of 250 mg tablet (125 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     30-45 kg:",
"     <sup>",
"      3",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     of 250 mg tablet (187.5 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;45 kg: One tablet (250 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unlabeled dosing (CDC, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;9 kg: 5 mg/kg/dose once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10-19 kg:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     of 250 mg tablet (62.5 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20-30 kg:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of 250 mg tablet (125 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     31-45 kg:",
"     <sup>",
"      3",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     of 250 mg tablet (187.5 mg) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;46 kg: One tablet (250 mg) once weekly",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F192232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F192233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary; only a small amount of mefloquine is renally eliminated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F192234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; however, half-life may be prolonged and plasma levels may be higher in patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 250 mg [equivalent to mefloquine base 228 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088616.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088616.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F192206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food and with at least 8 oz of water. When used for malaria prophylaxis, dose should be taken once weekly on the same day each week. If vomiting occurs within 30 minutes after the dose, an additional full dose should be given; if it occurs  within 30-60 minutes after dose, an additional half-dose should be given. Tablets may be crushed and suspended in a small amount of water, milk, or another beverage for persons unable to swallow tablets.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F192204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild-to-moderate acute malarial infections (including treatment of chloroquine-resistant malaria) and prevention of malaria caused by",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     or",
"     <i>",
"      P. vivax",
"     </i>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to geographical resistance and cross-resistance, consult current CDC guidelines.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13376663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of uncomplicated, chloroquine-resistant",
"     <i>",
"      P. vivax",
"     </i>",
"     malaria",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F192265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fatigue, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (3%), abdominal pain, appetite decreased, diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal dreams, abnormal T waves, ataxia, aggressive behavior, agitation, anxiety, arrhythmia, arthralgia, AV block, cardiac arrest (with concomitant use of propranolol), chest pain, conduction abnormalities (transient), confusion, depression, diaphoresis increased, dyspepsia, dyspnea, edema, encephalopathy, erythema, erythema multiforme, exanthema, flushing, forgetfulness, hallucinations, hearing impairment, hematocrit decreased, hyper-/hypotension, insomnia, irregular pulse, leukocytosis, leukopenia, liver function tests increased, loss of balance, malaise, mood changes, muscle cramps/weakness, palpitation, panic attacks, paranoia, paresthesia, pneumonitis (allergic etiology), psychosis, QT prolongation, restlessness, somnolence, Stevens-Johnson syndrome, suicidal ideation and behavior (causal relationship not established), tachycardia, thrombocytopenia, tremor, urticaria, vertigo, visual disturbances",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F192209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mefloquine, related compounds (eg, quinine and quinidine), or any component of the formulation; prophylactic use in patients with a history of seizures or psychiatric disorder (including active or recent history of depression, generalized anxiety disorder, psychosis, or schizophrenia)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F192191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agranulocytosis/aplastic anemia: Agranulocytosis and aplastic anemia have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Dizziness, loss of balance, and other CNS disorders (eg, seizures) have been reported; due to long half-life, effects may persist after mefloquine is discontinued. Use caution in activities requiring alertness and fine motor coordination (eg, driving, piloting planes, operating machinery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions ranging from mild skin reactions to anaphylaxis have occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric effects: May cause a range of psychiatric symptoms (anxiety, paranoia, depression, hallucinations and psychosis). Occasionally, symptoms have been reported to persist long after mefloquine has been discontinued. Suicidal ideation and suicide have been reported rarely (no causal relationship established). The appearance of psychiatric symptoms such as acute anxiety, depression, restlessness or confusion may be considered a prodrome to more serious events. Discontinue if unexplained neuropsychiatric disturbances occur. Use with caution in patients with a previous history of depression; prophylactic use is contraindicated in patients with active or recent history of psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with significant cardiac disease; ECG changes have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; elimination may be prolonged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     infections: Appropriate use:  In cases of life-threatening, serious, or overwhelming malaria infections due to",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     , patients should be treated with intravenous antimalarial drug. Mefloquine may be given orally to complete the course.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <i>",
"      Plasmodium vivax",
"     </i>",
"     infections: Appropriate use: In cases of acute",
"     <i>",
"      Plasmodium vivax",
"     </i>",
"     infection treated with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (eg, primaquine) to avoid relapse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: When using for treatment, use with caution in patients with a history of seizures; increase risk of seizures. Prophylactic use is contraindicated in patients with seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chloroquine: Concurrent use with chloroquine may increase risk of seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ketoconazole: Concurrent use with mefloquine is not recommended due to increased risk of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation; do not administer within 15 weeks of the last dose of mefloquine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Quinine derivatives: Concurrent use with quinidine or quinine may increase risk of ECG abnormalities and seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Early vomiting leading to treatment failure in children has been reported in some studies; consider alternate therapy if a second dose is not tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not recommended for the treatment of malaria acquired in Southeast Asia due to drug resistance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged use: If mefloquine is to be used for a prolonged period, liver function tests and ophthalmic examinations should be performed periodically.  (Retinal abnormalities have not been observed with mefloquine in humans; however, abnormalities have been reported with long-term administration to rats.)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F192262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F192196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of Aminoquinolines (Antimalarial). Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants: Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.  Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: Mefloquine may enhance the QTc-prolonging effect of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of quinidine when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of QuiNINE. Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of quinine when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F192224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Food increases bioavailability by ~40%. Management: Take with food and at least 8 oz of water. Maintain adequate nutrition and hydration, unless instructed to restrict fluid intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Mefloquine serum concentration may be decreased by St John's wort. Management: Avoid concurrent use.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F192212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mefloquine crosses the placenta and is teratogenic in animals. Malaria infection in pregnant women may be more severe than in nonpregnant women. Clinical experience with mefloquine has not shown teratogenic or embryotoxic effects in humans; use with caution during pregnancy if travel to endemic areas cannot be postponed. Nonpregnant women of childbearing potential are advised to use contraception and avoid pregnancy during malaria prophylaxis and for 3 months thereafter. In case of an unplanned pregnancy, treatment with mefloquine is not considered a reason for pregnancy termination. CDC treatment guidelines are available for the use of mefloquine in the treatment of malaria during pregnancy (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F192238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F192213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted in small quantities (~3% to 4% of a 250 mg dose); effect to nursing infant is unknown. Breast-feeding is not recommended during therapy and the long half-life of mefloquine should also be considered once therapy is complete.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F192214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food and with at least 8 oz of water.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mefloquine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (25): $264.74",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F192200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When use is prolonged, periodic liver function tests and ocular examinations",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Lariam (AE, AT, AU, BE, BF, BG, BH, BJ, CH, CI, CN, CY, CZ, DE, DK, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, HU, IE, IL, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, NO, OM, PE, PH, PL, PT, QA, RU, SA, SC, SD, SE, SL, SN, SY, TN, TR, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Laricam (JP);",
"     </li>",
"     <li>",
"      Larimef (IN);",
"     </li>",
"     <li>",
"      Mefliam (ZA);",
"     </li>",
"     <li>",
"      Mephaquin (BB, BM, BR, BS, BZ, CH, CR, EC, GT, GY, HK, HN, IL, JM, NI, PE, PT, SG, SR, SV, TT);",
"     </li>",
"     <li>",
"      Mequin (TH);",
"     </li>",
"     <li>",
"      Suton (TW);",
"     </li>",
"     <li>",
"      Tropicur (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F192190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mefloquine is a quinoline-methanol compound structurally similar to quinine; mefloquine's effectiveness in the treatment and prophylaxis of malaria is due to the destruction of the asexual blood forms of the malarial pathogens that affect humans,",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     ,",
"     <i>",
"      P. vivax",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F192208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~20 L/kg; blood, urine, CSF, tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to 2,8-bis-trifluoromethyl-4-quinoline carboxylic acid (inactive) and other metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Increased by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~3 weeks (range: 2-4 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~17 hours (range: 6-24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily bile and feces; urine (9% of total dose as unchanged drug, 4% of total dose as primary metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention,",
"      <i>",
"       CDC Health Information for International Travel 2012",
"      </i>",
"      . New York: Oxford University Press; 2012.",
"      <a href=\"file://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm\" target=\"_blank\">",
"       file://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, September 23, 2011. Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-15).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Malaria (Guidelines for Clinicians).&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horowitz H and Carbonaro CA, &ldquo;Inhibition of the",
"      <i>",
"       Salmonella",
"      </i>",
"      Typhi Oral Vaccine Strain, Ty21a, by Mefloquine and Chloroquine,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1992, 166(6):1462-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/21/17751/abstract-text/1431270/pubmed\" id=\"1431270\" target=\"_blank\">",
"        1431270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Panisko DM and Keystone JS, &ldquo;Treatment of Malaria - 1990,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1990, 39(2):160-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/21/17751/abstract-text/2183998/pubmed\" id=\"2183998\" target=\"_blank\">",
"        2183998",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White NJ, &ldquo;The Treatment of Malaria,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(11):800-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/21/17751/abstract-text/8703186/pubmed\" id=\"8703186\" target=\"_blank\">",
"        8703186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyler DJ, &ldquo;Malaria Chemoprophylaxis for the Traveler,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(1):31-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/21/17751/abstract-text/8505942/pubmed\" id=\"8505942\" target=\"_blank\">",
"        8505942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9602 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.102.30.19-B980F37D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17751=[""].join("\n");
var outline_f17_21_17751=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192228\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192267\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192231\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192251\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192232\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192233\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192234\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192203\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192187\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874703\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192206\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192204\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376663\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192265\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192209\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192191\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192262\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192196\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192224\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192198\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192212\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192238\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192213\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192214\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323363\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192200\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038673\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192190\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192208\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9602\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9602|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/38/31333?source=related_link\">",
"      Mefloquine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/1/1047?source=related_link\">",
"      Mefloquine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_21_17752="Diagnosis and management of intranasal foreign bodies";
var content_f17_21_17752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and management of intranasal foreign bodies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17752/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17752/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17752/contributors\">",
"     Aderonke Ojo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17752/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17752/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17752/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17752/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/21/17752/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4708033\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intranasal foreign bodies (FBs) occur most commonly in young children and consist of a variety of inorganic and organic objects. In most instances, the patient is asymptomatic. The majority of intranasal FBs are removed at initial presentation and do not require referral to an otolaryngologist. Button batteries and paired disc magnets can cause serious damage to nasal structures and merit urgent removal.",
"   </p>",
"   <p>",
"    The diagnosis and management of intranasal FBs is presented here. FBs of the outer ear, airway, and digestive tract are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28504?source=see_link\">",
"       \"Diagnosis and management of foreign bodies of the outer ear\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"       \"Airway foreign bodies in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35399?source=see_link\">",
"       \"Airway foreign bodies in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link\">",
"       \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21353?source=see_link\">",
"       \"Ingested foreign bodies and food impactions in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39654?source=see_link\">",
"       \"Rectal foreign bodies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373855773\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;More foreign bodies (FBs) are retrieved from the nose than from all other aero-digestive tract sites combined [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/1\">",
"     1",
"    </a>",
"    ]. Intranasal FBs typically present in toddlers and preschoolers and less often in older children, adolescents, and adults with intellectual or behavioral disabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/2\">",
"     2",
"    </a>",
"    ]. FBs are more frequently located on the right side due to the predominance of right-handed children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A wide variety of foreign bodies find their way into the nose including inorganic items, such as pearls and beads, pins, nails, screws, paper, stones, rubber, small toys, crayons, and chalk [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] and food items, such as beans, carrots, seeds, meat, apples, candy, and chewing gum [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/1,3,5,6\">",
"     1,3,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two types of FB deserve special mention because of their potential for damage to nasal structures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Button batteries",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Button batteries are found in many devices including toys, hearing aids, and household electronics. Once in the nose, they cause destruction because of strong electrical currents (rather than leakage of battery contents). Electrolysis at the negative battery pole generates hydroxide ions that cause alkaline tissue necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/7\">",
"       7",
"      </a>",
"      ]. If the negative pole is directed toward the nasal septum, this can result in septal perforation in under four hours (",
"      <a class=\"graphic graphic_picture graphicRef86432 \" href=\"UTD.htm?6/40/6791\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Paired disc magnets",
"      </strong>",
"      &ndash; Strong, one centimeter diameter, round disc magnets are used to attach some types of jewelry (eg, metal earrings and nose rings) and are popular in adolescents and young adults [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Instances have been described in which the magnets, one in each nostril, attach to each other high in the nasal septum and cannot be manually removed (",
"      <a class=\"graphic graphic_picture graphicRef86437 \" href=\"UTD.htm?22/41/23199\">",
"       picture 2",
"      </a>",
"      ). Prolonged attachment can cause perforation from chronic compression of the nasal septum [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Unlike disc batteries, this tissue damage occurs over a period of weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13572452\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal foreign bodies are most commonly located on the floor of the nasal passage just under the inferior turbinate or superiorly in the nasal cavity just in front of the middle turbinate (",
"    <a class=\"graphic graphic_figure graphicRef86435 \" href=\"UTD.htm?38/34/39459\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4708018\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal foreign bodies (FBs) are rare in normal healthy older children and adults. Relative frequencies of clinical findings in younger children and intellectually disabled patients with nasal FBs are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of nasal FB insertion without symptoms (71 to 88 percent)",
"     </li>",
"     <li>",
"      Mucopurulent nasal discharge (17 to 24 percent)",
"     </li>",
"     <li>",
"      Foul odor (9 percent)",
"     </li>",
"     <li>",
"      Epistaxis (3 to 6 percent)",
"     </li>",
"     <li>",
"      Nasal obstruction (1 to 3 percent)",
"     </li>",
"     <li>",
"      Mouth breathing (2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most FBs are inorganic (eg, pearls, beads, or small toys) and relatively asymptomatic. These more often come to attention because of parental concern although up to 25 percent of nasal foreign bodies are unsuspected by the caregiver [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unilateral purulent and foul-smelling nasal discharge in a young child strongly suggests the presence of a porous nasal FB such as paper or foam rubber or organic matter (eg, carrot, meat, or other food material) (",
"    <a class=\"graphic graphic_picture graphicRef86433 \" href=\"UTD.htm?13/47/14064\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/15\">",
"     15",
"    </a>",
"    ]. These objects produce local inflammatory reactions or become secondarily infected also leading to sneezing, epistaxis, nasal obstruction, foul-smelling nasal discharge, and facial pain from sinusitis.",
"   </p>",
"   <p>",
"    Button battery FBs may also produce a purulent nasal discharge and epistaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/16\">",
"     16",
"    </a>",
"    ]. In patients with associated tissue necrosis, the discharge may have a black color [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/17\">",
"     17",
"    </a>",
"    ]. Facial swelling with pain and fever may also occur and be mistaken for periorbital cellulitis or sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinician should carefully examine both nostrils and ears in patients with a nasal FB to ensure that no other objects are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13572187\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visualization of the foreign body (FB) establishes the diagnosis. In most children, this can be accomplished with the use of a headlight or otoscope after suctioning of purulent secretions (",
"    <a class=\"graphic graphic_picture graphicRef86438 \" href=\"UTD.htm?34/45/35542\">",
"     picture 4",
"    </a>",
"    ); however, some FBs that are located high in the nasal vault or posterior nasal cavity may elude detection with an otoscope or headlight. Thin or transparent FBs are also sometimes hard to find. In these patients, rigid or flexible fiberoptic endoscopy may be necessary to identify the FB [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most nasal FBs are radiolucent. Thus, plain radiographs are",
"    <strong>",
"     not",
"    </strong>",
"    routinely needed or helpful when the FB is clearly visualized on physical examination and the presence of a button battery or magnet is excluded.",
"   </p>",
"   <p>",
"    However, plain radiographs can establish the presence of button batteries or magnets within the nasal cavity when suspected. These studies are suggested when the type of FB is not obvious on physical examination or is associated with significant epistaxis, black nasal discharge, pain, or facial swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/9,20\">",
"     9,20",
"    </a>",
"    ]. Unsuspected FBs (either radio-opaque or encrusted in calcium salts) may also present as incidental findings on sinus radiographs or computed tomography performed for symptoms of clinical sinusitis or periorbital cellulitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86434 \" href=\"UTD.htm?37/30/38370\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/18,21\">",
"     18,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4708244\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, visualization of a nasal foreign body (FB) during physical examination or the presence of foul-smelling unilateral discharge makes the distinction of nasal FB from other entities associated with",
"    <strong>",
"     bilateral",
"    </strong>",
"    nasal discharge, such as sinusitis, upper respiratory tract infection, or allergic rhinitis straight forward. Occasionally, a child with bilateral nasal discharge may have placed FBs in both nasal cavities without the caregiver&rsquo;s knowledge [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, all patients with nasal discharge warrant careful examination of the nasal cavity to exclude a foreign body before other treatments (eg, antibiotics for sinusitis or allergy medications for allergic rhinitis) are prescribed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H7#H7\">",
"     \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22281?source=see_link&amp;anchor=H565532995#H565532995\">",
"     \"The common cold in children: Clinical features and diagnosis\", section on 'Nasal manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link&amp;anchor=H897856#H897856\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373855780\">",
"    <span class=\"h1\">",
"     FOREIGN BODY REMOVAL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373855853\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Button batteries in the nasal cavity and magnets that are attached across the nasal septum warrant urgent removal. Otherwise, nasal foreign body (FB) extraction is an elective procedure. Concern for migration of an inert nasal FB through the nasopharynx followed by aspiration into the trachea is not warranted in a normal healthy patient with intact airway reflexes. The estimated risk for this complication is less than 6 in 10,000 cases. In addition, there are no reports of bronchial FBs spontaneously arising from nasal FBs in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, aspiration of a nasal FB has occurred during attempts at removal and the risk is likely increased when extraction is attempted by inexperienced clinicians or under circumstances in which appropriate instruments or personnel to ensure adequate restraint are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373855860\">",
"    <span class=\"h2\">",
"     Indications for subspecialty consultation or referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with nasal foreign bodies (FBs), referral to an otolaryngologist is not necessary. As an example, in one case series of 60 children, 98 percent of nasal FBs were successfully removed by pediatric emergency clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, medical specialty is less important than experience, availability of proper equipment and restraint, and knowledge of which FBs are likely to require special skills for extraction.",
"   </p>",
"   <p>",
"    Otolaryngology referral is warranted for the following FBs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Posterior FBs (ie, not readily visualized by anterior rhinoscopy)",
"     </li>",
"     <li>",
"      Chronic or impacted FBs associated with marked inflammation, especially button batteries which warrant urgent removal",
"     </li>",
"     <li>",
"      Penetrating or hooked FBs",
"     </li>",
"     <li>",
"      Any FB that cannot be removed at initial attempt due to poor cooperation, bleeding, or limited instrumentation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373855867\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most nasal foreign bodies (FBs) can be removed using positive pressure techniques or direct instrumentation in the primary care office or emergency department. The procedure that is used is determined by the nature and location of the FB. Although success has been reported with nasal irrigation of the nasal passage",
"    <strong>",
"     not",
"    </strong>",
"    containing the foreign body, we do",
"    <strong>",
"     not",
"    </strong>",
"    advocate this technique given the theoretical potential for aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13572783\">",
"    <span class=\"h3\">",
"     Positive pressure techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon small case series and expert opinion, we suggest that patients with soft or smooth nasal foreign bodies (FBs) that totally occlude the anterior nasal cavity undergo removal using positive pressure techniques rather than instrumentation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/25,29-32\">",
"     25,29-32",
"    </a>",
"    ]. Having the patient blow his or her nose while occluding the nostril opposite of the FB (",
"    <a class=\"graphic graphic_picture graphicRef86445 \" href=\"UTD.htm?17/29/17879\">",
"     picture 5",
"    </a>",
"    ) is the easiest method and is frequently successful [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/29\">",
"     29",
"    </a>",
"    ]. However, this technique is only applicable to cooperative patients who are generally older than three years of age.",
"   </p>",
"   <p>",
"    Oral positive pressure by the parent while occluding the unaffected nostril has been described in case reports and small case series of children with nasal FBs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. In a systematic review of 152 children undergoing the technique, successful foreign body removal occurred in 60 percent with no reported complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/33\">",
"     33",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Visibility and time since insertion may be important factors in determining successful removal. As an example, mouth-to-mouth blowing by the parent (&ldquo;parent&rsquo;s kiss&rdquo;) successfully removed 15 of 19 nasal FBs with no complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/30\">",
"     30",
"    </a>",
"    ]. In this study, which was not included in the systematic review mentioned above, all FBs were visible with anterior rhinoscopy, and the median time since insertion was four hours (range one hour to two weeks). The children were allowed to sit or stand, depending upon their preference. The unaffected side of the nose was occluded and the parents were instructed to firmly seal their mouth over the child's mouth and give a short, sharp puff of air into the child's mouth.",
"   </p>",
"   <p>",
"    Children typically tolerate this procedure well without restraint. If the parent is unwilling or unable to perform this procedure, then the approach can be approximated using a bag-valve-mask, although patient cooperation is unlikely and restraint will probably be necessary.",
"   </p>",
"   <p>",
"    If removal by positive pressure techniques is unsuccessful, the clinician may proceed to instrumentation as described below. (See",
"    <a class=\"local\" href=\"#H13572790\">",
"     'Instrumentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nasal positive pressure is another method that has been described in small case series with evidence of barotrauma reported in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, in our opinion, the potential for excess application of pressure to the nasopharynx is high, and we do not advocate this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13572790\">",
"    <span class=\"h3\">",
"     Instrumentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon case series and expert opinion, we suggest that patients with nonocclusive foreign bodies in the anterior portion of the nose undergo removal by instrumentation rather than positive pressure techniques. Instrumentation permits intranasal foreign body (FB) removal under direct visualization and examination of the nasal cavity after extraction. Adequate restraint, appropriate illumination, and proper equipment are essential to success. [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/24,25,30\">",
"     24,25,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Instrumentation can be painful and warrants topical anesthesia (eg, a solution of 1 part",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    with 1 part 4 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) with proper attention to maximum weight-based dosing. Nasal drops should not be used on patients with lodged button batteries [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In young children and other uncooperative patients procedural sedation may be needed for successful FB removal. If procedural sedation is performed, special caution is advised given the proximity of the nasal FB to the airway when using medications that can blunt airway and respiratory reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25658?source=see_link\">",
"     \"Selection of medications for pediatric procedural sedation outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When safe removal of a nasal FB is doubtful based upon the setting or patient factors, removal in the operating room under general anesthesia with airway protection is advised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913011\">",
"    <span class=\"h4\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following equipment should be available:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sheet for wrapping or an immobilization device (",
"      <a class=\"graphic graphic_picture graphicRef86352 \" href=\"UTD.htm?27/24/28032\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Topical anesthesia and vasoconstrictor nose drops (eg, one part, 4 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      without epinephrine, mixed with one part",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"       oxymetazoline",
"      </a>",
"      nasal spray, maximum dose 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [0.1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 2 percent lidocaine solution]) (",
"      <a class=\"graphic graphic_picture graphicRef86450 \" href=\"UTD.htm?0/45/727\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Otoscope with an operating head (allows instrumentation under direct visualization)",
"     </li>",
"     <li>",
"      Nasal speculum",
"     </li>",
"     <li>",
"      Headlight or lamps (",
"      <a class=\"graphic graphic_picture graphicRef86450 \" href=\"UTD.htm?0/45/727\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Right angle hook, wire loop or curette (",
"      <a class=\"graphic graphic_picture graphicRef86450 \" href=\"UTD.htm?0/45/727\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lucae or Gruenwald nasal dressing forceps (",
"      <a class=\"graphic graphic_picture graphicRef86450 \" href=\"UTD.htm?0/45/727\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Alligator or Hartmann forceps (",
"      <a class=\"graphic graphic_picture graphicRef86450 \" href=\"UTD.htm?0/45/727\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Schuknecht foreign body remover (",
"      <a class=\"graphic graphic_picture graphicRef86356 \" href=\"UTD.htm?0/11/179\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Suction apparatus, including catheters of various sizes",
"     </li>",
"     <li>",
"      Irrigating devices",
"     </li>",
"     <li>",
"      5 to 8 French Fogarty, Foley, or Katz catheter",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913022\">",
"    <span class=\"h4\">",
"     Techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steps for removing an intranasal foreign body (FB) include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/14,15,25,30\">",
"     14,15,25,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately five minutes prior to the procedure, instill topical anesthetic and a topical vasoconstrictor into the nose (eg, one part, 4 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      without epinephrine] mixed with one part",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"       oxymetazoline",
"      </a>",
"      nasal spray, maximum dose 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [0.1",
"      <span class=\"nowrap\">",
"       mL/kg]).",
"      </span>",
"     </li>",
"     <li>",
"      For uncooperative patients, ensure proper restraint of the patient (",
"      <a class=\"graphic graphic_picture graphicRef86352 \" href=\"UTD.htm?27/24/28032\">",
"       picture 6",
"      </a>",
"      ) and, if needed, procedural sedation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"       \"Procedural sedation in children outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the patient is cooperative and the FB is readily seen in the anterior nasal cavity, use the nondominant hand to push the tip of the nose up with the patient sitting upright (",
"      <a class=\"graphic graphic_picture graphicRef86488 \" href=\"UTD.htm?22/22/22881\">",
"       picture 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For deeper FBs, insert a nasal speculum as shown in the figure (",
"      <a class=\"graphic graphic_figure graphicRef86489 \" href=\"UTD.htm?41/9/42143\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Remove the FB using specific instruments, depending upon the type of FB, as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Extract non-occlusive compressible objects such as foam rubber or ones with rough surfaces with alligator, Lucae, or Gruenwald nasal dressing forceps (",
"      <a class=\"graphic graphic_figure graphicRef86490 \" href=\"UTD.htm?32/37/33362\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Avoid using forceps for smooth objects that cannot be easily grasped. Unsuccessful attempts at removal will push the object deeper into the nasal cavity (",
"      <a class=\"graphic graphic_figure graphicRef86496 \" href=\"UTD.htm?15/12/15555\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Remove smooth objects or others that cannot be easily grasped using a blunt right-angle hook (bead, stones or other small objects) (",
"      <a class=\"graphic graphic_figure graphicRef86491 \" href=\"UTD.htm?20/4/20546\">",
"       figure 5",
"      </a>",
"      ). Remove smooth, round, solid objects (eg, a marble or bead) with balloon catheters (Fogarty of Foley). Lubricate the catheter (5 to 8 French Foley or Fogarty balloon catheter) with 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      jelly, or if anesthetic drops have already been applied, water soluble lubricating jelly and advance the uninflated catheter past the object. Inflate the balloon with 2 to 3 mL of air, and withdraw the catheter and the FB (",
"      <a class=\"graphic graphic_figure graphicRef86492 \" href=\"UTD.htm?32/14/32995\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Alternatively, use a metal suction catheter with a plastic umbrella at the tip (Schuknecht catheter) to remove smooth, round, solid objects (",
"      <a class=\"graphic graphic_picture graphicRef86356 \" href=\"UTD.htm?0/11/179\">",
"       picture 8",
"      </a>",
"      ). Place the plastic umbrella against the FB. Turn on the suction to 100 to 140 mmHg, and remove the FB [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cyanoacrylate glue also may be used to remove a FB from the nose. Apply a thin coat of cyanoacrylate glue to the cut end of a hollow plastic swab. Press the swab against the FB for 60 seconds and then remove the swab with the attached FB [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/38\">",
"       38",
"      </a>",
"      ]. The patient must remain still until the glue dries. Because of the time necessary, this technique is most appropriate for cooperative older children, adolescents, and adults.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25823583\">",
"    <span class=\"h3\">",
"     Magnet removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;When two round disc magnets used to attach some types of jewelry (eg, metal earrings and nose rings) are placed in each nostril, they may attach to each other high in the nasal septum (",
"    <a class=\"graphic graphic_picture graphicRef86437 \" href=\"UTD.htm?22/41/23199\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. In most instances, these can be removed by grasping one magnetic with a mosquito hemostat and pulling it away from the other magnet.",
"   </p>",
"   <p>",
"    Occasionally, because of the strength of the magnets, removal using forceps may not work because the magnetic attraction to the instruments may not exceed the force of attraction between the intranasal magnets [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. This problem can be overcome in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sequentially apply a pocket magnet pickup (available at automobile parts stores) to the impacted nasal magnets (",
"      <a class=\"graphic graphic_picture graphicRef86493 \" href=\"UTD.htm?13/36/13903\">",
"       picture 10",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Magnetize two instruments (eg, two Lucae or Gruenwald nasal dressing forceps) using two separate magnets (eg, cardiac pacemaker magnets) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/12\">",
"       12",
"      </a>",
"      ] and apply them simultaneously to the intranasal magnets.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13570906\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications may occur as a result of the nature of the foreign body (FB) such assize, shape and content; length of time the FB has been lodged; or as a result of removal attempts. The most serious complications can occur with intranasal button batteries; septal perforation with saddle nose deformity, nasal meatal stenosis, inferior turbinate necrosis, and collapse of the alar cartilage have all been described [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/16,18,39\">",
"     16,18,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Instrumentation of the nose may cause trauma to the nasal cavity with brief epistaxis that is typically controlled with direct pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17752/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26536?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of epistaxis in children\", section on 'Direct compression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic FBs of the nose may occlude the inferior or middle meatus and predispose the patient to infection, primarily sinusitis. Findings of sinusitis include fever for three or more consecutive days with ill appearance, and purulent nasal discharge or daytime cough and nasal discharge for 10 or more days. The treatment of sinusitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H7#H7\">",
"     \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=see_link\">",
"     \"Acute bacterial rhinosinusitis in children: Microbiology and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topic (see",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?1/38/1634?source=see_link\">",
"     \"Patient information: Removing objects stuck up the nose (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414473\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intranasal FBs most commonly occur in young children and are most commonly located on the floor of the nasal passage just under the inferior turbinate or superiorly in the nasal cavity just in front of the middle turbinate (",
"      <a class=\"graphic graphic_figure graphicRef86435 \" href=\"UTD.htm?38/34/39459\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H373855773\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13572452\">",
"       'Relevant anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most FBs are inorganic (eg, pearls, beads, or small toys) and relatively asymptomatic. Unilateral purulent and foul-smelling nasal discharge in a young child strongly suggests the presence of a porous nasal FB such as paper or foam rubber or organic matter (eg, carrot, meat, or other food material) (",
"      <a class=\"graphic graphic_picture graphicRef86433 \" href=\"UTD.htm?13/47/14064\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4708018\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intranasal button batteries are associated with purulent nasal discharge that is sometimes black in color, epistaxis, and facial pain with swelling and have significant potential for damage to nasal structures. (See",
"      <a class=\"local\" href=\"#H4708018\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Visualization of the FB establishes the diagnosis. The clinician should carefully examine both nostrils and ears in patients with a nasal FB to ensure that no other objects are present. Plain radiographs can establish the presence of button batteries or magnets within the nasal cavity when suspected but are not necessary for the diagnosis of other types of intranasal FBs. (See",
"      <a class=\"local\" href=\"#H13572187\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Button batteries in the nasal cavity and magnets that are attached across the nasal septum warrant urgent removal. Otherwise, nasal FB extraction is an elective procedure. (See",
"      <a class=\"local\" href=\"#H373855853\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with intranasal FBs, referral to an otolaryngologist is not necessary. Potential indications for referral to a specialist include posterior, impacted, or penetrating FBs and those that cannot be removed at the initial attempt due to poor cooperation, bleeding, or limited instrumentation. When safe removal of a nasal FB is doubtful based upon the setting or patient factors, removal in the operating room under general anesthesia with airway protection is advised. (See",
"      <a class=\"local\" href=\"#H373855860\">",
"       'Indications for subspecialty consultation or referral'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13572790\">",
"       'Instrumentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with soft or smooth nasal foreign bodies (FBs) that totally occlude the anterior nasal cavity undergo removal using positive pressure techniques rather than instrumentation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These techniques are described in the topic. (See",
"      <a class=\"local\" href=\"#H13572783\">",
"       'Positive pressure techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with nonocclusive foreign bodies in the anterior portion of the nose undergo removal by instrumentation rather than positive pressure techniques (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Instrumentation can be painful and warrants topical anesthesia and, in some patients, procedural sedation. Proper restraint is essential to success. The choice of instrument depends upon the type of foreign body as discussed in the topic. (See",
"      <a class=\"local\" href=\"#H13572790\">",
"       'Instrumentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14913022\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Successful removal of magnets that are adherent across the nasal septum (",
"      <a class=\"graphic graphic_picture graphicRef86437 \" href=\"UTD.htm?22/41/23199\">",
"       picture 2",
"      </a>",
"      ) may be accomplished using a mosquito hemostat to grasp and pull the magnets apart. A pocket magnet pickup (",
"      <a class=\"graphic graphic_picture graphicRef86493 \" href=\"UTD.htm?13/36/13903\">",
"       picture 10",
"      </a>",
"      ) or magnetized instruments may be used in difficult cases. (See",
"      <a class=\"local\" href=\"#H25823583\">",
"       'Magnet removal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/1\">",
"      Chinski A, Foltra F, Gregori D, et al.. Foreign bodies in children: A comparison between Argentina and Europe. Int J Pediatr Otorhinolaryngol 2012; [Epub ahead of print].",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/2\">",
"      Fran&ccedil;ois M, Hamrioui R, Narcy P. Nasal foreign bodies in children. Eur Arch Otorhinolaryngol 1998; 255:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/3\">",
"      Claudet I, Salanne S, Debuisson C, et al. [Nasal foreign body in infants]. Arch Pediatr 2009; 16:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/4\">",
"      Chinski A, Foltran F, Gregori D, et al. Nasal foreign bodies: the experience of the Buenos Aires pediatric otolaryngology clinic. Pediatr Int 2011; 53:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/5\">",
"      Figueiredo RR, Azevedo AA, K&oacute;s AO, Tomita S. Nasal foreign bodies: description of types and complications in 420 cases. Braz J Otorhinolaryngol 2006; 72:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/6\">",
"      Ogunleye AO, Sogebi OA. Nasal foreign bodies in the African children. Afr J Med Med Sci 2004; 33:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/7\">",
"      Litovitz T, Whitaker N, Clark L, et al. Emerging battery-ingestion hazard: clinical implications. Pediatrics 2010; 125:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/8\">",
"      Guidera AK, Stegehuis HR. Button batteries: the worst case scenario in nasal foreign bodies. N Z Med J 2010; 123:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/9\">",
"      Jonas NE, Meyer E. Magnetic foreign body on the nasal septum. S Afr J Surg 2007; 45:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/10\">",
"      Starke L. Easy removal of nasal magnets. Pediatr Emerg Care 2005; 21:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/11\">",
"      Greenberg M, Magit A. Magnetic nasal foreign bodies in a 9-year-old male: opposites attract when it comes to nasal foreign bodies. Int J Pediatr Otorhinolaryngol 2005; 69:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/12\">",
"      Yeh B, Roberson JR. Nasal magnetic foreign body: a sticky topic. J Emerg Med 2012; 43:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/13\">",
"      Shermetaro C, Charnesky M. Pediatric nasal septal perforation secondary to magnet misuse: a case report. Ear Nose Throat J 2007; 86:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/14\">",
"      Heim SW, Maughan KL. Foreign bodies in the ear, nose, and throat. Am Fam Physician 2007; 76:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/15\">",
"      Kalan A, Tariq M. Foreign bodies in the nasal cavities: a comprehensive review of the aetiology, diagnostic pointers, and therapeutic measures. Postgrad Med J 2000; 76:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/16\">",
"      Tong MC, Van Hasselt CA, Woo JK. The hazards of button batteries in the nose. J Otolaryngol 1992; 21:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/17\">",
"      Palmer O, Natarajan B, Johnstone A, Sheikh S. Button battery in the nose--an unusual foreign body. J Laryngol Otol 1994; 108:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/18\">",
"      Dane S, Smally AJ, Peredy TR. A truly emergent problem: button battery in the nose. Acad Emerg Med 2000; 7:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/19\">",
"      Gregori D, Salerni L, Scarinzi C, et al. Foreign bodies in the nose causing complications and requiring hospitalization in children 0-14 age: results from the European survey of foreign bodies injuries study. Rhinology 2008; 46:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/20\">",
"      Glynn F, Amin M, Kinsella J. Nasal foreign bodies in children: should they have a plain radiograph in the accident and emergency? Pediatr Emerg Care 2008; 24:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/21\">",
"      Ozdemir S, Akbas Y, G&ouml;rg&uuml;l&uuml; O, et al. Rhinolithiasis: review of 21 cases. Am J Rhinol Allergy 2010; 24:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/22\">",
"      Qureshi AA, Lowe DA, McKiernan DC. The origin of bronchial foreign bodies: a retrospective study and literature review. Eur Arch Otorhinolaryngol 2009; 266:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/23\">",
"      Mishra P, Bhakta P, Kumar S, et al. Sudden near-fatal tracheal aspiration of an undiagnosed nasal foreign body in a small child. Emerg Med Australas 2011; 23:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/24\">",
"      Tong MC, Ying SY, van Hasselt CA. Nasal foreign bodies in children. Int J Pediatr Otorhinolaryngol 1996; 35:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/25\">",
"      Kadish HA, Corneli HM. Removal of nasal foreign bodies in the pediatric population. Am J Emerg Med 1997; 15:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/26\">",
"      Mackle T, Conlon B. Foreign bodies of the nose and ears in children. Should these be managed in the accident and emergency setting? Int J Pediatr Otorhinolaryngol 2006; 70:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/27\">",
"      Lichenstein R, Giudice EL. Nasal wash technique for nasal foreign body removal. Pediatr Emerg Care 2000; 16:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/28\">",
"      Handler SD. Nasal wash technique for nasal foreign body removal. Pediatr Emerg Care 2000; 16:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/29\">",
"      Backlin SA. Positive-pressure technique for nasal foreign body removal in children. Ann Emerg Med 1995; 25:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/30\">",
"      Kiger JR, Brenkert TE, Losek JD. Nasal foreign body removal in children. Pediatr Emerg Care 2008; 24:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/31\">",
"      Botma M, Bader R, Kubba H. 'A parent's kiss': evaluating an unusual method for removing nasal foreign bodies in children. J Laryngol Otol 2000; 114:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/32\">",
"      Finkelstein JA. Oral Ambu-bag insufflation to remove unilateral nasal foreign bodies. Am J Emerg Med 1996; 14:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/33\">",
"      Cook S, Burton M, Glasziou P. Efficacy and safety of the \"mother's kiss\" technique: a systematic review of case reports and case series. CMAJ 2012; 184:E904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/34\">",
"      Navitsky RC, Beamsley A, McLaughlin S. Nasal positive-pressure technique for nasal foreign body removal in children. Am J Emerg Med 2002; 20:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/35\">",
"      Hills RW, Brown JC, Brownstein D. Barotrauma: a complication of positive pressure for nasal foreign body removal in a pediatric patient. Ann Emerg Med 2008; 52:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/36\">",
"      Kavanagh KT, Litovitz T. Miniature battery foreign bodies in auditory and nasal cavities. JAMA 1986; 255:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/37\">",
"      Brown L, Denmark TK, Wittlake WA, et al. Procedural sedation use in the ED: management of pediatric ear and nose foreign bodies. Am J Emerg Med 2004; 22:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/38\">",
"      Hanson RM, Stephens M. Cyanoacrylate-assisted foreign body removal from the ear and nose in children. J Paediatr Child Health 1994; 30:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17752/abstract/39\">",
"      Gomes CC, Sakano E, Lucchezi MC, Porto PR. Button battery as a foreign body in the nasal cavities. Special aspects. Rhinology 1994; 32:98.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83377 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17752=[""].join("\n");
var outline_f17_21_17752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H414473\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4708033\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H373855773\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13572452\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4708018\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13572187\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4708244\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H373855780\">",
"      FOREIGN BODY REMOVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H373855853\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H373855860\">",
"      Indications for subspecialty consultation or referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H373855867\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13572783\">",
"      - Positive pressure techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13572790\">",
"      - Instrumentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14913011\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14913022\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25823583\">",
"      - Magnet removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13570906\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H414473\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/83377\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/83377|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/30/38370\" title=\"diagnostic image 1\">",
"      Radio-opaque nasal foreign body",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/83377|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/34/39459\" title=\"figure 1\">",
"      Common locations of nasal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/9/42143\" title=\"figure 2\">",
"      Removal of nasal foreign body using a nasal speculum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/37/33362\" title=\"figure 3\">",
"      Removal of nasal foreign body foam rubber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/12/15555\" title=\"figure 4\">",
"      Smooth nasal foreign bodies avoid forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/4/20546\" title=\"figure 5\">",
"      Nasal foreign body removal button battery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/14/32995\" title=\"figure 6\">",
"      Nasal foreign body removal with a balloon catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/83377|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/40/6791\" title=\"picture 1\">",
"      Button battery removed from the nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/41/23199\" title=\"picture 2\">",
"      Magnets as nasal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14064\" title=\"picture 3\">",
"      Foam rubber foreign body in the nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/45/35542\" title=\"picture 4\">",
"      Cherry pit with secretions in the nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/29/17879\" title=\"picture 5\">",
"      Nasal foreign body positive pressure technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/24/28032\" title=\"picture 6\">",
"      Papoose restraint for ear or nose foreign body removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/45/727\" title=\"picture 7\">",
"      Items for nasal foreign body removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/11/179\" title=\"picture 8\">",
"      Schuknecht foreign body remover",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/22/22881\" title=\"picture 9\">",
"      Nasal foreign body removal without speculum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/36/13903\" title=\"picture 10\">",
"      Pocket magnet for removal of nasal magnets",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Microbiology and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35399?source=related_link\">",
"      Airway foreign bodies in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28504?source=related_link\">",
"      Diagnosis and management of foreign bodies of the outer ear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=related_link\">",
"      Foreign bodies of the esophagus and gastrointestinal tract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21353?source=related_link\">",
"      Ingested foreign bodies and food impactions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26536?source=related_link\">",
"      Management of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/38/1634?source=related_link\">",
"      Patient information: Removing objects stuck up the nose (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39654?source=related_link\">",
"      Rectal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25658?source=related_link\">",
"      Selection of medications for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22281?source=related_link\">",
"      The common cold in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_21_17753="Severe acute respiratory syndrome (SARS)";
var content_f17_21_17753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Severe acute respiratory syndrome (SARS)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17753/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17753/contributors\">",
"     Kenneth McIntosh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17753/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17753/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17753/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17753/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/21/17753/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In February 2003, the World Health Organization (WHO) reported about 300 cases of a rapidly progressive respiratory illness in the Guangdong Province of China with five deaths. Over the next month, similar cases were reported from Hong Kong, Vietnam, Singapore, and Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/1\">",
"     1",
"    </a>",
"    ]. By the end of the worldwide outbreak in July 2003, a total of 8096 cases were reported, with 774 deaths and a case-fatality rate of 9.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Termed severe acute respiratory syndrome (SARS) by the WHO, initial efforts centered on tracking cases, determining an etiology, establishing a laboratory test for diagnosis, evaluating therapies, and implementing infection control strategies to prevent further spread. WHO spearheaded these efforts in collaboration with the United States Centers for Disease Control and Prevention (CDC) and health authorities from a number of countries including particularly China, Hong Kong, Vietnam, Singapore, Thailand, and Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A novel coronavirus was detected in specimens from a number of the patients with SARS, and very quickly the virus was sequenced and fulfilled Koch's postulates [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines for surveillance, recognition, diagnosis, reporting, and public health management of this illness are available on the WHO and CDC websites [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. These sites should be consulted immediately whenever SARS is suspected, either as single cases or clusters.",
"   </p>",
"   <p>",
"    The case definition, epidemiology, etiology, clinical manifestations, diagnosis, treatment, and prevention of SARS will be reviewed here. Coronaviruses are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41176?source=see_link\">",
"     \"Coronaviruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of and in the immediate aftermath of the SARS epidemic, both the World Health Organization (WHO) and the CDC issued case definitions for SARS. The WHO has issued an updated version [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/11\">",
"     11",
"    </a>",
"    ]. This definition recognizes that, in the absence of current SARS activity in humans, laboratory confirmation using reliable and experienced laboratories, such as those at the WHO and the CDC, is a critical component of the case definition.",
"   </p>",
"   <p>",
"    According to the WHO, a case of SARS is notifiable if it occurs in an individual with laboratory confirmation of infection who",
"    <strong>",
"     either",
"    </strong>",
"    meets the clinical case definition",
"    <strong>",
"     or",
"    </strong>",
"    has worked in a laboratory with live SARS coronavirus or with clinical specimens infected with SARS coronavirus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical case definition used by the WHO includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of fever or documented fever",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      One or more symptoms of lower respiratory tract illness (cough, difficulty breathing, shortness of breath)",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Radiographic evidence of lung infiltrates consistent with pneumonia or acute respiratory distress syndrome (ARDS) or autopsy findings consistent with the pathology of pneumonia or ARDS without an identifiable cause",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      No alternative diagnosis fully explaining the illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory diagnostic tests that are required include one or both of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detection of virus (reverse transcriptase polymerase chain reaction) assay detecting viral RNA present in two separate samples, or virus culture from any clinical specimen. These two samples can be obtained from either two separate sites (eg, nasopharyngeal and stool) or from the same site, but at different times (eg, sequential nasopharyngeal aspirates).",
"     </li>",
"     <li>",
"      Detection of antibody (a rise in antibody titer, either from negative to positive or at least a four-fold increase) by enzyme-linked immunosorbent assay (ELISA)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunofluorescent assay (IFA).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The United States Centers for Disease Control and Prevention case definition is similar to the WHO case definition [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of SARS were first noted in Guangdong Province, China in November 2002. Between November 16, 2002 and February 28, 2003, 792 cases were reported in this province [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Healthcare workers and their contacts appeared to be disproportionately affected by the outbreak.",
"   </p>",
"   <p>",
"    The index case for the illness in Hong Kong was a physician from Guangdong province who traveled to Hong Kong five days after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/13\">",
"     13",
"    </a>",
"    ]. Other cases in Hong Kong developed in those with contact with the index or secondary cases, including individuals staying at the same hotel as the index patient. The index cases in Singapore, Thailand, Vietnam, and Canada were in travelers returning from Guangdong province or Hong Kong.",
"   </p>",
"   <p>",
"    The illness had many epidemiologic and clinical features of an infection, and early efforts to find an associated pathogen quickly centered around a new viral strain from the coronavirus family, first identified in February and March 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The virus spread rapidly from southern China and Hong Kong to Vietnam, Thailand, and Singapore, and then to Europe, Canada, and the United States.",
"   </p>",
"   <p>",
"    Local epidemics in Hong Kong, Singapore, Toronto, and parts of China through March led the World Health Organization (WHO) and the United States Centers for Disease Control and Prevention to issue several travel advisories on or around April 1, 2003. These were combined with extraordinary efforts at containment through application of infection control practices, particularly in hospitals. By July 2003, no new cases were reported worldwide, and the WHO lifted its last remaining travel advisory.",
"   </p>",
"   <p>",
"    During the remainder of 2003 and the first half of 2004, four small outbreaks of SARS were documented following the apparent end of the epidemic. Three outbreaks were related to laboratory transmission of the epidemic virus, and one was presumably from contact with animal sources. Since mid-2004, no cases have been reported. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Intermediate host and reservoir'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most illnesses occurred in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/17\">",
"     17",
"    </a>",
"    ]. Children 12 years or older had a clinical presentation similar to adults, whereas younger children had milder disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. No fatal cases were reported among children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Scope of outbreak",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2003 outbreak resulted in 8096 cases with 774 deaths and a case-fatality rate of 9.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/2\">",
"     2",
"    </a>",
"    ]. Older age was associated with a higher mortality rate, being as high as 43 percent in patients age 60 or older in Hong Kong compared with 13 percent in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cases of SARS occurred in 29 countries in Asia, Europe, and North America. China, including Hong Kong, had 83 percent of all cases. The United States had 27 probable cases with no secondary cases and no deaths. In Canada, mainly in Toronto, there were 251 cases (five imported and the rest secondary) with 43 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The small outbreaks that followed the major SARS epidemic are of considerable interest as models of possible future SARS outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/21\">",
"     21",
"    </a>",
"    ]. Two outbreaks that presumably originated in laboratories working with the SARS coronavirus involved only a single case with no secondary spread [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In a third laboratory-based outbreak that occurred in China in April 2004, there were nine cases in three generations of contacts and one death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/23\">",
"     23",
"    </a>",
"    ]. A fourth outbreak, in December 2003 and January 2004, consisted of four relatively mild and epidemiologically separate cases, all in Guangdong province in southern China, and all presumably from contact with infected animals, probably palm civets [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/21,24,25\">",
"     21,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These small outbreaks illustrate several important principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There must be strict control of laboratory strains.",
"     </li>",
"     <li>",
"      Laboratory strains, presumably because they represent strains that have been adapted to spread among humans, can cause outbreaks; in contrast, animal-derived strains are less likely to cause outbreaks without some period of adaptation.",
"     </li>",
"     <li>",
"      Control of possible animal intermediaries is important in preventing re-emergence of SARS. Since 2004, China has banned all consumption of palm civets [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intermediate host and reservoir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animals eaten as exotic foods in southern China were probably intermediate hosts. The Chinese government launched an effort to kill palm civets, a cat-like creature considered a culinary delicacy in China that was sometimes infected by a coronavirus similar to the SARS coronavirus. A direct link between civets and SARS has not been confirmed, although molecular studies have suggested that SARS coronaviruses isolated early in the epidemic were closely related to palm civet coronaviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two independent studies demonstrated infection of a relatively high percentage of horseshoe bats in China with viruses that have nucleotide sequences nearly identical to SARS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These findings have raised the possibility that bats may be an important reservoir for this disease. Moreover, bat coronaviruses with variable similarity to the SARS coronavirus have been found in bats on several continents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the clusters of cases in Hong Kong and Canada, SARS coronavirus clearly spread from person-to-person and could be acquired from face-to-face contact, suggesting droplet spread [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/13,34-36\">",
"     13,34-36",
"    </a>",
"    ]. Because of the rapid and extensive spread of SARS in Hong Kong, there has also been speculation that other modes of spread, such as fecal-oral or airborne, might be possible. Because of several \"superspreader\" events, including likely spread on an aircraft [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/37\">",
"     37",
"    </a>",
"    ], it seems probable that airborne spread may be important in at least some patients.",
"   </p>",
"   <p>",
"    Transmission to healthcare workers has been a common feature of most SARS outbreaks. A possible contributing factor is that peak viral shedding in respiratory secretions, as determined by PCR, occurs 6 to 11 days following the onset of illness, at a time of severe respiratory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. This late viral excretion peak is an unusual feature of SARS when compared with other respiratory viral infections.",
"   </p>",
"   <p>",
"    Fomites are another possible contributor to nosocomial transmission. SARS virus RNA is present in stool, and was detected on a variety of hospital surfaces during outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/34\">",
"     34",
"    </a>",
"    ]. This emphasizes the need for strict surface hygiene practices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Molecular epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that, after one or more instances of spread from animals to humans, the SARS coronavirus adapted through mutation, deletions, and possibly recombination, until it transmitted readily among humans. The virus that spread worldwide was derived primarily from a single infected individual who traveled from Guangdong Province to Hong Kong and infected numerous individuals in a superspreading event [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/40\">",
"     40",
"    </a>",
"    ]. The virus that was epidemic in China and produced the majority of probable infections was more variable [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/26,41\">",
"     26,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period for SARS is usually 2 to 7 days [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/20\">",
"     20",
"    </a>",
"    ]. Approximately 95 percent of patients will develop symptoms within 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, after possible exposure, an individual should be monitored for the development of symptoms for at least 10 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prognostic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have identified a number of risk factors for poor outcomes in patients with SARS. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/17,20,39\">",
"       17,20,39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diabetes, chronic hepatitis B, and other underlying comorbid conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/17,39,42\">",
"       17,39,42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Atypical symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated serum lactate dehydrogenase (LDH) on admission [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/17,43\">",
"       17,43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relatively few infections and no deaths were reported in children or adolescents in a survey from Hong Kong [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early in the course of the investigations, it was suspected that SARS was a viral respiratory illness. A novel coronavirus was detected in specimens from a number of patients with SARS, and the virus was sequenced and fulfilled Koch's postulates [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Coronaviruses are usually agents of the common cold and generally do not cause severe respiratory disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41176?source=see_link\">",
"     \"Coronaviruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Investigators at the US Centers for Disease Control and Prevention identified a novel coronavirus in cell cultures inoculated with specimens from two patients in Thailand and Hong Kong [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/15\">",
"     15",
"    </a>",
"    ]. At the same time, coronaviruses were isolated from index cases in Germany and Hong Kong [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. Preliminary sequence analysis suggested that the viruses were similar and represented a previously undescribed coronavirus.",
"   </p>",
"   <p>",
"    The SARS coronavirus genome has an organization similar to other coronaviruses, but is not closely related to other characterized coronaviruses by phylogenetic analysis and sequence comparisons [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/6,7,44\">",
"     6,7,44",
"    </a>",
"    ]. Through a variety of clinical, animal, and laboratory studies, the etiologic association between the SARS coronavirus and SARS has been clearly established [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the pathogenesis and immune responses to SARS coronavirus is limited. Autopsy studies of patients who died during the first 10 days of illness confirm that the lung is an early target [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/45\">",
"     45",
"    </a>",
"    ]. Virus was consistently found in the lung and intestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In fatal cases, virus was found in multiple organs, including the brain.",
"   </p>",
"   <p>",
"    The adaptive immune system is probably critical to recovery from SARS, as demonstrated in experiments in mouse models [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/46\">",
"     46",
"    </a>",
"    ]. It is also likely that the innate immune system plays a role, both in defense against and in the pathogenesis of SARS. Genetic studies have pointed to the IL-12 receptor and the mannose-binding lectin (MBL) as potential important first lines of defense [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiotensin-converting enzyme 2 (ACE2) and CD209L (L-SIGN) are functional receptors for SARS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In an animal model, infection of ACE2 knockout mice led to recovery of low quantities of infectious virus compared to large amounts in the wild-type mice [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/51\">",
"     51",
"    </a>",
"    ]. The authors of this report hypothesized that infection with SARS results in downregulation of ACE2 and subsequent lung pathology, since ACE2 has a key protective role in acute lung injury. Several cellular proteolytic enzyme systems also facilitate entry of virus into the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;SARS is an unusual respiratory viral disease, since the prodrome is often somewhat prolonged, lasting for three to seven days and is characterized by fever (temperature &ge;100.5&ordm;F [&gt;38&ordm;C]) malaise, headache, and myalgias [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/54\">",
"     54",
"    </a>",
"    ]. Unlike virtually all other respiratory viral prodromes, most patients have no upper respiratory symptoms during this stage. At the end of this prodrome, the respiratory phase typically begins with a nonproductive cough. Dyspnea may follow and may progress to respiratory failure, with progressive pulmonary infiltrates on chest x-ray, necessitating mechanical ventilation.",
"   </p>",
"   <p>",
"    A comprehensive review of the clinical manifestations associated with SARS summarizes data from 752 patients from mainland China (190 cases), Hong Kong (388 cases), Canada (154 cases), and Singapore (20 cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/4\">",
"     4",
"    </a>",
"    ]. The most common symptoms and signs on presentation to hospital were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever &mdash; 100 percent",
"     </li>",
"     <li>",
"      Cough &mdash; 66 percent",
"     </li>",
"     <li>",
"      Chills",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rigors &mdash; 52 percent",
"     </li>",
"     <li>",
"      Myalgias &mdash; 49 percent",
"     </li>",
"     <li>",
"      Dyspnea &mdash; 46 percent",
"     </li>",
"     <li>",
"      Headache &mdash; 39 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other less common symptoms were diarrhea (20 percent), and chest pain or pleurisy (22 percent). Sore throat and rhinorrhea were seen in 17 and 14 percent, respectively. Symptoms observed in 346 laboratory-proven cases in Taiwan were similar [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/55\">",
"     55",
"    </a>",
"    ]. All respiratory symptoms (cough, dyspnea, pleuritic pain) became more common and severe as the disease progressed. Approximately 25 percent of patients required transfer to the intensive care unit, usually for mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/13,39,42,56-58\">",
"     13,39,42,56-58",
"    </a>",
"    ]. Death was usually caused by a combination of adult respiratory distress syndrome and multi-organ failure.",
"   </p>",
"   <p>",
"    Asymptomatic infection during the large SARS epidemic was infrequent, although animal handlers in southern China were found to have a high rate of antibody with no history of typical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common laboratory abnormalities were depressed total lymphocytes (66 percent) and elevated lactate dehydrogenase (LDH, 46 percent) and alanine aminotransferase (44 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/4\">",
"     4",
"    </a>",
"    ]. Thrombocytopenia was present in 30 percent, usually as the respiratory phase peaked. High LDH was associated with a poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/17,43\">",
"     17,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest x-ray patterns ranged from normal to diffuse interstitial infiltrates characteristic of acute respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Bilateral peripheral infiltrates were common, usually in the middle or lower lung zones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62522 \" href=\"UTD.htm?14/7/14448\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomographic (CT) scanning can show parenchymal abnormalities in patients with apparently normal chest x-rays (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75323 \" href=\"UTD.htm?30/40/31360\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/62\">",
"     62",
"    </a>",
"    ]. Infiltrates are usually ground glass in character and peripheral in location.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information about the effect of SARS on pregnant women and their fetuses is limited. Two reports from the same group at a hospital in Hong Kong suggested that pregnant women with SARS had a higher mortality rate and higher rates of both intubation and ICU admission than nonpregnant women with SARS but that transmission of the virus to the infant did not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Complications, such as miscarriages, preterm deliveries, and small for gestational age neonates were frequent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse alveolar damage with varying degrees of organization is seen on pathologic examination in patients with SARS who have acute lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/45,65\">",
"     45,65",
"    </a>",
"    ]. Histologic features vary with the stage of disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the early phase, hyaline membranes, interstitial and intraalveolar edema, and vascular congestion are present.",
"     </li>",
"     <li>",
"      In the organizing phase, fibroblast proliferation occurs both in the interstitium and alveolar spaces.",
"     </li>",
"     <li>",
"      In the organizing phase, the majority of fibroblast proliferation occurs within alveolar septa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the 2002 to 2003 epidemic, the CDC supplied reagents to laboratories in the United States to test for serum coronavirus antibodies from paired acute and convalescent samples from suspected cases. Because of justified concerns about false-positive diagnostic tests, the WHO requires that positive laboratory tests from suspected cases be repeated and confirmed in central WHO laboratories.",
"   </p>",
"   <p>",
"    When SARS is suspected, specimens for polymerase chain reaction (PCR) testing should be obtained from at least two sites, such as the respiratory tract, stool, and serum or plasma. PCR testing should be performed as early in the illness as possible and, if symptoms progress or persist, repeated 5 to 7 days later. Acute and convalescent serum should also be collected for serologic testing. The results required to establish the diagnosis of SARS are discussed above. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Case definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum antibody, usually measured by ELISA, is the most sensitive of available tests. However, antibodies typically develop several weeks into the illness, making serologic testing less useful for diagnosis during the acute phase. As an example, the mean time to seroconversion was 19 and 20 days in two series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/39,66\">",
"     39,66",
"    </a>",
"    ], and a small number of patients failed to develop antibody even later in the illness.",
"   </p>",
"   <p>",
"    Due to the antigenic similarity among coronaviruses, antibodies to SARS coronavirus sometimes develop after other respiratory coronavirus infections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Thus, serologic testing for SARS may give false-positive results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reverse transcriptase PCR (RT-PCR), including quantitative real-time RT-PCR, was performed on respiratory, stool, and serum or plasma samples in many patients with SARS, but no systematic study has been performed to determine the relative value of each type of specimen at various stages of illness.",
"   </p>",
"   <p>",
"    The following findings have been observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RT-PCR assays performed on samples obtained early in the illness had sensitivities as low as 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. Optimization using real-time PCR increased the sensitivity in some studies.",
"     </li>",
"     <li>",
"      The sensitivity of serum or plasma appears to be greatest early in the illness (between 1 and 7 days after onset of fever) and diminishes markedly with time [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nasopharyngeal aspirates may, if all conditions are optimized, be sensitive at the time of admission to the hospital [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/72\">",
"       72",
"      </a>",
"      ], but appear to be most sensitive at the time of peak respiratory symptoms, usually during the second week of illness [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/39,70\">",
"       39,70",
"      </a>",
"      ]. In one study that included 75 patients, 32 percent had a positive RT-PCR assay three days following the onset of illness compared with 68 percent at day 14 [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stool samples remain PCR-positive for the longest period, with 65 of 67 samples (97 percent) in one report being positive a mean of 14 days after illness onset [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both serum and respiratory virus titers as measured by real-time RT-PCR have been correlated with prognosis, with higher titers associated with worse prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific treatment is currently recommended except for meticulous supportive care [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/74\">",
"     74",
"    </a>",
"    ]. As with other viral infections, antibacterial agents are ineffective. In addition, no antiviral agents have been found to provide benefit for treating SARS. During the epidemic, most patients were treated with high-dose glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , but most experts now agree that neither treatment had a clear beneficial effect, and immediate and late toxicities were common [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"     Lopinavir-ritonavir",
"    </a>",
"    may have some activity against the virus in vitro, but its clinical efficacy has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/77\">",
"     77",
"    </a>",
"    ]. Treatments used in smaller number of patients or animal models have included interferon-alpha and convalescent plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stringent infection control practices are crucial for the prevention of SARS, since other modalities such as a vaccine and monoclonal antibodies remain in development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Infection control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The control of SARS through the rigorous application of barrier methods represents one of the landmark accomplishments of infectious diseases epidemiology and public health coordination. One of the characteristics of the infection, namely the low contagiousness of patients during the prodrome, probably contributed to the success of control efforts, since patients could, in the outbreak situation, be identified and placed on precautions before they became most infectious to contacts. But the disappearance of SARS in July 2003, only nine months after it had first been detected, was a substantial international public health accomplishment. Isolation of patients, rigorous use of masks, gloves and gowns, closure of schools, hospitals, and clubs and quarantine of exposed individuals probably all contributed to containment of the outbreak [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Details of recommended hospital, community and home precautionary measures are available from the CDC through their web site [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Vaccine development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts are underway to prepare a vaccine for the prevention of SARS, and a large number of candidate vaccines have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/82\">",
"     82",
"    </a>",
"    ]. Most efforts have concentrated on developing antibody (either secretory or systemic, or both) to the surface S glycoprotein, since neutralizing antibody is directed against the receptor-binding portion of this molecule (",
"    <a class=\"graphic graphic_figure graphicRef74041 \" href=\"UTD.htm?18/15/18678\">",
"     figure 1",
"    </a>",
"    ). There is controversy regarding the potential inclusion of the M protein as a component of a vaccine. Although the M protein is an immunodominant protein and may be important as a target of cell-mediated immunity, there is disagreement about its capacity to induce neutralizing antibody, and therefore its importance as an antigen in a preventive vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. There is some concern that, by analogy with some animal coronavirus diseases, immunization might cause paradoxically severe disease on subsequent exposure to natural infection.",
"   </p>",
"   <p>",
"    The following illustrate several approaches that are being evaluated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Macaques immunized with a vaccine constructed of three structural proteins from a prototype SARS strain with adenovirus vectors developed neutralizing antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DNA vaccine approaches have induced antigen-specific antibody and cellular immune responses, as well as protection in murine models [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intranasal immunization of monkeys with an attenuated parainfluenza virus that expressed the SARS spike protein resulted in no viral shedding after exposure to the SARS virus [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the following is a model of a vaccine that produced paradoxically severe disease on subsequent exposure to the SARS coronavirus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mice immunized intradermally with vaccinia virus constructs containing the nucleoprotein gene of the SARS coronavirus developed severe pneumonia following subsequent intranasal exposure to SARS coronavirus itself, in contrast to those immunized with vaccinia virus constructs containing the S-protein gene, who were protected [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tests of these candidate vaccines have not been carried out in human subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of monoclonal antibodies is another potential approach to the prevention of SARS, although none are available for clinical use. Humanized monoclonal antibodies directed at specific portions of the S-glycoprotein have been developed singly and in combination to effectively neutralize virus in vitro and prevent infection in animal models, as illustrated by the following examples (",
"    <a class=\"graphic graphic_figure graphicRef74041 \" href=\"UTD.htm?18/15/18678\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human monoclonal antibody to the S1 domain of the spike protein led to potent neutralization of SARS coronavirus in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several widely conserved amino acids in the receptor binding domain in the S1 region of the S-glycoprotein have been identified that are critical in neutralization of the virus [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A combination of two noncompeting human monoclonal antibodies broadened protection in vitro by reducing immune escape [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17753/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/42/4770?source=see_link\">",
"       \"Patient information: Severe Acute Respiratory Syndrome (SARS) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In February 2003, the WHO reported about 300 cases of a rapidly progressive respiratory illness in the Guangdong Province of China with five deaths. Over the next month, similar cases were reported from Hong Kong, Vietnam, Singapore, and Canada. The outbreak resulted in a total of 8096 cases with 774 deaths and a case-fatality rate of 9 to 12 percent. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When SARS is suspected, specimens for polymerase chain reaction (PCR) testing should be obtained from at least two sites, such as the respiratory tract, stool, and serum or plasma. PCR testing should be performed as early in the illness as possible and, if symptoms progress or persist, repeated 5 to 7 days later. Acute and convalescent serum should also be collected for serologic testing. The results required to establish the diagnosis of SARS are discussed above. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Case definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Animals eaten as exotic foods in southern China, particularly the palm civet, were probably intermediate hosts. Some data have raised the possibility that bats may also be a reservoir for this virus. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Intermediate host and reservoir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based upon the clusters of cases in Hong Kong and Canada, SARS coronavirus clearly spreads from person-to-person and can be acquired from face-to-face contact, suggesting droplet spread. Other modes of spread, such as fecal-oral, airborne, and fomites might also be possible. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SARS begins with a prodrome lasting for three to seven days characterized by fever, malaise, headache, and myalgias. At the end of this prodrome, the respiratory phase typically begins with a nonproductive cough. Dyspnea may follow and may progress to respiratory failure. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diffuse alveolar damage with varying degrees of organization is seen on pathologic examination in patients with SARS who have acute lung injury. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT using antiviral therapy or glucocorticoids for the treatment of SARS (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Meticulous supportive care should be provided, such as mechanical ventilation when indicated. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meticulous infection control practices are crucial for the prevention of SARS, since other modalities such as a vaccine and monoclonal antibodies remain in development. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of severe acute respiratory syndrome--worldwide, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:226.",
"     </a>",
"    </li>",
"    <li>",
"     WHO: Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 (Based on data as of the 31 December 2003) file://www.who.int/csr/sars/country/table2004_04_21/en/index.html. 2004 (Accessed December 1, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/3\">",
"      Christian MD, Poutanen SM, Loutfy MR, et al. Severe acute respiratory syndrome. Clin Infect Dis 2004; 38:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/4\">",
"      Peiris JS, Yuen KY, Osterhaus AD, St&ouml;hr K. The severe acute respiratory syndrome. N Engl J Med 2003; 349:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/5\">",
"      Fouchier RA, Kuiken T, Schutten M, et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 2003; 423:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/6\">",
"      Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/7\">",
"      Ruan YJ, Wei CL, Ee AL, et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003; 361:1779.",
"     </a>",
"    </li>",
"    <li>",
"     In the Absence of SARS-CoV Transmission Worldwide: Guidance for Surveillance, Clinical and Laboratory Evaluation, and Reporting Version 2 file://www.cdc.gov/ncidod/sars/pdf/absenceofsars.pdf (Accessed April 1, 2010).",
"    </li>",
"    <li>",
"     Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS) Version 2. Supplement I: Infection Control in Healthcare, Home, and Community Settings file://www.cdc.gov/ncidod/sars/guidance/I/index.htm (Accessed April 1, 2010).",
"    </li>",
"    <li>",
"     WHO guidelines for the global surveillance of severe acute respiratory syndrome (SARS). Updated recommendations, October 2004. file://www.who.int/csr/resources/publications/WHO_CDS_CSR_ARO_2004_1/en/index.html (Accessed April 1, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/11\">",
"      Case definitions for the 4 diseases requiring notification to WHO in all circumstances under the IHR (2005). Wkly Epidemiol Rec 2009; 84:52.",
"     </a>",
"    </li>",
"    <li>",
"     Supplement B: SARS Surveillance Appendix B1: Revised CSTE SARS Surveillance Case Definition December 2003 file://www.cdc.gov/ncidod/sars/guidance/b/pdf/app1.pdf 2003 (Accessed December 1, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/13\">",
"      Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/14\">",
"      Drosten C, G&uuml;nther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/15\">",
"      Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/16\">",
"      Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/17\">",
"      Leung GM, Hedley AJ, Ho LM, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med 2004; 141:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/18\">",
"      Hon KL, Leung CW, Cheng WT, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 2003; 361:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/19\">",
"      Stockman LJ, Massoudi MS, Helfand R, et al. Severe acute respiratory syndrome in children. Pediatr Infect Dis J 2007; 26:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/20\">",
"      Donnelly CA, Ghani AC, Leung GM, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003; 361:1761.",
"     </a>",
"    </li>",
"    <li>",
"     WHO: Global Alert and Response (GAR): Severe Acute Respiratory Syndrome (SARS) file://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/ (Accessed December 1, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/22\">",
"      Lim PL, Kurup A, Gopalakrishna G, et al. Laboratory-acquired severe acute respiratory syndrome. N Engl J Med 2004; 350:1740.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. China confirms SARS infection in another previously reported case; summary of cases to date &ndash; Update 5, 30 April 2004. file://www.who.int/csr/don/2004_04_30/en/ (Accessed April 2, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/24\">",
"      Liang G, Chen Q, Xu J, et al. Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg Infect Dis 2004; 10:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/25\">",
"      Wang M, Yan M, Xu H, et al. SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis 2005; 11:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/26\">",
"      Zhao GP. SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era. Philos Trans R Soc Lond B Biol Sci 2007; 362:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/27\">",
"      Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 2004; 303:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/28\">",
"      He Y, Li J, Li W, et al. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol 2006; 176:6085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/29\">",
"      Tu C, Crameri G, Kong X, et al. Antibodies to SARS coronavirus in civets. Emerg Infect Dis 2004; 10:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/30\">",
"      Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 2005; 102:14040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/31\">",
"      Li W, Shi Z, Yu M, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005; 310:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/32\">",
"      Drexler JF, Gloza-Rausch F, Glende J, et al. Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol 2010; 84:11336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/33\">",
"      Quan PL, Firth C, Street C, et al. Identification of a severe acute respiratory syndrome coronavirus-like virus in a leaf-nosed bat in Nigeria. MBio 2010; 1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/34\">",
"      Booth TF, Kournikakis B, Bastien N, et al. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis 2005; 191:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/35\">",
"      Donnelly CA, Fisher MC, Fraser C, et al. Epidemiological and genetic analysis of severe acute respiratory syndrome. Lancet Infect Dis 2004; 4:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/36\">",
"      Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/37\">",
"      Olsen SJ, Chang HL, Cheung TY, et al. Transmission of the severe acute respiratory syndrome on aircraft. N Engl J Med 2003; 349:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/38\">",
"      Cheng PK, Wong DA, Tong LK, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet 2004; 363:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/39\">",
"      Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/40\">",
"      Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of individual variation on disease emergence. Nature 2005; 438:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/41\">",
"      Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003; 302:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/42\">",
"      Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289:2801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/43\">",
"      Choi KW, Chau TN, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med 2003; 139:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/44\">",
"      Marra MA, Jones SJ, Astell CR, et al. The Genome sequence of the SARS-associated coronavirus. Science 2003; 300:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/45\">",
"      Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol 2003; 200:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/46\">",
"      Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol 2010; 84:9318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/47\">",
"      Tang F, Liu W, Zhang F, et al. IL-12 RB1 genetic variants contribute to human susceptibility to severe acute respiratory syndrome infection among Chinese. PLoS One 2008; 3:e2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/48\">",
"      Ip WK, Chan KH, Law HK, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis 2005; 191:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/49\">",
"      Jeffers SA, Tusell SM, Gillim-Ross L, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 2004; 101:15748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/50\">",
"      Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/51\">",
"      Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/52\">",
"      Shulla A, Heald-Sargent T, Subramanya G, et al. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol 2011; 85:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/53\">",
"      Huang IC, Bosch BJ, Li F, et al. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem 2006; 281:3198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/54\">",
"      Centers for Disease Control and Prevention (CDC). Preliminary clinical description of severe acute respiratory syndrome. MMWR Morb Mortal Wkly Rep 2003; 52:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/55\">",
"      Hsueh PR, Yang PC. Severe acute respiratory syndrome epidemic in Taiwan, 2003. J Microbiol Immunol Infect 2005; 38:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/56\">",
"      Chan JW, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003; 58:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/57\">",
"      Hsu LY, Lee CC, Green JA, et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003; 9:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/58\">",
"      Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/59\">",
"      Bitar R, Weiser WJ, Avenda&ntilde;o M, et al. Chest radiographic manifestations of severe acute respiratory syndrome in health care workers: the Toronto experience. AJR Am J Roentgenol 2004; 182:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/60\">",
"      M&uuml;ller NL, Ooi GC, Khong PL, Nicolaou S. Severe acute respiratory syndrome: radiographic and CT findings. AJR Am J Roentgenol 2003; 181:3.",
"     </a>",
"    </li>",
"    <li>",
"     Wong, KT, Antonio, GE, Hui, DS, et al. Severe Acute Respiratory Syndrome: Radiographic Appearances and Pattern of Progression in 138 Patients. Radiology 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/62\">",
"      M&uuml;ller NL, Ooi GC, Khong PL, et al. High-resolution CT findings of severe acute respiratory syndrome at presentation and after admission. AJR Am J Roentgenol 2004; 182:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/63\">",
"      Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 2004; 191:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/64\">",
"      Lam CM, Wong SF, Leung TN, et al. A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome. BJOG 2004; 111:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/65\">",
"      Nicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003; 361:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/66\">",
"      Chen X, Zhou B, Li M, et al. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis 2004; 189:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/67\">",
"      Chan KH, Cheng VC, Woo PC, et al. Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63. Clin Diagn Lab Immunol 2005; 12:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/68\">",
"      Patrick DM, Petric M, Skowronski DM, et al. An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus. Can J Infect Dis Med Microbiol 2006; 17:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/69\">",
"      Tang P, Louie M, Richardson SE, et al. Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. CMAJ 2004; 170:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/70\">",
"      Poon LL, Guan Y, Nicholls JM, et al. The aetiology, origins, and diagnosis of severe acute respiratory syndrome. Lancet Infect Dis 2004; 4:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/71\">",
"      Ng EK, Hui DS, Chan KC, et al. Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem 2003; 49:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/72\">",
"      Poon LL, Chan KH, Wong OK, et al. Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol 2003; 28:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/73\">",
"      Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis 2004; 10:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/74\">",
"      Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006; 3:e343.",
"     </a>",
"    </li>",
"    <li>",
"     Lv, H, de Vlas, SJ, Liu, W, et al. Avascular osteonecrosis after treatment of SARS: a 3-year longitudinal study. Trop Med Int Health 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/76\">",
"      Chiou HE, Liu CL, Buttrey MJ, et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest 2005; 128:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/77\">",
"      Groneberg DA, Poutanen SM, Low DE, et al. Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis 2005; 5:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/78\">",
"      Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003; 290:3222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/79\">",
"      Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003; 9:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/80\">",
"      Pang X, Zhu Z, Xu F, et al. Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing, 2003. JAMA 2003; 290:3215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/81\">",
"      Svoboda T, Henry B, Shulman L, et al. Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto. N Engl J Med 2004; 350:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/82\">",
"      Enjuanes L, Dediego ML, Alvarez E, et al. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res 2008; 133:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/83\">",
"      Liu J, Sun Y, Qi J, et al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J Infect Dis 2010; 202:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/84\">",
"      Pang H, Liu Y, Han X, et al. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J Gen Virol 2004; 85:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/85\">",
"      Buchholz UJ, Bukreyev A, Yang L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A 2004; 101:9804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/86\">",
"      Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003; 362:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/87\">",
"      Huang J, Ma R, Wu CY. Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses. Vaccine 2006; 24:4905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/88\">",
"      Bukreyev A, Lamirande EW, Buchholz UJ, et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004; 363:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/89\">",
"      Yasui F, Kai C, Kitabatake M, et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 2008; 181:6337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/90\">",
"      Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 2004; 101:2536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/91\">",
"      Bian C, Zhang X, Cai X, et al. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody. Virology 2009; 383:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17753/abstract/92\">",
"      ter Meulen J, van den Brink EN, Poon LL, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 2006; 3:e237.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3027 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17753=[""].join("\n");
var outline_f17_21_17753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Scope of outbreak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intermediate host and reservoir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Molecular epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Incubation period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prognostic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Infection control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Vaccine development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3027\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3027|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/7/14448\" title=\"diagnostic image 1\">",
"      SARS CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/40/31360\" title=\"diagnostic image 2\">",
"      SARS CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3027|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/15/18678\" title=\"figure 1\">",
"      Coronavirus replication",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41176?source=related_link\">",
"      Coronaviruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/42/4770?source=related_link\">",
"      Patient information: Severe Acute Respiratory Syndrome (SARS) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_21_17754="Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging";
var content_f17_21_17754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17754/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17754/contributors\">",
"     H Richard Alexander, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17754/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17754/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/21/17754/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/21/17754/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/21/17754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant mesothelioma is a highly lethal malignancy of the serosal membranes of the pleura, peritoneum, pericardium, or tunica vaginalis testes. This is a rare disease. As an example, of the approximately 3300 cases of mesothelioma diagnosed in the United States every year, only 10 to 15 percent are peritoneal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The peritoneum is the second most frequent site of origin of mesothelioma, following the pleura. The pathogenesis of all forms of mesothelioma is strongly associated with industrial pollutants, of which asbestos is the principal carcinogen associated with the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology of malignant mesothelioma\", section on 'Asbestos exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignant peritoneal mesothelioma (MPM) is an understudied disease, largely because most molecular and clinical studies have been conducted predominantly in patients with the more common pleural variant. However, it is not clear that the two diseases are similar. While they share the same predominant risk factor (asbestos exposure), gene expression profiles of pleural and peritoneal mesotheliomas are distinct, suggesting differences in molecular pathogenesis between the two [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will cover the epidemiology, histology, clinical features, diagnosis and staging of MPM. Treatment of MPM and the epidemiology, pathology, clinical presentation, diagnosis, and staging of pleural, pericardial, and testicular mesothelioma are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35593?source=see_link\">",
"     \"Malignant peritoneal mesothelioma: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=see_link\">",
"     \"Epidemiology of malignant mesothelioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=see_link\">",
"     \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, malignant peritoneal mesothelioma (MPM) accounts for about 10 to 15 percent of all cases of mesothelioma, and there are about 400 new cases diagnosed annually [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Mesothelioma rates are rising worldwide, largely a reflection of occupational asbestos exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/1,4,7,8\">",
"     1,4,7,8",
"    </a>",
"    ]. The incidence is expected to peak between 2015 and 2025. However, pleural mesothelioma accounts for most of the rising number of cases. At least in the US, incidence rates of MPM have remained stable over the last 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=see_link\">",
"     \"Epidemiology of malignant mesothelioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to pleural mesothelioma, which has a male predominance (male to female ratio of between four and five to one), men comprise a smaller proportion of cases of MPM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/1,2,4,10\">",
"     1,2,4,10",
"    </a>",
"    ]. As an example, in a study of the 10,589 cases of mesothelioma reported to the SEER database between 1973 and 2005, 44 percent of the 1112 peritoneal cases arose in women as compared to 19 percent of the 9211 pleural primaries [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The higher proportion of females who develop MPM is generally interpreted to reflect a higher background rate of mesothelioma that is unrelated to asbestos exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Asbestos'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The median age at presentation is 53, younger than that of the average patient with pleural mesothelioma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. Although MPM is typically a disease of adults, childhood cases have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Asbestos",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a strong relationship between asbestos exposure and the development of mesothelioma at any location. The lifetime risk of developing mesothelioma among asbestos workers is thought to be as high as 10 percent, and the latency period between exposure and the development of mesothelioma is approximately 30 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology of malignant mesothelioma\", section on 'Asbestos exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The link between exposure to asbestos and MPM is less strong than it is for pleural mesothelioma, particularly among women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/11,16-18\">",
"     11,16-18",
"    </a>",
"    ]. In a population-based study that was based upon telephone interviews of mesothelioma cases and controls, the attributable risk for exposure to asbestos was 58 percent for peritoneal and 88 percent for pleural mesothelioma among men, and 23 percent for both types among women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/11\">",
"     11",
"    </a>",
"    ]. The reason for this gender difference is unclear, but misclassification of exposure history in women may be in part responsible.",
"   </p>",
"   <p>",
"    Nevertheless, asbestos is the best defined risk factor for MPM, as reflected by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In cohorts of workers exposed to asbestos, MPM was responsible for 0.1 to 1 percent of all deaths [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The role of occupational asbestos exposure in causing MPM was confirmed in two community-based studies [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/11,19\">",
"       11,19",
"      </a>",
"      ]. In one, the odds ratio of a peritoneal cancer was 180 (95% CI 23.5 to 1375) for insulation workers and 7.6 (95% CI 2.3 to 25.5) for manufacturers of nonmetallic mineral products, including asbestos.",
"     </li>",
"     <li>",
"      Two studies provide evidence for an increased risk of MPM with non-occupational (ie, household or residential) exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MPM induced by asbestos generally requires a higher cumulative dose than its pleural counterpart [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. The risk of MPM is proportional to the square of cumulative exposure, while the risk of pleural mesothelioma rises less than linearly with the cumulative asbestos dose [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, the risk of pleural mesothelioma appears to rise more steeply at low levels of exposure, while at higher levels of exposure, peritoneal tumors predominate.",
"   </p>",
"   <p>",
"    This concept can be illustrated by an early study examining the relative risk (RR) of developing pleural or peritoneal mesothelioma based upon the type of occupation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/23\">",
"     23",
"    </a>",
"    ]. Relative risks (RRs) ranged from 2.6 in construction workers to 46.1 in insulation workers. Occupations with the highest overall RR had a higher proportion of peritoneal primaries. In fact, 44 percent of the mesotheliomas that arose in these groups were peritoneal. The biologic basis underlying this observation is not understood.",
"   </p>",
"   <p>",
"    The main fiber type implicated in the US is amosite (an amphibole); in contrast to pleural mesothelioma, chrysotile has not been convincingly shown to cause MPM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology of malignant mesothelioma\", section on 'Asbestos exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although asbestos exposure is the predominant defined risk factor, there are also case reports of MPM arising in irradiated fields, although the number is small overall and the magnitude of the risk is undefined [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Due to the low number of reported cases, full-scale epidemiologic studies on the relationship between prior irradiation and peritoneal mesothelioma have not been possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology of malignant mesothelioma\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to other mineral fibers (eg, erionite, a silicate fiber of the zeolite family) is reported to be a risk factor for peritoneal as well as pleural mesothelioma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology of malignant mesothelioma\", section on 'Asbestos exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MPM has been reported in three separate cohorts of patients who received thorotrast for radiological examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The cumulative incidence of MPM in these series is 0.2 to 0.6 percent, higher than that seen in many cohorts of asbestos-exposed workers (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Asbestos'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    A large number of pleural mesotheliomas contain sequences of the papovavirus, simian virus 40 (SV40), and this has been seen in peritoneal mesothelioma as well. In one study, 7 of 11 German cases of MPM were positive for SV40 sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the causal nature of this association has been questioned, and laboratory contamination may explain some of the findings [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology of malignant mesothelioma\", section on 'Viral oncogenes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cases of MPM have also been reported in the setting of chronic peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], and an increased risk of MPM has been associated with a diet low in vegetable consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND IMAGING FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no signs or symptoms that are specific for malignant peritoneal mesothelioma (MPM). Although most cases are symptomatic, a few are diagnosed incidentally, after inquiry into an unrelated process, such as infertility, or recognized during a routine physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of cases of MPM present with diffuse peritoneal involvement and are variably referred to as diffuse peritoneal mesothelioma, malignant peritoneal mesothelioma or just peritoneal mesothelioma. However, a minority of cases has localized disease, and they have a different presentation and natural history [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse MPM is highly aggressive, with a few exceptions (such as the well-differentiated papillary mesotheliomas that occur in women) (see",
"      <a class=\"local\" href=\"#H8237767\">",
"       'Well-differentiated papillary mesothelioma'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      In contrast, patients with a localized MPM usually have a good prognosis following complete surgical excision.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12630199\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Diffuse versus localized peritoneal mesothelioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of diffuse MPM are related to ascites or tumor progression within the abdominal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Common complaints include abdominal distention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increasing abdominal girth, abdominal pain or discomfort, nausea, anorexia, and weight loss. Gastrointestinal complications such as bowel obstruction are usually a manifestation of advanced disease.",
"   </p>",
"   <p>",
"    Due to the nonspecific nature of the presenting symptoms, many patients already have an advanced disease burden at diagnosis. A minority is asymptomatic and diagnosed incidentally, often as the result of a palpated abdominal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abdominal distention (increased abdominal girth), the most frequent initial symptom, is present in 30 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. It can cause early satiety, dysphagia, and shortness of breath, all of which contribute to weight loss, impaired performance status, and overall inanition. Abdominal distension may also manifest as a new or worsening abdominal wall hernia, which, if subject to attempted surgical repair, may reveal the unsuspected diagnosis of a mesothelioma.",
"   </p>",
"   <p>",
"    Most patients with abdominal distention due to excess energy intake or who develop progressive accumulation of ascites associated with nonmalignant conditions (eg, cirrhosis) gain weight. Decreasing weight associated with loss of lean body mass in a patient with progressively increasing abdominal girth should raise suspicion for malignant ascites secondary to a peritoneal surface malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39928?source=see_link&amp;anchor=H4#H4\">",
"     \"Malignancy-related ascites\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pain is the second most common initial symptom and is present at diagnosis in 27 to 58 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/38,44-46\">",
"     38,44-46",
"    </a>",
"    ]. In most cases, the pain is diffuse and nonspecific, although a small minority present with an acute abdomen secondary to perforation or obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The less common localized form of MPM presents as a focal, circumscribed mass that may invade locally and extend into adjacent organs, but typically does not spread diffusely throughout the peritoneal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Patients may complain of localized abdominal pain or have a palpable abdominal or pelvic mass [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12630315\">",
"    <span class=\"h3\">",
"     Pattern of spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidity and mortality from MPM are almost invariably due to disease progression within the peritoneal cavity. However, MPM may also extend into the pleural cavity during the latter stages of disease progression, causing a pleural effusion.",
"   </p>",
"   <p>",
"    Uncommonly, MPM metastasizes to the abdominal and pelvic lymph nodes. Lymph node metastases are found in approximately 20 to 28 percent of patients undergoing cytoreductive surgery for diffuse MPM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Notably, the majority of clinically suspicious lymph nodes are not pathologically positive [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distant metastases are very uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. In a multi-institutional registry-based series of 294 patients with MPM, only 12 had extraabdominal metastases (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Paraneoplastic phenomena",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of paraneoplastic phenomena have been described in the setting of mesothelioma, including [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Thrombocytosis",
"     </li>",
"     <li>",
"      Malignancy-related thrombosis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"       \"Hypercoagulable disorders associated with malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"     <li>",
"      Rarely, Coombs-positive hemolytic anemia (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H3#H3\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Antibody detection: the direct Coombs' test'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11317884\">",
"    <span class=\"h3\">",
"     Diffuse mesothelioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) is the most useful initial diagnostic study and is typically the first test ordered in a patient with abdominal pain and increasing abdominal girth. The peritoneal masses and nodules may enhance on CT after intravenous injection of iodinated contrast material. However, CT, as with other imaging modalities, tends to underestimate the actual burden of disease. Positron emission tomography (PET scanning) has been used for staging, but it is not reliable for assessing disease extent in MPM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The imaging patterns and features of MPM are shown equally well on magnetic resonance imaging (MRI). Limited reports describe the signal intensity of MPM as intermediate to low on T1-weighted images and intermediate to high on T2-weighted images [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/61\">",
"     61",
"    </a>",
"    ]. More recently, diffusion-weighted and dynamic gadolinium-enhanced MRI have been shown to accurately reflect disease burden in the abdominal cavity both initially and during posttreatment follow-up evaluation of patients with MPM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/62\">",
"     62",
"    </a>",
"    ]. MRI may become the primary assessment method in a patient undergoing long-term follow-up evaluation after initial treatment for MPM who cannot receive iodinated contrast or in a woman with a pelvic mass found at clinical examination or ultrasound.",
"   </p>",
"   <p>",
"    Diffuse MPM can produce a variety of patterns on cross-sectional imaging:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse and widespread involvement of the peritoneal cavity, tumor infiltration, and",
"      <span class=\"nowrap\">",
"       irregular/nodular",
"      </span>",
"      thickening of the peritoneum in a sheet-like fashion.",
"     </li>",
"     <li>",
"      Less commonly, there is a focal pattern of involvement with a dominant intraperitoneal mass with or without associated peritoneal studding [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/63\">",
"       63",
"      </a>",
"      ]. In some studies, this pattern has been more common with the sarcomatous subtype [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the primary tumor, moderate to extensive (rarely massive) ascites is present in 60 to 100 percent of newly diagnosed patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73499 \" href=\"UTD.htm?37/53/38740\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/44,64\">",
"     44,64",
"    </a>",
"    ]. Other findings include omental",
"    <span class=\"nowrap\">",
"     caking/thickening,",
"    </span>",
"    scalloping or direct invasion of intraabdominal organs such as the liver, and diaphragmatic involvement; multiloculated large cystic areas may also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sheet-like pattern of growth may extend to the visceral peritoneal surfaces of the small bowel, encasing it and leading to the appearance of a thick intestinal wall on cross sectional images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58254 \" href=\"UTD.htm?28/55/29555\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/63\">",
"     63",
"    </a>",
"    ]. Infiltration of the small bowel mesentery can lead to fixation of the position of the bowel loops and the mesentery, with apparent straightening of the course of the mesenteric vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/63,66-68\">",
"     63,66-68",
"    </a>",
"    ]. These findings, in conjunction with a linearly oriented tumor in the mesentery, produce a characteristic \"pleated\" appearance on cross-sectional imaging (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74187 \" href=\"UTD.htm?27/28/28098\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcifications within diffuse MPM are considered rare. Calcified plaques are seen less often than with pleural mesothelioma; however, calcified pleural plaques and other signs associated with asbestos exposure may be present in the chest in up to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Published frequencies of positive CT findings are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef82228 \" href=\"UTD.htm?41/18/42283\">",
"     table 1",
"    </a>",
"    ). For patients being considered for aggressive locoregional therapy, results from the initial staging CT scan can be used to predict the likelihood of complete surgical cytoreduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35593?source=see_link&amp;anchor=H135336274#H135336274\">",
"     \"Malignant peritoneal mesothelioma: Treatment\", section on 'Cytoreductive surgery and intraperitoneal chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Localized mesothelioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized mesothelioma is an uncommon manifestation of the disease. The localized type of MPM appears as a heterogeneous, solid intraperitoneal mass on cross sectional imaging. The margins are often irregular, and there may be scalloping or direct invasion of adjacent visceral structures such as the liver, spleen, or pelvic organs. Localized, loculated ascitic fluid may be present, but manifestations of diffuse peritoneal involvement (generalized ascites, omental caking, and peritoneal nodularity) are characteristically absent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on imaging findings, the differential diagnosis for a typical diffuse MPM includes peritoneal carcinomatosis, serous peritoneal carcinoma, ovarian carcinoma in women, lymphomatosis, and tuberculous peritonitis. There are no imaging features that are specific for MPM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/44\">",
"     44",
"    </a>",
"    ], although some features may help to suggest a specific diagnosis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36614?source=see_link\">",
"     \"Tuberculous peritonitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver metastases and lymphadenopathy are more common with peritoneal carcinomatosis from gastrointestinal tract primary neoplasms than they are with MPM [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The finding of diffuse adenopathy with a lack of omental involvement should raise suspicion for lymphomatosis.",
"     </li>",
"     <li>",
"      Tuberculous peritonitis is usually characterized by smooth peritoneal thickening, mesenteric lymphadenopathy with central necrosis, ascites with high attenuation, and splenomegaly.",
"     </li>",
"     <li>",
"      In women, the main differential is between diffuse MPM and serous carcinoma of the peritoneum [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/69\">",
"       69",
"      </a>",
"      ]. This entity is a primary neoplasm arising within the peritoneum but is not likely of mesothelial cell origin. Instead, it is considered to arise from ovarian epithelial rests that are a remnant of the ovary's descent into the pelvis. Any of the pelvic adnexa may, in fact, be a source of these cells. These tumors are histologically, immunophenotypically, and clinically distinct from mesothelioma, but similar to epithelial carcinomas of the ovary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link&amp;anchor=H7#H7\">",
"       \"Epithelial ovarian cancer: Pathology\", section on 'Peritoneal carcinoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Two related primary malignancies of the peritoneum with distinctive characteristics on CT are well-differentiated papillary mesothelioma, and multicystic mesothelioma. These tumors are important to distinguish from diffuse peritoneal mesothelioma because their treatment strategy is primarily surgical and the clinical course is largely benign. (See",
"      <a class=\"local\" href=\"#H8237760\">",
"       'Peritoneal mesothelioma variants'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11317891\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum chemistries and tumor markers are of no value in establishing a diagnosis of MPM. Elevated levels of hyaluronan, CA-125, alpha fetoprotein, carcinoembryonic antigen, and mesothelin are found in some patients, and there is often a correlation between elevated levels and disease progression. However, for diagnostic purposes, the specificity of all of these tumor markers is low [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/44,70\">",
"     44,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of these markers (particularly CA-125 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/70\">",
"     70",
"    </a>",
"    ] and mesothelin) may prove useful to follow response to therapy or for posttreatment surveillance, if they are initially elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11317970\">",
"    <span class=\"h3\">",
"     Mesothelin and soluble mesothelin-related peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesothelin is a glycoprotein that is expressed on the surface of normal mesothelial cells and highly overexpressed in malignant mesothelioma. Soluble mesothelin-related peptides (SMRPs) are believed to be either cleaved peptide fragments of mesothelin, or abnormal variants of mesothelin that are unable to bind to membranes and are found in the serum. Mesothelin and its associated peptide fragments appear to be of some value as tumor markers in mesothelioma, although limited to the epithelioid and biphasic subtypes. The bulk of the data are in patients with the pleural variant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=see_link&amp;anchor=H1568139510#H1568139510\">",
"     \"Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma\", section on 'Mesothelin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An ELISA is commercially available (Mesomark&trade; assay) to measure serum levels of SMRPs that are shed into the circulation in patients with mesothelioma. Lack of sensitivity and specificity limits the utility of this marker for diagnostic purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. As an example, in one report, elevated levels (&ge;9",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    were seen in 40 of 56 (71 percent) of patients with mesothelioma (primary site not specified), in 13 percent of randomly selected hospitalized patients without a diagnosis of cancer, and in 8 of 21 patients with advanced ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum levels of SRMP are potentially more useful as a marker of disease activity in patients with an established diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/71,73\">",
"     71,73",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of peritoneal mesothelioma should be considered in any individual with evidence of a diffuse malignant process in the abdomen on initial clinical and radiographic evaluation, and it can usually be established cytologically or by biopsy.",
"   </p>",
"   <p>",
"    In general, cytologic analysis of ascitic fluid is of limited diagnostic utility. Although a diagnosis of mesothelioma can be made cytologically [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/74\">",
"     74",
"    </a>",
"    ], fluid cytology is often inconclusive and has a low yield [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/45,58\">",
"     45,58",
"    </a>",
"    ]. The differentiation between benign or malignant causes of mesothelial cell proliferation can be especially difficult. Cytology does not allow for assessment of true stromal invasion into the peritoneum or the underlying viscera, the defining parameter of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/75\">",
"     75",
"    </a>",
"    ]. Invasion can only be seen on histologic study of solid tumor material. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39928?source=see_link&amp;anchor=H21#H21\">",
"     \"Malignancy-related ascites\", section on 'Cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CT-guided core needle biopsy or laparoscopic biopsy may both provide sufficient material to make a tissue diagnosis. Features seen on hematoxylin and eosin (H&amp;E)-stained sections and immunohistochemical staining characteristics usually allow the differentiation of mesothelioma from other tumors. Because of the propensity for mesothelioma to seed needle tracts or trocar sites [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/45\">",
"     45",
"    </a>",
"    ], the site of the",
"    <span class=\"nowrap\">",
"     biopsy/laparoscopic",
"    </span>",
"    port sites are usually excised at the time of surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35593?source=see_link&amp;anchor=H135336288#H135336288\">",
"     \"Malignant peritoneal mesothelioma: Treatment\", section on 'Technique'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grossly, MPM is characterized macroscopically by hundreds to thousands of individual tumor nodules of varying size and consistency that are usually diffusely disseminated throughout the peritoneal cavity (",
"    <a class=\"graphic graphic_picture graphicRef82141 \" href=\"UTD.htm?3/2/3109\">",
"     picture 1",
"    </a>",
"    ). The lesions may range from diffuse subcentimeter gray hard nodules to large nodular masses that spread in sheets and coalesce to form plaques and masses, replacing the omentum, circumferentially encasing the bowels, and invading solid organs, mesentery, and diaphragm. These tumors may have a gelatinous consistency, depending on the hyaluronic acid content, and as they progress, they interrupt peritoneal lymphatics and produce exudative fluid from their surfaces, resulting in ascites.",
"   </p>",
"   <p>",
"    Histologic examination of routine hematoxylin-eosin stained sections allows the classification of MPM into one of three broad histologic subtypes, epithelioid, sarcomatoid, and biphasic (mixed); the characteristic histological patterns are similar to those encountered in pleural mesothelioma (",
"    <a class=\"graphic graphic_picture graphicRef59108 \" href=\"UTD.htm?38/45/39640\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/76\">",
"     76",
"    </a>",
"    ]. Tubulopapillary (well-differentiated) mesothelioma, a rare variant that is seen more often in the peritoneum than in the pleura, is discussed below. (See",
"    <a class=\"local\" href=\"#H8237767\">",
"     'Well-differentiated papillary mesothelioma'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29204?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathology of malignant pleural mesothelioma\", section on 'Histology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epithelioid malignant mesotheliomas are composed of cells that resemble normal mesothelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/40\">",
"       40",
"      </a>",
"      ]. Architecturally, they form a tubulopapillary or trabecular pattern. Flattened or cuboidal cells with monotonous nuclei line the papilla or tubules. Mitotic figures are uncommon. The tumor infiltrates submesothelial connective tissue, fat,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      muscle. There may be other characteristics, such as signet-ring cell structure or a desmoplastic response, which makes it difficult to distinguish from another adenocarcinoma on histologic analysis alone.",
"     </li>",
"     <li>",
"      The sarcomatous pattern, which is less common in the peritoneum as compared to the pleura, is typically composed of tightly packed spindle cells. Malignant osteoid, chondroid, or muscular elements may be present within the tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A biphasic tumor is defined as one with both epithelioid and sarcomatous components, each contributing more than 10 percent to the overall histology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As in the pleura, peritoneal mesotheliomas with a sarcomatoid component have a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/45,77\">",
"     45,77",
"    </a>",
"    ]. In one report, the median survival for the epithelioid subgroups of MPM was 55 months, compared to 13 months for the combined sarcomatoid and biphasic subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/45\">",
"     45",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    The distinction between benign and malignant mesothelial proliferations is sometimes challenging:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histologic evidence of invasion is the defining parameter in the distinction between malignant or benign mesothelial proliferations. However, even in biopsy or surgical specimens, mesothelial cells are frequently subject to entrapment in adhesions, fat lobules and inflammatory tissue that may falsely suggest stromal invasion. In particular, the pelvic adnexa are notorious for granulomatous and adhesive mesothelial entrapment, due to the intense inflammatory conditions that frequent this part of the anatomy. Also, cells in ascites can sediment onto a mesothelial surface which, when biopsied, resembles a mesothelial proliferation that has subserosal invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Atypia and necrosis are more common in malignant tumors but are neither sufficiently sensitive nor specific for distinguishing between benign and malignant mesothelium.",
"     </li>",
"     <li>",
"      A promising but still new area of investigation that may help to differentiate benign from malignant mesothelium is immunohistochemical labeling of telomerase. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29204?source=see_link&amp;anchor=H5#H5\">",
"       \"Pathology of malignant pleural mesothelioma\", section on 'Immunohistochemistry'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although immunohistochemical staining (IHC) for several markers can assist in identifying mesothelial cells, none is specific for mesothelioma. Instead, a panel of markers is generally used to help differentiate a mesothelioma from more common tumors, such as metastatic adenocarcinoma, peritoneal serous carcinoma, and soft tissue sarcoma, which might have a similar histologic appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/63,67,78,79\">",
"     63,67,78,79",
"    </a>",
"    ]. The most useful of these are summarized below (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29204?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathology of malignant pleural mesothelioma\", section on 'Immunohistochemistry'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast to adenocarcinomas, MPM produces large amounts of hyaluronic acid, and the distinction can be easily made with the use of colloidal iron or alcian blue and hyaluronidase.",
"     </li>",
"     <li>",
"      Another differentiating feature is the presence or absence of neutral mucin as determined by the periodic acid Schiff (PAS) stain and diastase; MPM is invariably devoid of neutral mucin [",
"      <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/80-82\">",
"       80-82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mesotheliomas usually stain negative for other adenocarcinoma markers, including CEA, LeuM1, Ber-Ep4, B72.3, Bg8, and MOC-31.",
"     </li>",
"     <li>",
"      Most mesotheliomas stain positively for calretinin, cytokeratins",
"      <span class=\"nowrap\">",
"       5/6,",
"      </span>",
"      Wilms tumor-1 (WT-1), thrombomodulin, and mesothelin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, IHC staining for cytokeratin",
"    <span class=\"nowrap\">",
"     5/6,",
"    </span>",
"    calretinin and WT-1 (positive markers for mesothelioma), and CEA, Ber-Ep4, LeuM1 and Bg8 (negative in mesothelioma) represents the most helpful panel of markers for MPM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/63,67,76\">",
"     63,67,76",
"    </a>",
"    ].The use of at least two mesothelioma markers and two carcinoma markers is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, when an epithelioid mesothelioma is extremely dedifferentiated or if it is a desmoplastic variant, ultrastructural analysis via electron microscopy may be beneficial, although it is rarely needed. Among patients who have a peritoneal primary tumor, electron microscopy is less helpful for the differentiation of a sarcomatous mesothelioma from a soft tissue sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29204?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathology of malignant pleural mesothelioma\", section on 'Electron microscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     STAGING AND THE STAGING WORKUP",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no uniformly accepted staging system for MPM. The peritoneal cancer index, which is derived from radiographic imaging and intraoperative evaluation, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35593?source=see_link&amp;anchor=H135336281#H135336281\">",
"     \"Malignant peritoneal mesothelioma: Treatment\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the low frequency of disease spread outside of the peritoneum, a staging evaluation for distant metastases is generally not needed, unless there are symptoms suggesting metastases to a distant organ. For patients who present with a pleural effusion, further diagnostic testing with thoracentesis or video-assisted thoracoscopic surgery (VATS) is important to eliminate the possibility of tumor spread into the pleural cavity, which might alter the therapeutic approach. A novel tumor-nodal-metastases or &ldquo;TNM&rdquo; staging system has been proposed that takes into account the extent of disease in the peritoneum (T stage), the presence of intra-abdominal lymph node metastases (N), and the absence or presence of extra-abdominal disease (M) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/54\">",
"     54",
"    </a>",
"    ]. T stage is calculated based on the peritoneal cancer index (PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/83\">",
"     83",
"    </a>",
"    ]), a measure of the volume and extent of tumor deposits as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      T1 &ndash; PCI 1-10",
"     </li>",
"     <li>",
"      T2 &ndash; PCI 11-20",
"     </li>",
"     <li>",
"      T3 &ndash; PCI 21-30",
"     </li>",
"     <li>",
"      T4 &ndash; PCI 31-39",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stage groupings, which were associated with a progressive decrease in survival, were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &ndash; T1 N0 M0; five-year survival 87 percent",
"     </li>",
"     <li>",
"      Stage II &ndash; T2-3 N0 M0; five-year survival 53 percent",
"     </li>",
"     <li>",
"      Stage III &ndash; T4 N0-1 M0, T1-4 N1 M01-, and T1-4 N0-1 M1; five-year survival 29 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35593?source=see_link\">",
"     \"Malignant peritoneal mesothelioma: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8237760\">",
"    <span class=\"h1\">",
"     PERITONEAL MESOTHELIOMA VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two rare variants of peritoneal mesothelioma. Both are characterized by indolent behavior and the potential for malignant transformation to MPM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8237767\">",
"    <span class=\"h2\">",
"     Well-differentiated papillary mesothelioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-differentiated papillary mesothelioma is a rare clinicopathologic entity that is distinct from MPM. It occurs predominantly in women of reproductive age and most often arises from the peritoneal surfaces of the pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/63\">",
"     63",
"    </a>",
"    ]. There is no reported association with asbestos exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These indolent tumors are small (most &lt;2 cm) and typically identified as an incidental finding at surgery performed for another indication [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. On histologic analysis, the tumors have a well-developed papillary architecture with uniform, flat or cuboidal epithelium lining the papilla. Invasion is absent. These tumors must be differentiated from ordinary diffuse MPM with focal papillary architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The radiologic appearance is rarely described. There may be plaque-like calcification that diffusely involves the visceral and parietal peritoneum without the presence of an associated soft tissue mass [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/88\">",
"     88",
"    </a>",
"    ]. Rarely, there is peritoneal thickening, multiple peritoneal nodules, omental infiltration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascites.",
"   </p>",
"   <p>",
"    Well-differentiated papillary mesothelioma is generally considered a low-grade malignancy, with a high rate of cure following complete surgical resection, although long-term follow-up is required because of the potential to recur and progress to true MPM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35593?source=see_link&amp;anchor=H135336358#H135336358\">",
"     \"Malignant peritoneal mesothelioma: Treatment\", section on 'Well-differentiated papillary mesothelioma'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8237774\">",
"    <span class=\"h2\">",
"     Multicystic mesothelioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multicystic mesothelioma is an unusual cystic tumor that most commonly arises from the pelvic peritoneal surfaces in young and middle-aged women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/40,89-91\">",
"     40,89-91",
"    </a>",
"    ]. Men represent only 17 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/90\">",
"     90",
"    </a>",
"    ]. There is no association with asbestos exposure.",
"   </p>",
"   <p>",
"    There is ongoing debate as to the origin of this lesion. This controversy is reflected in the variety of names used to describe this entity, including multicystic mesothelioma (the predominant terminology used), cystic mesothelioma, benign cystic mesothelioma, and peritoneal inclusion cyst. Many women have a history of prior pelvic surgery, endometriosis, or pelvic inflammatory disease, which some consider support for classification as a reactive mesothelial proliferation. Furthermore, the histologic appearance is bland and the biologic behavior is indolent, despite the high rate of recurrence after surgical treatment (up 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/89\">",
"     89",
"    </a>",
"    ]. The presence of this lesion has not altered patient survival in the vast majority of cases. However, there have been isolated reports of malignant transformation to aggressive diffuse malignant mesothelioma, a finding that tends to favor (but does not prove) a neoplastic rather than reactive origin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/40,69,90-92\">",
"     40,69,90-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of cases present with chronic or intermittent lower abdominal or pelvic pain, but occasionally, the diagnosis is made incidentally at surgery or on cross-sectional imaging. On CT or MRI scan, the cysts have fluid attenuation values, and the septae enhance with IV iodinated contrast and gadolinium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/61\">",
"     61",
"    </a>",
"    ]. There may be thick-walled cysts that appear as soft tissue attenuation lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/93\">",
"     93",
"    </a>",
"    ]. On ultrasound, there are multiseptated structures that have an intimate anatomic association with the uterus and ovaries. The fluid within the cysts is usually anechoic. The main differential diagnosis is with cystic lymphangioma, cystic epithelial neoplasms of the ovaries, endometriosis, and pseudomyxoma peritonei.",
"   </p>",
"   <p>",
"    Pathologically, these tumors are large (mean size at diagnosis 13 cm) and consist of multiple grape-like clusters of mesothelium-lined cysts that grow along the pelvic peritoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?17/21/17754/abstract/63,94\">",
"     63,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the disease is well characterized histologically, the pathogenesis, natural history, and clinical management are not well defined. The clinical course is usually indolent, and surgical resection can be curative. However, as with the well-differentiated papillary mesothelioma, long-term follow-up is needed, since local recurrence can occur in up to 50 percent from 1 to 27 years after initial diagnosis, and malignant transformation is reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35593?source=see_link&amp;anchor=H135336365#H135336365\">",
"     \"Malignant peritoneal mesothelioma: Treatment\", section on 'Multicystic mesothelioma'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant peritoneal mesothelioma (MPM) is an aggressive neoplasm that arises from the lining mesothelial cells of the peritoneum and spreads rapidly within the confines of the abdominal cavity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with mesothelioma arising in other sites, there is a strong relationship between asbestos exposure and the development of MPM. However, the link between exposure to asbestos and peritoneal mesothelioma is less strong than it is for pleural mesothelioma, particularly among women. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of cases of MPM present with diffuse peritoneal involvement. Common complaints include abdominal distention",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increasing abdominal girth, abdominal pain, nausea, anorexia, and weight loss. Rarely, patients present with a paraneoplastic syndrome (fever, thrombocytosis, hypoglycemia). (See",
"      <a class=\"local\" href=\"#H12630199\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The imaging patterns and features of MPM are shown equally well on CT and magnetic resonance imaging. The pattern of involvement is usually diffuse and widespread involvement of the peritoneal cavity with tumor infiltration and",
"      <span class=\"nowrap\">",
"       irregular/nodular",
"      </span>",
"      thickening of the peritoneum in a sheetlike fashion, usually with moderate to extensive ascites. Less commonly, there is a focal pattern of involvement with a dominant intraperitoneal mass with or without associated peritoneal studding. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radiographic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      None of the radiographic findings is sufficiently specific for MPM to avoid the need for tissue diagnosis. Ascitic fluid cytology is often inconclusive, especially in distinguishing between malignant and benign mesothelial proliferations. CT-guided core needle biopsy or laparoscopic biopsy may provide sufficient material to establish the diagnosis, which usually requires a panel of immunohistochemical stains. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis and histology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no tumor markers with sufficient sensitivity or specificity to be useful in the diagnostic evaluation of a patient with suspected MPM. (See",
"      <a class=\"local\" href=\"#H11317891\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no uniformly accepted staging system for MPM. Given the very low risk of extraabdominal spread, a radiographic staging workup is generally not needed in the absence of symptoms. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Staging and the staging workup'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two rare variants of peritoneal mesothelioma, well-differentiated papillary mesothelioma and multicystic mesothelioma (peritoneal inclusion cyst), which are both are characterized by a localized presentation, indolent behavior, and the potential for malignant transformation to MPM. (See",
"      <a class=\"local\" href=\"#H8237760\">",
"       'Peritoneal mesothelioma variants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/1\">",
"      Teta MJ, Mink PJ, Lau E, et al. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev 2008; 17:525.",
"     </a>",
"    </li>",
"    <li>",
"     SEER Cancer Statistics Review - Mesothelioma fast stats. file://seer.cancer.gov/faststats/selections.php?series=cancer (Accessed on April 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/3\">",
"      Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007; 18:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/4\">",
"      Rodr&iacute;guez D, Cheung MC, Housri N, Koniaris LG. Malignant abdominal mesothelioma: defining the role of surgery. J Surg Oncol 2009; 99:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/5\">",
"      L&oacute;pez-R&iacute;os F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006; 66:2970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/6\">",
"      Borczuk AC, Cappellini GC, Kim HK, et al. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 2007; 26:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/7\">",
"      Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/8\">",
"      Watterson A, Gorman T, Malcolm C, et al. The economic costs of health service treatments for asbestos-related mesothelioma deaths. Ann N Y Acad Sci 2006; 1076:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/9\">",
"      Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control 2009; 20:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/10\">",
"      Hemminki K, Li X. Time trends and occupational risk factors for peritoneal mesothelioma in Sweden. J Occup Environ Med 2003; 45:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/11\">",
"      Spirtas R, Heineman EF, Bernstein L, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 1994; 51:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/12\">",
"      Averbach AM, Sugarbaker PH. Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res 1996; 81:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/13\">",
"      Niggli FK, Gray TJ, Raafat F, Stevens MC. Spectrum of peritoneal mesothelioma in childhood: clinical and histopathologic features, including DNA cytometry. Pediatr Hematol Oncol 1994; 11:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/14\">",
"      Moran CA, Albores-Saavedra J, Suster S. Primary peritoneal mesotheliomas in children: a clinicopathological and immunohistochemical study of eight cases. Histopathology 2008; 52:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/15\">",
"      Cioffredi LA, J&auml;nne PA, Jackman DM. Treatment of peritoneal mesothelioma in pediatric patients. Pediatr Blood Cancer 2009; 52:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/16\">",
"      Goldblum J, Hart WR. Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors. Am J Surg Pathol 1995; 19:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/17\">",
"      Kerrigan SA, Turnnir RT, Clement PB, et al. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer 2002; 94:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/18\">",
"      Roggli VL, Sharma A, Butnor KJ, et al. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 2002; 26:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/19\">",
"      Cocco P, Dosemeci M. Peritoneal cancer and occupational exposure to asbestos: results from the application of a job-exposure matrix. Am J Ind Med 1999; 35:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/20\">",
"      Newhouse ML, Thompson H. Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area. 1965. Br J Ind Med 1993; 50:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/21\">",
"      Vianna NJ, Polan AK. Non-occupational exposure to asbestos and malignant mesothelioma in females. Lancet 1978; 1:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/22\">",
"      Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000; 44:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/23\">",
"      McDonald AD, McDonald JC. Malignant mesothelioma in North America. Cancer 1980; 46:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/24\">",
"      Berry G, Reid A, Aboagye-Sarfo P, et al. Malignant mesotheliomas in former miners and millers of crocidolite at Wittenoom (Western Australia) after more than 50 years follow-up. Br J Cancer 2012; 106:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/25\">",
"      Amin AM, Mason C, Rowe P. Diffuse malignant mesothelioma of the peritoneum following abdominal radiotherapy. Eur J Surg Oncol 2001; 27:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/26\">",
"      Weissmann LB, Corson JM, Neugut AI, Antman KH. Malignant mesothelioma following treatment for Hodgkin's disease. J Clin Oncol 1996; 14:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/27\">",
"      Antman KH, Corson JM, Li FP, et al. Malignant mesothelioma following radiation exposure. J Clin Oncol 1983; 1:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/28\">",
"      Baris I, Simonato L, Artvinli M, et al. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int J Cancer 1987; 39:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/29\">",
"      Andersson M, Wallin H, J&ouml;nsson M, et al. Lung carcinoma and malignant mesothelioma in patients exposed to Thorotrast: incidence, histology and p53 status. Int J Cancer 1995; 63:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/30\">",
"      van Kaick G, Dalheimer A, Hornik S, et al. The german thorotrast study: recent results and assessment of risks. Radiat Res 1999; 152:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/31\">",
"      Ishikawa Y, Mori T, Machinami R. Lack of apparent excess of malignant mesothelioma but increased overall malignancies of peritoneal cavity in Japanese autopsies with Thorotrast injection into blood vessels. J Cancer Res Clin Oncol 1995; 121:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/32\">",
"      Shivapurkar N, Wiethege T, Wistuba II, et al. Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas. Int J Cancer 2000; 85:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/33\">",
"      Rivera Z, Strianese O, Bertino P, et al. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med 2008; 14:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/34\">",
"      Riddell RH, Goodman MJ, Moossa AR. Peritoneal malignant mesothelioma in a patient with recurrent peritonitis. Cancer 1981; 48:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/35\">",
"      Gentiloni N, Febbraro S, Barone C, et al. Peritoneal mesothelioma in recurrent familial peritonitis. J Clin Gastroenterol 1997; 24:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/36\">",
"      Schiffman MH, Pickle LW, Fontham E, et al. Case-control study of diet and mesothelioma in Louisiana. Cancer Res 1988; 48:2911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/37\">",
"      Sugarbaker PH, Yan H, Grazi RV, Shmookler BM. Early localized peritoneal mesothelioma as an incidental finding at laparoscopy. Report of a case and implications regarding natural history of the disease. Cancer 2000; 89:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/38\">",
"      Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol 1981; 8:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/39\">",
"      Antman KH, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980; 68:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/40\">",
"      Levy AD, Arn&aacute;iz J, Shaw JC, Sobin LH. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics 2008; 28:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/41\">",
"      D'Abbicco D, Conversano A, Epifania BR, et al. Splenic localization of the peritoneal mesothelioma: case report and literature revue. Updates Surg 2012; 64:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/42\">",
"      Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21:4560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/43\">",
"      Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003; 89:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/44\">",
"      Kebapci M, Vardareli E, Adapinar B, Acikalin M. CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur Radiol 2003; 13:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/45\">",
"      Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003; 12:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/46\">",
"      van Gelder T, Hoogsteden HC, Versnel MA, et al. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989; 43:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/47\">",
"      Salemis NS, Tsiambas E, Gourgiotis S, et al. Peritoneal mesothelioma presenting as an acute surgical abdomen due to jejunal perforation. J Dig Dis 2007; 8:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/48\">",
"      Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009; 27:6237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/49\">",
"      Baratti D, Kusamura S, Cabras AD, et al. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2010; 17:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/50\">",
"      Pappa L, Machera M, Tsanou E, et al. Subcutaneous metastasis of peritoneal mesothelioma diagnosed by fine-needle aspiration. Pathol Oncol Res 2006; 12:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/51\">",
"      Ord&oacute;&ntilde;ez NG, Smith JL Jr. Peritoneal malignant mesothelioma with multiple distant skin metastases. Arch Dermatol 1983; 119:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/52\">",
"      Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2009; 16:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/53\">",
"      Roberts GH. Distant visceral metastases in pleural mesothelioma. Br J Dis Chest 1976; 70:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/54\">",
"      Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer 2011; 117:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/55\">",
"      de Pangher Manzini V. Malignant peritoneal mesothelioma. Tumori 2005; 91:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/56\">",
"      Ust&uuml;nda�� Y, Can U, Benli S, et al. Internal carotid artery occlusion in a patient with malignant peritoneal mesothelioma: is it a sign of malignancy-related thrombosis? Am J Med Sci 2000; 319:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/57\">",
"      Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999; 70:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/58\">",
"      Manzini Vde P, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 2010; 21:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/59\">",
"      Selleslag DL, Geraghty RJ, Ganesan TS, et al. Autoimmune haemolytic anaemia associated with malignant peritoneal mesothelioma. Acta Clin Belg 1989; 44:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/60\">",
"      Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol 2008; 98:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/61\">",
"      Szklaruk J, Tamm EP, Choi H, Varavithya V. MR imaging of common and uncommon large pelvic masses. Radiographics 2003; 23:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/62\">",
"      Low RN, Barone RM. Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 2012; 19:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/63\">",
"      Takeshima Y, Amatya VJ, Kushitani K, Inai K. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases. Am J Clin Pathol 2008; 130:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/64\">",
"      Ros PR, Yuschok TJ, Buck JL, et al. Peritoneal mesothelioma. Radiologic appearances correlated with histology. Acta Radiol 1991; 32:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/65\">",
"      Park JY, Kim KW, Kwon HJ, et al. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roentgenol 2008; 191:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/66\">",
"      Yan TD, Haveric N, Carmignani CP, et al. Computed tomographic characterization of malignant peritoneal mesothelioma. Tumori 2005; 91:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/67\">",
"      Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007; 31:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/68\">",
"      Guest PJ, Reznek RH, Selleslag D, et al. Peritoneal mesothelioma: the role of computed tomography in diagnosis and follow up. Clin Radiol 1992; 45:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/69\">",
"      Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005; 123:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/70\">",
"      Baratti D, Kusamura S, Martinetti A, et al. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2007; 14:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/71\">",
"      Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006; 12:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/72\">",
"      Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012; 30:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/73\">",
"      Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010; 28:3316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/74\">",
"      Patel NP, Taylor CA, Levine EA, et al. Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. Am J Clin Pathol 2007; 128:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/75\">",
"      Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000; 24:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/76\">",
"      Husain AN, Colby TV, Ord&oacute;&ntilde;ez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/77\">",
"      Hesdorffer ME, Chabot JA, Keohan ML, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol 2008; 31:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/78\">",
"      Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D. Cytologic malignancy versus benignancy: how useful are the \"newer\" markers in body fluid cytology? Arch Pathol Lab Med 2008; 132:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/79\">",
"      Onofre FB, Onofre AS, Pomjanski N, et al. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer 2008; 114:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/80\">",
"      Corson JM. Pathology of mesothelioma. Thorac Surg Clin 2004; 14:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/81\">",
"      Suzuki Y. Diagnostic criteria for human diffuse malignant mesothelioma. Acta Pathol Jpn 1992; 42:767.",
"     </a>",
"    </li>",
"    <li>",
"     Peritoneum, Preperitoneum, and Related Structures. In: Rosai and Ackerman's Surgical Pathology, 9th, Rosai J (Ed), Mosby, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/83\">",
"      Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/84\">",
"      Hoekman K, Tognon G, Risse EK, et al. Well-differentiated papillary mesothelioma of the peritoneum: a separate entity. Eur J Cancer 1996; 32A:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/85\">",
"      Hoekstra AV, Riben MW, Frumovitz M, et al. Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature. Gynecol Oncol 2005; 98:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/86\">",
"      Daya D, McCaughey WT. Well-differentiated papillary mesothelioma of the peritoneum. A clinicopathologic study of 22 cases. Cancer 1990; 65:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/87\">",
"      Butnor KJ, Sporn TA, Hammar SP, Roggli VL. Well-differentiated papillary mesothelioma. Am J Surg Pathol 2001; 25:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/88\">",
"      Lovell FA, Cranston PE. Well-differentiated papillary mesothelioma of the peritoneum. AJR Am J Roentgenol 1990; 155:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/89\">",
"      Katsube Y, Mukai K, Silverberg SG. Cystic mesothelioma of the peritoneum: a report of five cases and review of the literature. Cancer 1982; 50:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/90\">",
"      Weiss SW, Tavassoli FA. Multicystic mesothelioma. An analysis of pathologic findings and biologic behavior in 37 cases. Am J Surg Pathol 1988; 12:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/91\">",
"      Gonz&aacute;lez-Moreno S, Yan H, Alcorn KW, Sugarbaker PH. Malignant transformation of \"benign\" cystic mesothelioma of the peritoneum. J Surg Oncol 2002; 79:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/92\">",
"      DeStephano DB, Wesley JR, Heidelberger KP, et al. Primitive cystic hepatic neoplasm of infancy with mesothelial differentiation: report of a case. Pediatr Pathol 1985; 4:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/93\">",
"      Sugarbaker P, Yan T, Zappa L, et al. Thin-walled cysts as a pathognomonic CT finding in cystic mesothelioma. Tumori 2008; 94:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/21/17754/abstract/94\">",
"      Pickhardt PJ, Bhalla S. Primary neoplasms of peritoneal and sub-peritoneal origin: CT findings. Radiographics 2005; 25:983.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2504 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.15-CF2E8830EA-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17754=[""].join("\n");
var outline_f17_21_17754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Asbestos",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION AND IMAGING FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12630199\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Diffuse versus localized peritoneal mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12630315\">",
"      - Pattern of spread",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Paraneoplastic phenomena",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11317884\">",
"      - Diffuse mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Localized mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11317891\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11317970\">",
"      - Mesothelin and soluble mesothelin-related peptide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS AND HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      STAGING AND THE STAGING WORKUP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8237760\">",
"      PERITONEAL MESOTHELIOMA VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8237767\">",
"      Well-differentiated papillary mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8237774\">",
"      Multicystic mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2504\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2504|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/53/38740\" title=\"diagnostic image 1\">",
"      CT imaging findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/55/29555\" title=\"diagnostic image 2\">",
"      MPM 55yr man",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/28/28098\" title=\"diagnostic image 3\">",
"      MPM 73yr man",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2504|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/2/3109\" title=\"picture 1\">",
"      Gross appearance MPM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/45/39640\" title=\"picture 2\">",
"      H and E subtypes MPM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2504|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/18/42283\" title=\"table 1\">",
"      CT findings MPM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=related_link\">",
"      Epidemiology of malignant mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39928?source=related_link\">",
"      Malignancy-related ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35593?source=related_link\">",
"      Malignant peritoneal mesothelioma: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29204?source=related_link\">",
"      Pathology of malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=related_link\">",
"      Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36614?source=related_link\">",
"      Tuberculous peritonitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_21_17755="Part B premium 2012";
var content_f17_21_17755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Part B (medical insurance) monthly premium",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        If your yearly income is",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        You pay",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        File individual tax return",
"       </td>",
"       <td class=\"subtitle2\">",
"        File joint tax return",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        $85,000 or below",
"       </td>",
"       <td>",
"        $170,000 or below",
"       </td>",
"       <td>",
"        $99.90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        $85,001-$107,000",
"       </td>",
"       <td>",
"        $170,001-$214,000",
"       </td>",
"       <td>",
"        $139.90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        $107,001-$160,000",
"       </td>",
"       <td>",
"        $214,001-$320,000",
"       </td>",
"       <td>",
"        $199.80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        $160,001-$214,000",
"       </td>",
"       <td>",
"        $320,001-$428,000",
"       </td>",
"       <td>",
"        $259.70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Above $214,000",
"       </td>",
"       <td>",
"        Above $428,000",
"       </td>",
"       <td>",
"        $319.70",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: US Department of Health and Human Services: Centers for Medicare and Medicaid Services.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17755=[""].join("\n");
var outline_f17_21_17755=null;
var title_f17_21_17756="DSM-IV-TR diagnostic criteria for major depression";
var content_f17_21_17756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for major depression",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        A. Five (or more) of the following symptoms have been present during the same 2-week period,&nbsp;and represent a change from previous functioning. At least one of the symptoms is either depressed mood or loss of interest or pleasure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        (Note: Do not include symptoms that are clearly due to a general medical condition, or mood-incongruent delusions or hallucinations.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Depressed mood most of the day, nearly every day (or alternatively can be irritable mood in children and adolescents)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Markedly diminished interest or pleasure in all, or almost all, activities, nearly every day&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Significant weight loss while not dieting, weight gain, or decrease or increase in appetite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Insomnia or hypersomnia nearly every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Psychomotor agitation or retardation nearly every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Fatigue or loss of energy nearly every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Feelings of worthlessness or excessive or inappropriate guilt nearly every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Diminished ability to think or concentrate, or indecisiveness, nearly every day&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. The symptoms do not meet criteria for a Mixed Episode.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. The symptoms are not due to the direct physiological effects of substance or a general medical condition.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E. The symptoms are not better accounted for by Bereavement, ie, after the loss of a loved one, the symptoms persist for longer than two months or are characterized by marked functional impairment, morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms, or psychomotor retardation.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision. American Psychiatric Association, Washington, DC 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17756=[""].join("\n");
var outline_f17_21_17756=null;
var title_f17_21_17757="Int prognostic index NHL";
var content_f17_21_17757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    International Prognostic Index for non-Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"       International Prognostic Index",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       Age &gt;60",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       Serum lactate dehydrogenase concentration above normal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       ECOG performance status &ge;2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       Ann Arbor stage III or IV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       Number of extranodal disease sites &gt;1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       One point is given for each of the above characteristics present in the patient, for a total score ranging from zero to five. When applied to the initial group of 2031 patients with aggressive NHL treated with anthracycline-based regimens that did NOT include rituximab, five-year overall survival (OS) and complete response (CR) rates according to score were as follows:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Score",
"      </td>",
"      <td class=\"subtitle2\">",
"       Risk group",
"      </td>",
"      <td class=\"subtitle2\">",
"       5-yr OS, percent",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"1\">",
"       CR rate, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0 to 1",
"      </td>",
"      <td>",
"       Low risk",
"      </td>",
"      <td>",
"       73",
"      </td>",
"      <td>",
"       87",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       Low-intermediate risk",
"      </td>",
"      <td>",
"       51",
"      </td>",
"      <td>",
"       67",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td colspan=\"1\">",
"       High-intermediate risk",
"      </td>",
"      <td>",
"       43",
"      </td>",
"      <td>",
"       55",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4 to 5",
"      </td>",
"      <td>",
"       High risk",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       44",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"4\">",
"       This same score applied to 1063 patients treated with rituximab plus CHOP or CHOP-like chemotherapy predicted the following",
"       <sup>",
"        [2]",
"       </sup>",
"       :",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Score",
"      </td>",
"      <td class=\"subtitle2\">",
"       3-yr EFS",
"      </td>",
"      <td class=\"subtitle2\">",
"       3-yr PFS",
"      </td>",
"      <td class=\"subtitle2\">",
"       3-yr OS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0 to 1",
"      </td>",
"      <td>",
"       81",
"      </td>",
"      <td>",
"       87",
"      </td>",
"      <td>",
"       91",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       69",
"      </td>",
"      <td>",
"       75",
"      </td>",
"      <td>",
"       81",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       53",
"      </td>",
"      <td>",
"       59",
"      </td>",
"      <td>",
"       65",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4 to 5",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       59",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"       Age adjusted International Prognostic Index",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"4\" rowspan=\"1\">",
"       For this score, all of the prognostic factors listed above, with the exception of age and number of extranodal sites, are given one point, for a score ranging from zero to three. When applied to the group of 761 patients &gt;60 years of age, five-year OS and CR rates according to the adjusted score were as follows:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Score",
"      </td>",
"      <td class=\"subtitle2\">",
"       Risk Group",
"      </td>",
"      <td class=\"subtitle2\">",
"       5-yr OS, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       CR rate, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       Low risk",
"      </td>",
"      <td>",
"       56",
"      </td>",
"      <td>",
"       91",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       Low-intermediate risk",
"      </td>",
"      <td>",
"       44",
"      </td>",
"      <td>",
"       71",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       High-intermediate risk",
"      </td>",
"      <td>",
"       37",
"      </td>",
"      <td>",
"       56",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       High risk",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       36",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EFS: event-free survival; PFS: progression-free survival.",
"    </div>",
"    <div class=\"reference\">",
"     1. Adapted from: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987.",
"     <br>",
"      2. Adapted from: Ziepert, M, Hasenclever, D, Kuhnt, E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28:2373.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17757=[""].join("\n");
var outline_f17_21_17757=null;
var title_f17_21_17758="Ocular melanoma Fundus photo";
var content_f17_21_17758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraocular melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 157px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fundus photographs of 58-year-old male with 18 mm intraocular melanoma before and 18 months after proton therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Evangelos Gragoudas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17758=[""].join("\n");
var outline_f17_21_17758=null;
var title_f17_21_17759="Bladder endometriosis on cystoscopy";
var content_f17_21_17759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bladder endometriosis: Cystoscopic image",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cystoscopic appearance of an endometriotic nodule on the posterior bladder wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_21_17759=[""].join("\n");
var outline_f17_21_17759=null;
